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Over the last two decades, the discovery of antibodies directed against neuronal surface 
antigens in patients with different forms of encephalitis has provided a basis for 
immunotherapies in previously undefined disorders. These important findings have raised 
questions regarding the role of neuronal antibodies in patients with other possibly immune-
mediated diseases. Nevertheless, the pathogenicity of specific neuronal surface antibodies has 
not been adequately demonstrated in animal models.  
The presence of neuronal surface antigens in other disorders was examined by three 
approaches in patients with narcolepsy type 1, in patients with chronic neurological conditions 
(temporal lobe epilepsy and patients with neurodegenerative disorders), and in healthy and 
other disease controls. To establish an animal model, antibodies against contactin-associated 
protein 2 (CASPR2) were injected intraperitoneally daily into mice that were given a single 
lipopolysaccharide injection to open the blood brain barrier. Behavioural performance was 
studied over five days, and the mouse brains carefully investigated for presence of bound 
antibodies and neuropathological changes. 
Overall, patients with central nervous system disorders showed a higher frequency of 
antibodies compared to controls, but no antibodies specific to any one disorder were identified. 
Mice with high serum CASPR2 antibodies showed altered working memory and anxiety-like 
behaviours only in a social context. There were human immunoglobulins bound to the brain 
parenchyma along with a mild Purkinje cell loss and astrocytosis in the cerebellum, increased 
c-fos expression in the piriform-entorhinal cortex and hypothalamus, and microglial and 
astrocyte activation. These results not only support a pathogenic role for CASPR2 antibodies 
but provide the first demonstration in this field that a brief opening of the blood brain barrier is 
sufficient to allow access of antibodies into the brain with behavioural and neuropathic 
consequences. These findings are of relevance to other neuronal antibodies and stimulate 
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Chapter 1: Introduction  
 
“…the organism possesses certain contrivances by means of which the immune reaction, so 
easily produced by all kinds of cells, is prevented from acting against the organism’s own 
elements and so giving rise to autotoxins…so that we might be justified in speaking of a “horror 
autotoxicus” of the organism. These contrivances are naturally of the highest importance for 
the individual.” 
 
With these words, in 1901, Paul Ehrlich proposed for the first time the idea that individuals 
might make antibodies that were toxic to themselves, posing the basis for the concept of 
autoimmunity (Ehrlich P, 1957). The mechanisms’ “contrivances” were subsequently defined 
as “tolerance”.  
As Burnet theorised “The need and the capacity to distinguish between what is 
acceptable as self and what must be rejected as alien is the evolutionary basis of immunology” 
(Burnet M, 1969). Tolerance is achieved through central and peripheral mechanisms. Central 
tolerance is established in the thymus, where developing lymphocytes undergo positive 
selection in the cortex before maturing and entering the circulation; in the meantime, 
lymphocytes with potential reactivity against self-peptides are negatively selected and deleted 
in the thymic medulla. Once in the periphery, mature T cells are subjected to a secondary 
selection (peripheral tolerance) by which the majority of self-reactive T cells are deleted or 
rendered anergic. If immature B cells express surface IgM that recognises ubiquitous self-cell-
surface antigens, they are eliminated by a process known as clonal deletion. Mature B cells are 
also under the control of peripheral tolerance.  
However, despite the strict vigilance of central and peripheral tolerance, small numbers 
of potentially self-reacting lymphocytes can still ‘escape’ into the periphery, even in otherwise 
normal individuals. The existence of these potential self-reactive T and/or B lymphocytes, and 
the ability of the B cells to produce autoantibodies, does not necessarily lead to pathology 
(Salinas GF et al. 2013). Accordingly, autoimmunity can sometimes be classified as 
‘physiological’ (Hang LM et al. 1997; Avrameas S and Selmi C, 2013). Physiological 
autoimmunity is usually transient, without evidence of clinical disease. This is exemplified by 
the presence of naturally occurring autoantibodies (Panda S and Ding JL, 2015), which help 
eliminate degraded self- and foreign antigens for maintenance of homeostasis. Therefore, to be 





1.1 How to define autoimmunity: The Witebsky’s criteria 
 
Given the existence of naturally occurring auto-antibodies in the population, there is a need to 
apply specific criteria to establish the autoimmune nature of a disease. These criteria are based 
on the Koch/Witebsky postulates (reviewed in Rose NR and Bona C, 1993), which were later 
adapted to antibody-mediated diseases (Drachman DB, 1990), and are based on the following 
principles:  
1. Presence of auto-antibody or self-reactive lymphocytes during the clinical manifestation in 
the sera or affected tissue; 
2. Transfer of pathology by antibodies or lymphocytes from an affected individual to 
laboratory animals or to cells in culture;  
3. Experimental disease must show immunopathological lesions that parallel those in the 
natural disease.  
Three lines of evidence exist for the pathogenicity of autoantibodies: 
• Circumstantial - these include clinical observations such as a) presence of genetic 
susceptibility (i.e recurrence in the same family and HLA association); b) association of 
antibodies with a specific clinical phenotype; c) response to immunotherapy. 
• Indirect - reproduction of the autoimmune disease in experimental animals through active 
immunisation.  
• Direct - from transfer of pathogenic antibody from a human subject to experimental animals. 
1.2 Immunoglobulins structure and mechanisms of antibody-mediated autoimmunity 
  
Immunoglobulins (Ig) are made of two heavy (H) and two light (L) chains, where the L chain 
can consist of either a κ or a λ chain. Each component chain contains one NH2-terminal 
“variable” (V) domain and one or more COOH-terminal “constant” (C) domains. In humans, 
Ig are of five different isotypes: M, G, D, A, E, which differ in structure, concentration and 
functional features. The choice of isotype is dependent upon the antigen itself and the signaling 
pathways that are activated, as well as the local microenvironment (Janeway CA Jr et al. 2001).  
Immunoglobulin-antigen interactions take place between the paratope, the site on the Ig 
at which the antigen binds, and the epitope, which is the site on the antigen that is bound. In 
vivo, immunoglobulins tend to be produced against intact antigens in soluble form, and thus 




IgGs are the main isotype found in the body and they have the longest serum half-life 
of all immunoglobulin isotypes. Papain digests IgG into two Fab fragments, each of which can 
bind antigen, and a single Fc fragment. Pepsin splits IgG into an Fc fragment and a single 
dimeric F(ab)2 that can cross-link as well as bind antigens.  
Based on structural, antigenic and functional differences in the constant region of the 
heavy chain, IgG are divided into four subclasses, numbered in reference to the rank order 
(IgG1>IgG2>IgG3>IgG4) of the serum levels of these antibodies in the blood of healthy 
individuals. The IgG subclasses exhibit different functional activities. Activation of the 
complement cascade is an important means of clearance of opsonized pathogens. Affinity for 
C1q, which is the first component of the complement pathway, differs between members of the 
IgG subclasses, IgG3>IgG1>IgG2, while IgG4 antibodies fail to fix complement. Within the 
secondary antibody response, there is skewing in the predominant subclass that is induced. For 
example, IgG1 and IgG3 antibodies are generally induced in response to protein antigens 
whereas IgG2 and IgG4 are associated with polysaccharide antigens. The response to a given 
antigen can also result in a skewed IgG subclass response and this is frequently a source of 
investigation as it can correlate with protection from disease or for the design of vaccines. 
Specific subclasses can also be associated with individual disease processes. For example, 
antibodies against LGI1 or MuSK are mainly IgG4.  
Fc receptors for immunoglobulin link the humoral immune compartment to the cellular 
immune compartment. The net result of binding of Ig to the Fc receptor is a function of the 
receptor, the cell on which it is expressed, and on ancillary signals. Fc receptors for IgG are 
termed FcγR. In humans, three classes of FcγR have been identified as FcγRI, II and III. IgG 
subclasses show different affinity for the three classes of FcγR (I, II and III). IgG1 and IgG3 
bind to all three FcγR classes. IgG4 binds only FcγRII and III, albeit significantly weaker than 
the binding of IgG1, and IgG2 binds only to FcγRII.  
 
1.3 Mechanism of antibody mediated damage 
 
Antibodies can affect their targets through different mechanisms (reviewed in Ludwig RJ et al. 
2017):  
1. Complement activation. Complement is a component of the innate immune system. 
Antibodies activate complement through the classical pathway, where C1 binds with its C1q 




C4b and C3b are also able to bind to the Fc domains of the antigen-associated IgG or IgM, to 
its Fc portion. Binding of C1q leads to the subsequent activation of serine protease C1r and 
C1s, propagating the cascade. Antibody-independent pathways are known as the alternative and 
lectin pathways. All three pathways converge at the assembly of C3 convertase, a proteolytic 
enzyme that cleaves C3 in to C3a and C3b molecules. The terminal stage of the complement 
cascade is the formation and insertion of the membrane attack complex (MAC, also known as 
C9) into the cell surface, which disrupts the integrity of the cell membrane, resulting in osmotic 
lysis and destruction of the targeted cell. In addition, cleaved peptide fragments C3a, C4a and 
C5a are anaphylatoxins and promote inflammation, and C3b fragments bind to the surface of 
antibody bound cells, and act to mark the cell for phagocytosis.  
2. Antibody mediated cell-mediated cytotoxicity (ADCC). This is part of the adaptive immune 
response by which an effector cell actively lyses a target whose membrane-surface antigens 
have been bound by specific antibodies. ADCC requires an effector cell which classically is a 
natural killer (NK) cell; however, macrophages, neutrophils and eosinophils can also mediate 
ADCC.   
3. Neutralization or alteration of function of targeted molecules. Antibodies to cellular 
receptors can activate intracellular signaling cascades thereby modulating the cellular function 
or triggering apoptotic pathways.  
4. Binding to neurotransmitter receptors and mediating receptor internalization, with 
consecutive reduction of their surface expression. Antibodies to cell surface molecules can also 
block functions including cellular interactions with soluble molecules, other cells, or 
extracellular matrix components and can, thereby, change molecular or cellular function.  These 
are the aspects that are most relevant to this Thesis. 
5. Induction of inflammation at the site of autoantibody binding, which occur though 
recruitment of effector immune cells and relies of cytokines and chemokines.  
1.4 The prototype of neurological antibody mediated disorders: myasthenia gravis 
 
Myasthenia gravis (MG) is an autoimmune disorder characterised by muscle weakness and 
fatigability caused by antibodies directed against components of the postsynaptic muscle 
endplate localised at the neuromuscular junction (NMJ). Over two-thirds of all patients with 
MG begin with symptoms localised to their eye muscles (ocular MG) (Berrih-Aknin S and Le 




resulting in generalised MG. Approximately 15% of patients with MG have a thymoma, and 
50% of thymoma patients develop MG (Romi F, 2011). 
In 1960, Simpson suggested that MG was caused by autoantibodies to the acetylcholine 
receptor (AChR) (Simpson JA, 1960). Nowadays the pathogenicity of these antibodies is 
clearly established. Indeed about 90% of generalised MG is caused by pathogenic 
autoantibodies to muscle nicotinic AChRs. Plasmapheresis leads to a substantial, but 
temporary, improvement in muscle function (Pinching AJ et al. 1976). In animals, experimental 
MG (EAMG) can be induced by immunisation with AChR purified from the electric organ of 
Electrophorus electricus (Patrick J and Lindstrom J, 1973) or by injection of monoclonal 
antibodies (mAbs) to AChR (Tzartos S et al. 1987). Moreover, injection of patients’ IgG or 
isolated AChR autoantibodies from affected individuals into laboratory animals passively 
transfers several features of MG (Toyka KV et al. 1977; Kordas G et al. 2014). The pathological 
autoantibodies are directed at conformation-dependent extracellular epitopes on AChRs, 
especially the AChR α1 subunits (Vincent A et al. 2001). The predominant isotypes of 
autoantibodies to AChR are IgG1 and IgG3. These autoantibodies impair neuromuscular 
transmission primarily by three mechanisms:  
1) Focal complement-mediated lysis of the postsynaptic membrane that destroys the 
postsynaptic membrane that contains the AChRs and, therefore, disrupts synaptic morphology 
(Engel AG, 1984; Engel AG and Arahata K, 1987); 
 2) Cross-linking of AChRs by the autoantibodies on the surface of the postsynaptic 
membrane that accelerates endocytosis and lysosomal destruction of AChRs (Drachman DB et 
al. 1978);  
3) Inhibition of AChR function by direct blockage of acetylcholine (ACh) binding sites 
(Bufler J et al. 1998) (Figure 1.1).  
The loss of AChR numbers or function results in the recruitment of fewer muscle fibres and a 
decrement in the compound muscle action potential (CMAP).  
AChR antibodies are present in around 80% of patients with generalised MG. Around 
half of those patients without AChR antibodies have antibodies, instead, to muscle-specific 
kinase (MuSK) (Hoch W et al. 2001). MuSK is an essential component for NMJ formation 
through its interaction with low-density lipoprotein receptor-related protein 4 (LRP4), a 
receptor for agrin (a protein secreted from the motor neuron terminal) (Kim N et al. 2008; Zhang 
B et al. 2008). MuSK mediates clustering and stabilisation of AChR in developing and mature 
muscle. Patients with MuSK-antibody mediated MG have more focal involvement and wasting 




























A) Immunoglobulin G1 (IgG1) and IgG3 can activate the complement cascade via their Fc 
domains, which interact with complement proteins C1 and C1q. The complement cascade 
culminates in the formation of the membrane attack complex which disrupts the phospholipid 
bilayer, resulting in loss of the junction folds and acetylcholine receptors (AChRs). B) IgG1 and 
IgG3 can crosslink antigenic targets, leading to internalisation and degradation of the antigen in 
lysosomes. C)  Some AChR autoantibodies can directly block AChR currents. D) Muscle skeletal 
receptor tyrosine-protein kinase (MuSK) autoantibodies are mainly of the IgG4 subclass. They 
inhibit agrin-induced binding of low-density lipoprotein receptor-related protein 4 (LRP4) to 





Autoantibodies to MuSK are mainly of the IgG4 isotype and the IgG4 fraction alone can 
transfer disease to mice (Klooster R et al. 2012). The binding of IgG4 autoantibodies to MuSK 
disrupts its interaction with agrin-bound LRP4 and directly suppress the postsynaptic tyrosine 
kinase pathway thus indirectly reducing the metabolic stability of endplate AChRs, but IgG1-3 
also disrupt this pathway by a different mechanism (Koneczny I et al. 2013) (Figure 1.1).  
The knowledge of the antibody mechanisms in MG have promoted the development of 
novel therapies, particularly therapies based on the inhibition of complement pathways (Soltys 
J et al. 2009). MG is an ideal disease for antigen-specific immunotherapy because of its clearly 
defined autoantigen. Theoretically, an antigen-specific immunotherapy would eliminate the 
pathogenic autoimmune response to autoantigen without affecting the other functions of the 
immune system, and thus avoiding severe adverse effects. The idea of specific 
immunosuppression of autoimmune response to AChR by administration of AChR peptides or 
fragments has been investigated in EAMG for many years. For instance, a vaccine using AChR 
cytoplasmic domains has been shown to be effective at specifically suppressing EAMG (Luo J 
and Lindstrom J, 2014), but none of the many published approaches have reached the clinic. 
 
1.5 Antibody-mediated CNS autoimmune disorders 
 
The brain has long been considered an immunologically privileged organ due to the presence 
of the blood brain barrier (BBB) which ideally prevents the access of antibodies and immune 
cells from the peripheral circulation. In the late ’60s there was the first description of an 
autoimmune limbic encephalitis (LE) in three patients with small cells lung carcinoma (SCLC) 
(Corsellis JA et al. 1968). Subsequently a few more cases were described and different 
onconeural antigens, such as Hu, Yo, CRMP5 and Ma2, were discovered (Dalmau J and 
Rosenfeld MR, 2008). The presence of antibodies against intracellular antigens (nuclear or 
cytoplasmic) have been described in patients with a range of central and peripheral neurological 
manifestations including LE, cerebellar ataxia and sensory neuropathy, and are commonly 
associated with an underlying malignancy; they are referred to as paraneoplastic neurological 
disorders. Despite the presence of an antibody, these disorders are not considered to be 
antibody-mediated due to the following lines of evidence (reviewed in Dalmau J and Rosenfeld 
MR, 2008):  
1) Intracellular antigens are inaccessible to circulating antibodies; 
2) Attempts to transfer human disease by passive transfer of patient IgG or active 




of disease in vivo, despite inducing antibody responses (Graus F et al. 1991; Greenlee JE et al. 
1995);  
3) Patients generally do not improve clinically with immunotherapies aimed to reduce 
antibody levels.  
Indeed, these diseases are considered to be T-cell mediated as supported by neuropathological 
findings showing extensive cytotoxic T-cell infiltrates and neuronal death in patients’ post 
mortem brain tissue (Dalmau J et al. 1991; Giometto B et al. 1997). These paraneoplastic 
antibodies are likely to be bystanders of a T-cell immune response; however, their detection is 
important for the identification of an underlying malignancy. Since these antibodies are not 
pathogenetically relevant, they will not be discussed further.  
Neuromyotonia (NMT), also known as Isaacs’ syndrome, is a rare disorder 
characterised by spontaneous and continuous muscle activity at rest, which manifests clinically 
as visible muscle twitching (90%), cramps (70%), myopathy, stiffness and impaired muscle 
relaxation (reviewed in Maddison P, 2006). Indirect evidence for an autoimmune aetiology 
came from the demonstration that plasma exchange significantly reduced the number of 
neuromyotonic discharges, and injection of the antibodies into mice (passive transfer) produced 
a raised threshold to d-tubocurarine in the diaphragm muscle (Sinha S et al. 1991; Newsom-
Davis J and Mills Kr, 1993). In 1995, Shillito P et al. developed a radioimmunoprecipitation 
assay (RIA) using mammalian brain extract as a concentrated source of Kv1 type voltage-gated 
potassium channels (VGKCs). VGKCs were labelled with iodinated alpha-dendrotoxin (125I- 
αDTX), a neurotoxin derived from the venom of the Dendroaspis angusticeps (Green mamba 
snake) which binds specifically to the Kv1.1, 1.2 and 1.6 subtypes of the Shaker channel family 
(Scott VE et al. 2002). The authors found that three of six patients studied precipitated 125I-
αDTX counts that were significantly higher than controls levels (Shillito P et al. 1995), 
indicating that their antibodies had bound to the VGKC or related proteins.  
In 2001, Liguori et al. reported a 76-year-old man with Morvan’s syndrome (MoS) and 
antibodies against VGKCs (Liguori R et al. 2001). The striking response to plasmapheresis, the 
presence of oligoclonal bands in the cerebrospinal fluid (CSF), and the absence of 
morphological alterations but suggestion of diffusion of IgG into the thalamus and striatum at 
postmortem, when the patient died subsequently, all supported an antibody-mediated basis for 
the condition. This began a shift from the paradigm that only peripheral antibodies could cause 
disease, to recognition that antibodies could also affect the central nervous system. This was 




without tumours or onconeural antibodies, first in two patients (Buckley C et al. 2001) and then 
in two small case series (Vincent A et al. 2004; Thieben MJ et al.2004).   
In 2005, the field began to extend to other antibody-mediated CNS diseases. Seven 
patients with subacute limbic encephalitis were described, six with antibodies that bound the 
neuropil of hippocampus or cerebellum on rat brain sections and one to an intracellular antigen 
(Ances BM et al. 2005). Only in one case was the pattern of reactivity compatible with VGKC-
antibodies whereas in the other cases the antigens appeared diverse, but all expressed on the 
neuronal cell membrane and dendrites. All patients, except the one with antibodies to 
intracellular antigens, had dramatic clinical and neuroimaging responses to immunotherapy or 
tumour resection. On the basis of these features the authors suggested a classification of 
antibody-associated encephalitis with implications for prognosis and treatment. One group 
comprises patients with antibodies to intracellular antigens including most of the previously 
characterised paraneoplastic antibodies, whereas the other comprised patients with antibodies 
that react with the brain neuropil and includes VGKC antibodies and the collectively termed 
‘novel neuropil antibodies’.  
Soon after, a new disorder, presenting with prominent psychiatric symptoms, seizures, 
memory deficits and decreased level of consciousness in young women, in association with 
ovarian teratomas, was described (Vitaliani R et al. 2005). This disorder was considered to 
represent a new category of severe but treatment-responsive paraneoplastic encephalitis and 
further studies led to the identification of the antigen as the GluN1 subunit of the N-methyl-D-
aspartic acid receptor (NMDAR) (Dalmau J et al. 2007).  
 In 2010, it was found that the VGKC antibodies were actually directed against two 
proteins that co-precipitate with the Kv1 subunits, contacting-associated protein 2 (CASPR2) 
and leucine rich glioma inactivated protein 1 (LGI1) (Irani SR et al. 2010), rather than the 
VGKC itself. In the following years, in the effort of elucidating the cause of previously 
considered idiopathic encephalitis, several new neuronal surface antigen-antibodies (NSA-Abs) 
involved in autoimmune encephalitis were identified, each one associated with partly 
characteristic clinical features, as summarised in Table 1.1. In the meantime, more and more 
studies focused on demonstrating the pathogenic role of the antibodies and on elucidating the 
underlying pathogenetic mechanisms (summarised in Table 1.2). In the following paragraphs 
the methods of detection, the triggering factors and the main antibodies against neuronal surface 




Table 1. 1 Neuronal surface antibody-mediated autoimmune encephalitis 
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Continuation table 1.1 
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  Pleocytosis No Unknown Genetic variation at 
this locus has been 
associated with a 
range of behavioral 
phenotypes 
Abbreviations: Abs: antibodies; ALS: amyotrophic lateral sclerosis; CSF: cerebrospinal fluid; HL: Hodgkin’s 
lymphoma; HLA: human leukocyte antigen; HSV: Herpes Simplex virus; FBDS: facio-brachial dystonic seizures; GI: 
gastrointestinal; LE: limbic encephalitis; MoS: Morvan’s syndrome; NMT: neuromyotonia; OBs: oligoclonal bands; 
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GlyR α1 subunit   IgG1 Cross-linking 
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Unknown  No 
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GABABR R1 subunit   mainly 
IgG1 
Unknown Unknown No 











D2R D2   IgG Unknown Unknown No 
IgLON5 Ig-like 
domain 2 
















Continuation of table 1.2      
mGluR5 mGluR5    IgG; 
unknown 
Unknown Unknown No 
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DRG: dorsal root ganglia; HEK: human embryonic kidney cells; LTP: long-term potentiation; PNS: peripheral 















The proteins targeted by antibodies associated with autoimmune encephalitis are proteins and 
channels expressed on the neuronal surface, often at both pre- and post-synaptic levels on 
inhibitory (gabaergic) and/or excitatory (glutamatergic) neurons in the CNS (adapted from 





1.5.1. Methods of detection of NSA-Abs 
 
Since the antibodies directed against NSA-Ab are directed against extracellular portions of the 
protein and its conformational epitopes, it is important that the method of detection of these 
antibodies preserves the native structure of the protein. Cell-based assays (CBAs), which 
measure the binding visually (Figure 1.3) or by flow cytometry, using live cells that preserve 
the structure of membrane proteins, meet these requirements. CBAs have been shown to be 
superior for the detection of NSA-Ab compared to other methods such as western blots (WB) 
or peptide enzyme-linked immunosorbent assays (ELISAs), in which the proteins are not 
necessarily conformational (Waters PJ et al. 2012).  
CBAs and flow cytometry use live cells transiently transfected with the protein of 
interest and then incubated with patient’s serum, and antibody binding is detected by a 
secondary immunofluorescent anti-human antibody. This method is, of course, only valid for 
known antigens.  
In order to identify new antigenic targets two commonly used methods are: 
1) Immunohistochemistry on rat brain sections: antibodies to neuronal antigens usually bind 
the neuropil, each with a specific pattern; 
2) Immunofluorescence on hippocampal rat neurons in culture: the majority of NSA-Ab 
recognise protein expressed on hippocampal neurons.     
If binding is found with these screening methods, the following steps are the identification of 
the target by mass spectroscopy and the establishment of a new specific CBA. 
 
1.5.2. Triggering causes of autoimmune encephalitis 
 
Tumours 
NSA-Ab can be associated with cancer and the frequency and type of tumour varies accordingly 
to the type of disease and the autoantibody. Some autoimmune encephalitis rarely associates 
with tumours, as in the case of LGI1 encephalitis (Irani SR et al. 2010; Lai M et al. 2010), 
whereas others show strong association with cancer such as small cell carcinoma with GABAB 
receptor antibodies, or teratoma with NMDAR encephalitis (Hoftberger R et al.  2013; Jeffery 
OJ et al. 2013; Dalmau J et al. 2007). In the cases with tumours, the neoplastic cells express the 
neural surface antigen against which the antibodies are directed. Therefore, it is thought that 
the ectopic expression of neuronal proteins by the tumour breaks immune tolerance for these 








A) Schematic representation of human embryonic kidney (HEK) cells expressing a protein 
of interest after transfection. On the left: an example of positive serum containing specific 
IgG directed against the target protein; bound IgG antibodies on the cell surface are detected 
by a secondary anti-human IgG antibody. On the right: a negative serum does not contain 
antibodies specific for that antigen. B) Microphotographs of HEK cell from a positive (left) 
and negative (right) control.  
  




In the case of ovarian teratoma, the tumour itself contains mature or immature neural tissue 
(Dalmau J et al. 2007) which express NMDARs that likely contribute in triggering the 
autoimmune response. In line with this hypothesis, the tumours of these patients contain larger 
amounts of inflammatory infiltrates compared with the teratomas from patients who do not 
develop anti-NMDA receptor encephalitis (Tuzun E et al. 2009).  
 
Herpes Simplex and other viruses  
Several recent reports describe the occurrence of NSA-Abs within weeks of herpes simplex 
virus (HSV) infection of the CNS (Armangue T el al. 2015, Armangue T et al. 2013; Hacohen 
Y et al. 2014). Most cases show new synthesis of antibodies against NMDAR and less 
frequently against other receptors or NSA (GABAA receptors, dopamine receptors, 
uncharacterised cell surface proteins) (Armangue T el al. 2015; Hacohen Y et al. 2014; 
Mohammad SS et al. 2014). In these cases, treatment with immunotherapy rather than viral 
therapy associates with neurological improvement. This observation suggests that 
autoantibodies may be generated in the context of inflammation and neural damage caused by 
a primary viral infection. Indeed, a possible link between other infections and anti-NMDA 
receptor encephalitis has been suggested (varicella zoster virus, mycoplasma), but the number 
of cases is too small to confirm this association (Gable S et al. 2009; Schabitz WR et al. 2014). 
 In a substantial number of patients with autoimmune encephalitis (AE), the trigger of 
the autoimmune response is unknown; in these cases, screening studies for an occult tumour or 
recent viral infections are negative. The young age and lack of tumour risk factors in some 
patients, as well as long clinical follow-up during which patients remain tumour free, support 
the existence of other unknown immunological triggers. The fact that some patients have other 
autoantibodies with a frequency higher than expected in the normal population suggest an 
underlying predisposition to autoimmunity (Florance NR et al. 2009; Lai M et al. 2009; Tuzun 
E et al. 2011).  
Genetic susceptibility to develop AE has only been investigated in a few of these 
disorders. Recent studies show specific human leukocyte antigen (HLA) associations in patients 
with LGI1 and IgLON5 antibodies (Gelpi E et al. 2016; Van Sonderen ARD et al. 2017). LGI1-
antibody associated encephalitis with HLA-DR7 and HLA-DRB4 was identified. Interestingly, 
this haplotype association did not appear to apply to patients who developed the disorder in the 
context of a systemic tumour, suggesting that the absence of those haplotypes could raise 
suspicion for an underlying tumour or paraneoplastic mechanism (Van Sonderen ARD et al. 




1.5.3. Anti-NMDAR encephalitis  
 
Anti-NMDAR encephalitis, the classical syndrome associated with NMDAR antibodies, is the 
most commonly recognised AE. Up to 70% of patients have prodromal symptoms consisting 
of headache, fever, nausea, vomiting, diarrhoea, or upper respiratory-tract symptoms. 
Psychiatric symptoms, such as memory problems, confusion, abnormal behavior, paranoia and 
hallucinations may also be present, in addition to seizures, dyskinesia, autonomic instability, 
catatonia, hypoventilation, lethargy and language deficits. Hypoventilation and memory 
problems appear more frequently in adults (Dalmau J et al. 2011). Although initially only 
recognised as a neurological syndrome in the context of ovarian teratoma, it is now known that 
the majority of patients have no neoplasia (around 60-70%) and that the disease can affect men 
and women of all ages (Irani SR, Bera K et al. 2010, Titulaer MJ et al. 2013).  
Despite the severity of the clinical picture, brain MRI is normal in approximately half 
of patients, with hyperintensity visible in the other half (Dalmau J et al. 2011; Dalmau J et al. 
2008; Irani SR, Bera K et al. 2010). However, EEG often show diffuse slow and disorganized 
activity, and some epileptic discharges, and CSF analysis reveals lymphocytosis early in the 
disease, sometimes associated with raised protein levels (Dalmau J et al. 2008; Dalmau J et al. 
2011; Irani SR, Bera K et al. 2010). As the disease progresses, CSF-specific oligoclonal bands 
and evidence of intrathecal NMDAR autoantibody synthesis can be detected (Irani SR, Bera K 
et al. 2010). The prognosis of NMDAR-encephalitis is largely time-dependent, including time 
to diagnosis, time to tumour removal (when present), and time to initiation of 
immunosuppressive therapy.  
Overall about 75% of patients experience only mild long-term deficits or recover 
completely, but the remaining quarter have severe sequelae, and mortality due to intensive care 
complications can be up to 7% (Dalmau J et al. 2011; Wandinger KP et al. 2011; Titulaer MJ 
et al. 2013).  
In paraneoplastic cases, response to tumour removal and first-line therapy is 
approximately 80%, whereas patients without tumours have an initial response rate of 48%. 
Second-line therapy, most commonly rituximab and/or cyclophosphamide, is often needed in 
patients without tumours and in those with a late diagnosis. Approximately 65% of patients 
show substantial improvements with second-line immunotherapy (Dalmau J et al. 2011; 
Titulaer MJ et al. 2013). Patients can relapse, especially those without tumours, although 




Pathogenic mechanism of NMDAR antibodies  
The NMDAR is a subtype of ionotropic glutamate receptor composed of two GluN1 (also called 
NR1) and two GluN2/3 (also called NR2 and NR3) subunits that form a central ion channel. 
Patients’ antibodies were shown to react against the NR1 subunit and to significantly decrease 
NR1, NR2A, NR2B and NMDAR surface and total cluster densities in a titre-dependent fashion 
with consequent reduction of synaptic NMDAR currents but without disruption of the neuronal 
structure. The reduction of NMDAR expression is mediated by the antibodies that cross-link 
NMDARs, resulting in their internalisation, and appeared to be independent from complement 
deposition (Hughes EG et al. 2010). In parallel, the antibodies alter receptor trafficking. At the 
synaptic level they induce dispersal of GluN2A-NMDAR, preventing their dynamic synaptic 
retention through the blockade of the interaction between the extracellular domains of GluN1/2 
subunits and ephrin-B2 receptors (EPHB2R) whereas at the extrasynaptic level they reduce the 
GluN2B-NMDAR dynamics through endocytosis (Mikasova L et al. 2012) (Figure 1.4). All 
together these changes affect long term potentiation, which is the cellular substrate of learning 
and memory, explaining some, but not all, the symptoms observed in patients. 
The pathogenicity of NMDAR-Abs has been partially demonstrated in animal models. In 
mice, a single intraventricular (ICV) injection of immunoglobulin G (IgG) from individuals 
with anti-NMDAR encephalitis induced, in association with the chemoconvulsant 
pentylenetetrazol, more frequent and severe seizures than a single injection with IgG from 
control individuals (Wright S et al. 2015). Continuous intraventricular infusions of CSFs pooled 
from individuals with anti-NMDAR encephalitis to mice over 14 days reproduced some of the 
clinical features observed in patients such as memory deficits, anhedonia and depression-like 
behaviours but no other core features such as motor disorders or seizures. IgG deposition and a 
decrease in NMDAR clusters was observed in the hippocampi of NMDAR-Abs injected mice, 
which resolved within days after discontinuing the infusion (Planagumà J et al. 2015). These 
two animal models support the proposed mechanisms of cross-linking, internalisation and 
altered NMDAR trafficking, and together with the absence of complement activation, explain 
why patients often respond promptly to immunotherapy. Indeed, a good clinical outcome 
correlates with a significant decrease of NMDAR-Abs in patients’ CSF (Dalmau J et al. 2008).
 However, recent findings demonstrated that patients may have long term cognitive 
deficit and structural hippocampal damage as shown by brain MRI, in which severity correlated 
with disease duration and delayed and inefficient treatment (Finke C et al. 2016). This suggests 





























In normal conditions GluN2A receptors are anchored at the synaptic levels through the 
interaction with the ephrin receptor, EPHB2R, whereas GluN2B are more extrasynaptic. 
Patients’ IgGs against NMDAR prevent the interaction between NMDAR and EPHB2R in the 
synaptic area causing their lateral displacement. Moreover, patients’ IgGs reduce surface 
NMDAR expression, likely by causing their internalisation and degradation (adapted from 
Mikasova L et al. 2012).  
  




impact on neuronal function in a way that is not yet understood. Nevertheless, it is possible that 
the long-term damage is related to the accumulation of excitatory mediators such as glutamate 
at synaptic levels as occurs when NMDAR-antagonists are administered to normal animals. 
Indeed, patients’ CSFs and purified IgGs resulted in an acute increase of both glutamate levels 
and the excitability of the motor cortex in a rat model (Manto M et al. 2010). It is worth noting 
that in experimental animal studies, NMDAR-antagonists are able to produce reversible or 
irreversible effects depending on the dosage and duration of the administration (Newcomer JW 
et al. 2000). 
 
1.5.4 LGI1 antibody related syndromes 
After the discovery that VGKC antibodies were associated with some cases of NMT, their 
presence was also identified in patients with CNS diseases (Buckley C et al. 2001; Vincent A. 
et al. 2004). It was subsequently found that the ‘VGKC’ autoantibodies actually bound to 
contactin-associated protein 2 (CASPR2) or LGI1 (Irani SR et al. 2010; Lai M et al. 2010); 
both of these proteins co-precipitate with the Kv1 subunits, which explains why the 
autoantibodies were able to precipitate the dendrotoxin-labelled VGKCs.  
Autoantibodies to LGI1 (LGI1-Abs) are the most common autoantibody in patients with 
limbic encephalitis (LE), a clinical syndrome characterised by the acute development of mood 
changes, anxiety, short term memory deficit and seizures due to an inflammatory process 
involving the limbic system that includes the medial temporal lobes, hippocampus, amygdala, 
and fronto-basal and cingulate cortices (Graus F et al. 2016). LGI1-Ab encephalitis 
preferentially affects elderly patients (median age 60 years) with a male predominance (Irani 
SR et al. 2010; Lai M et al. 2010). Most patients do not have cancer (5% have thymoma). 
 The onset of an overt limbic dysfunction can be preceded by episodes of facio-brachial 
or crural seizures that last a few seconds and occur many times during the day; these episodes 
have been described as facio-brachial dystonic seizures (FBDS) (Irani SR et al. 2011; Irani SR 
et al. 2013). MRI studies show basal ganglia hyperintensity in 42% of patients with this type of 
seizure, suggesting a basal ganglia contribution (Flanagan EP et al. 2015). About 70% of the 
patients show substantial neurological improvement after immunotherapy, but only 35% are 
able to return to their baseline cognitive function. Clinical relapses occur in 24–35% of the 






Pathogenic mechanism of LGI1 antibodies  
LGI1 mutations have been associated with an autosomal dominant lateral temporal lobe 
epilepsy manifesting often with auditory features (Kalachikov S et al. 2002), and epilepsy is 
also one of the features of the autoimmune encephalopathy associated with LGI1-Abs. 
However, the autoimmune form of epilepsy in this case is characterised by contractions of 
homolateral face, arm and sometimes leg, known as FBDS, whereas auditory seizures are rare 
(Irani SR et al. 2011). LGI1 antibodies are predominantly IgG4. Since these antibodies do not 
fix complement and are less effective than IgG1 in crosslinking and internalising the target 
antigen, they are thought to affect their targets by interference with protein-protein interactions. 
LGI1 is a protein secreted by the presynaptic terminals of neurons. This protein binds 
to ADAM22 and ADAM33, two proteins involved in cell-cell adhesion and located post-
synaptically and pre-synaptically respectively. LGI1 forms a bridge between these two proteins 
establishing a physical contact between the pre- and the post-synapse which is believed to play 
an important role in synaptic maturation (Fukata Y et al. 2006; Owuor K et al. 2009). Binding 
to ADAM22, LGI1 regulates AMPA receptor-mediated synaptic currents in the hippocampus. 
Binding to ADAM23, LGI1 selectively prevents inactivation of the presynaptic voltage-gated 
potassium channel Kv1.1 mediated by a cytoplasmic regulatory protein, Kvβ (Schulte U et al. 
2006).  
LGI1 antibodies disrupt the ligand-receptor interaction of LGI1 with ADAM22, 
resulting in reversible reduction in synaptic AMPARs in cultured hippocampal neurons 
(Ohkawa T et al. 2013) (Figure 1.5). This observation, along with the presence of the antibodies 
in the CSF and the good response to immunotherapy support a pathogenic role of these 
antibodies. Indeed, their pathogenicity has been recently confirmed by a passive transfer animal 
model which showed severe memory impairment, but not seizures, in LGI1-Ab injected mice 
(Petit-Pedrol M et al. 2018). Moreover, LGI1-Abs have been detected in the sera of cats with a 
spontaneous form of autoimmune encephalitis with complex partial seizures with orofacial 
involvement. Postmortem analysis in these cases, showed complement deposition, a feature 
also shared by post-mortem examination of the small number of available brains from patients 
with LGI1-related encephalitis (Klang A et al. 2014). The finding of complement deposition 
suggests that LGI1-Abs are able to induce neuronal death through complement activation which 
may explain why, despite a good response to immunotherapy, only 35% of patients return to 
their baseline cognitive function (Ariño H et al 2016). This appears to be inconsistent with the 
observation that LGI1-Abs belong to the IgG4 subclass, which is classically considered unable 






LGI1 interacts with presynaptic ADAM23 and postsynaptic ADAM22 organizing 
a trans-synaptic protein complex that includes presynaptic Kv1.1 potassium 
channels and postsynaptic AMPA receptors. LGI1-Abs interfere with the normal 
interactions of LGI1 probably decreasing the levels of the postsynaptic AMPA 
receptors and altering the function of the presynaptic Kv1 channels, leading to 
increased neuronal excitability (adapted from Van Sonderen A, Petit-Pedrol M et 
al. 2017).  
 
 





the relatively small, but more pathogenic, IgG1 antibodies that are present in patients with 
limbic encephalitis (Irani SR et al. 2010; Thompson J et al. 2018).   
 
1.5.5 CASPR2 antibody related syndromes 
CASPR2 is one of the targets within the complex of proteins that includes the voltage-gated 
potassium channels (VGKCs). CASPR2 antibodies (CASPR2-Abs) have been associated with 
CNS symptoms including cognitive impairment, memory loss, hallucinations, delusions, 
cerebellar symptoms and epilepsy as well with peripheral nerve involvement with pain, 
neuropathy and hyperexcitability causing neuromyotonia (NMT). Some patients present with 
Morvan Syndrome (MoS), characterised by the combination of neuromyotonia, neuropathic 
pain, encephalopathy with hallucinations, and a characteristic sleep disorder described as 
agrypnia excitata (Liguori R et al. 2001; Provini F et al. 2011). This term (agrypnia - loss of 
sleep; excitata - increased motor activity and restlessness) was developed to describe the sleep 
disturbances that occur in several pathogenically unrelated diseases such as fatal familial 
insomnia (a prion disease) or delirium tremens (Montagna P and Lugaresi E, 2002). Patients 
with agrypnia excitata have severe insomnia, dream-like stupor (hallucinations and enacted 
dreams), sympathetic hyperactivity (hyperthermia, perspiration, tachypnea, tachycardia, and 
hypertension), and motor agitation. Key neurophysiological features include the loss of slow-
wave sleep, which represents the transitional process of falling asleep, and the presence of 
abnormal REM sleep without atonia in the antigravity muscles (Montagna P and Lugaresi E, 
2002).  
Approximately 20% of patients with CASPR2-Ab associated symptoms have an 
underlying thymoma (Vincent A and Irani SR, 2010; Irani SR et al. 2010; Irani SR et al. 2012; 
Van Sonderen A, Arino H et al. 2016). Immunotherapy and treatment of the tumour (when 
appropriate) resulted in improvement in 93% of the patients, but 25% had relapses (Van 
Sonderen A, Arino H et al. 2016).  
Pathogenic mechanisms of CASPR2-Abs 
CASPR2 is a neurexin-related cell adhesion molecule expressed in the central and peripheral 
nervous system and CASPR2-Abs react with both the brain and peripheral nerve tissues (Irani 
SR et al. 2010). CASPR2 is essential for clustering Kv1.1 and Kv1.2 at the juxtaparanodes of 
myelinated axons (Figure 1.6). These channels are important for repolarisation of the nerve 







CASPR2 localises at the juxtaparanode of myelinated axons. CASPR2 binds to 
contactin-2/TAG-1 via its extracellular domain and links to PDZ-binding proteins, and 
to the cytoskeleton via protein 4.1B, stabilizing Kv1 channels (from Giannoccaro MP 
et al. 2018). 
 




 For CASPR2-Abs the mechanisms of action are still largely unclear. CASPR2-Abs are 
mainly IgG4, and therefore the most likely common mechanism of their action is a disruption 
of the interaction of CASPR2 with its associated molecules rather than internalisation and 
complement activation which are typical of IgG1, 2 and 3 antibodies. Accordingly, a recent 
study showed that CASPR2-Abs do not reduce CASPR2 expression on the surface of cultured 
hippocampal neurons, but they appeared to act by altering CASPR2 interaction with contactin-
2 (Patterson KR et al. 2018). However, these findings contrasted with the pathology in a case 
showing reduced CASPR2 expression in the brain (Sundal C et al. 2017) and with two 
pathological cases associated with the presence of complement deposition (Liguori R et al. 
2001; Kortvelyessy P et al. 2015). These discrepancies might be related to several factors; in 
particular, IgG1 CASPR2 antibodies are present in many of the patients, and may be responsible 
for complement mediated neuronal loss, and different antibody levels may explain some of the 
limitations of the in vitro studies, which only partially reproduce the variety of mechanisms 
involved in vivo. 
How CASPR2-Abs produce the CNS symptoms is still largely unknown. CASPR2 is 
expressed throughout the brain as well as at the juxtaparanodes of motor and sensory axons 
(Figure 1.6). CASPR2-Abs have been described in association with several different disorders 
ranging from cerebellar ataxia to a wide range of movement disorder. Such a broad spectrum 
of presentations could be related to difference in epitope specificity, antibody titres and or the 
site of antibody production. A recent study showed that CASPR2-Abs can bind to different 
epitopes, although the majority reacted against the first extracellular discoidin domain. No 
correlation of antibody specificity with the phenotype was made (Olsen Al et al. 2015). One 
study found CASPR2-Abs in the CSF and serum in patients with autoimmune encephalitis, 
whereas they were detected only in the serum in patients with NMT or MoS (Joubert B et al. 
2016). The highest antibody titres appear to be specific for LE, MoS and ataxia (Bien CG et al. 
2017), and CASPR2 antibodies are usually low in patients with neuromyotonia, explaining why 
they might not have been detected in the CSF.   
 A study, using cultured hippocampal neurons, showed that serum IgGs targeted 
inhibitory interneurons where they reduced the number of synaptic gephyrin clusters (Pinatel 
D et al. 2015) which anchors GABAA receptors. More recently, however, treatment of cultured 
dorsal root ganglia (DRG) neurons with CASPR2-Abs caused a reduction in Kv1 channel 
surface expression and consequent neuronal hyperexcitability (Dawes JM et al. 2018). The 




injections showing that these antibodies are able to cause mechanical-pain hypersensitivity in 
the exposed mice. However, the effects on the CNS were not investigated.  
 Interestingly, mutations in the CNTNAP2 gene, encoding for CASPR2, are associated 
with focal epilepsy, schizophrenia and autism spectrum disorder (Friedman JI et al. 2008). Two 
recent studies using a maternal-fetal transfer model showed that the offspring of dams injected 
with CASPR2-Abs demonstrated behavioural disorders and neuropathological features 
(Brimberg L et al. 2016; Coutinho E et al. 2017) raising interesting questions about the role of 
these antibodies in neurodevelopment disorders. 
 
1.5.6 GABAA receptor antibody related syndromes 
Autoantibodies to the GABAA receptor (GABAAR) were first reported in some patients with 
AE characterised by encephalitis, prominent seizures or status epilepticus, and multifocal MRI 
abnormalities (Ohkawa T et al. 2014; Petit-Pedrol M et al. 2014). They were then found in 
patients with a wider spectrum of disorders (Pettingill P et al. 2015; Spatola M et al. 2017) such 
as focal neurological signs, hemiparesis, dyskinesias, aphasia or oculomotor disturbances. CSF 
findings are variable and abnormal in most cases and include pleocytosis, elevated protein 
concentration, or oligoclonal bands (Petit-Pedrol M et al. 2014). Coexistence of other 
autoantibodies occurs in some patients including thyroid peroxidase (TPO), GAD65, and 
GABAB receptor antibodies (Ohkawa T et al. 2014; Petit-Pedrol M et al. 2014). Approximately 
75% of the patients develop multifocal FLAIR and T2 hyperintense MRI abnormalities 
involving various cortical and subcortical brain regions (Spatola M et al. 2017). This finding 
provides a clue towards the identity of the disorder. Approximately 30% of the patients have 
an underlying tumour, mainly a thymoma; older patients are more likely to have a tumour than 
younger patients (Spatola M et al. 2017). Treatment with anticonvulsants is frequently 
ineffective, and pharmacologically induced coma can be necessary to control seizure activity. 
In a recent review of all reported cases, 86% of the patients improved with immunotherapy and 
the other 14% died of status epilepticus or secondary medical complications (Spatola M et al. 
2017).  
Pathogenic mechanisms of GABAA -Abs 
The GABAA receptor is a ligand-gated ion channel that mediates the majority of fast inhibitory 
transmission in the brain (Macdonald RL and Olsen RW, 1994). GABAARs are 




with autoantibodies against the GABAAR, the predominant targets are α1 and β3, and less 
frequently the subunit 𝛾2 (Petit-Pedrol M et al. 2014; Pettingill P et al. 2015; Spatola M et al. 
2017). In cultured primary neurons, application of patients’ antibodies led to a reduction of 
synaptic and extrasynaptic density of GABAAR receptors (Ohkawa T et al. 2014; Petit-Pedrol 
M et al. 2014; Pettengill P et al. 2015). Animal models have not yet been reported. 
 
1.5.7 GABAB receptor antibody related syndromes 
Antibodies against the GABAB receptor (GABABR) associate with LE accompanied by 
prominent seizures or status epilepticus, with 50% of patients having an underlying SCLC 
(Hoftberger R et al.  2013; Lancaster E et al. 2010; Jain A et al. 2015). Most patients have 
complete or substantial neurological improvement after immunotherapy and tumour therapy 
when needed. The neurological outcome is similar in patients with or without tumour, but the 
long-term prognosis is dictated by the presence of SCLC and cancer recurrence.  
 
Pathogenic mechanism of GABABR-Abs 
The GABABR is a G protein-coupled receptor for the inhibitory neurotransmitter GABA. The 
receptors are heterodimers comprised of two subunits, GABA-B1 and GABA-B2, which are 
both necessary for receptor function (Bettler B et al. 2004). GABA-B1 binds GABA with its 
extracellular domain, and GABA-B2 activates G proteins intracellularly.  
GABABR autoantibodies bind the extracellular domain of the GABA-B1 subunit (Lancaster E 
et al. 2010). The potential pathogenic effects of patients’ autoantibodies were recently 
examined using cultured rat hippocampal neurons. In culture, neurons develop numerous 
synapses and spontaneously produce synaptic currents and actions potentials. This electrical 
activity is attenuated by the application of the GABABR agonist baclofen. Application of 
patients’ autoantibodies did not modify the levels of cell surface or synaptic receptors but 
abrogated the effects of baclofen on culture excitability, suggesting that GABABR-Abs may 
directly block the function of the receptor (Jain A et al. 2015). Although the exact mechanism 
whereby antibodies block GABABR function is unknown, the findings provide a plausible 
explanation for the extremely common seizures and life-threatening status epilepticus seen in 







1.5.8 AMPA receptor antibody related syndromes 
Most patients with AMPAR-Abs develop a typical LE, 40% of them showing additional 
symptoms beyond the limbic system, and only a few patients presenting with a different 
syndrome, such as rapidly progressive dementia or psychosis (Hoftberger R et al. 2015; Lai M 
et al. 2009). About 70% of the patients have an underlying tumour including SCLC, thymoma, 
ovarian or breast cancer, or teratoma. Approximately 70% of the patients respond to 
immunotherapy or treatment of the tumour, most showing a partial neurological response. 
Patients who do not receive aggressive immunotherapy are more likely to have clinical relapses. 
The presence of concurrent paraneoplastic antibodies was found associated with additional 
symptoms and a poor prognosis (Hoftberger R, et al. 2015).  
 
Pathogenic mechanisms of AMPAR-Abs 
The AMPA receptor is an ionotropic glutamate receptor that mediates most of the fast- 
excitatory transmission in the brain (Shepherd JD and Huganir RL, 2007). The majority of 
AMPA receptors are tetramers composed of GluA1, 2, 3, or 4 subunits that combine in a brain 
region-dependent manner (Palmer CL et al. 2005). The highest levels of GluA1/2 and GluA2/3 
receptors are found in the hippocampus, subiculum, cerebellum, caudate-putamen, and cerebral 
cortex (Sprengel R, 2006). The AMPAR-Abs are directed against extracellular epitopes of the 
GluA1 or GluA2 subunits (Lai M et al. 2009). Preincubation of cultured rodent neurons with 
patients’ IgG to either GluA1 or GluA2 led to a decrease of synaptic clusters of AMPA receptor 
subunits and to a reduction of fluorescence intensity of the remaining AMPA receptor clusters 
(Lai M et al. 2009; Peng X et al. 2015). As a result, frequency and peak amplitude of AMPA 
receptor-mediated miniature excitatory postsynaptic currents (mEPSC) were reduced in 
primary neurons following incubation with antibodies to the GluA1 and GluA2 receptor subunit 
(Lai M et al. 2009; Peng X et al. 2015). These preliminary findings point toward a direct 
pathogenic effect of patients’ AMPA receptor autoantibodies on synaptic function, but the 
evidence is sparse and animal models have not been developed. 
1.5.9 GlyR antibody related syndromes  
Antibodies against the glycine receptor (GlyR-Abs) have been described in patients with stiff-
person syndrome (SPS) and with progressive encephalitis with rigidity and myoclonus 
(PERM). SPS is characterised by muscle stiffness, rigidity, and painful spams predominantly 




spontaneous or triggered by movement or sensory (tactile, auditory) and emotional stimuli. 
Patients with SPS have a normal brain and spinal MRI, and the CSF is often normal except for 
the presence of oligoclonal bands in 35% of the patients (Saiz A et al. 2008). PERM has a more 
aggressive clinical course compared with SPS. In addition to encephalomyelitis with rigidity 
and myoclonus, other symptoms include sensory problems (pruritus and neuropathic pain), 
brainstem dysfunction (nystagmus, ophthalmoparesis, dysphagia, trismus), and dysautonomia 
(profuse sweating, dry mouth, bladder dysfunction). Brain and spinal MRI are usually normal, 
but the CSF frequently shows pleocytosis (Carvajal-González A et al. 2014).  
 
Pathogenic mechanisms of GlyR-Abs  
Glycine receptors (GlyRs) are pentameric proteins belonging to the superfamily of ligand gated 
ion channels. These receptors can exist as α1-4 subunits homers or as heteromers consisting of 
α and β subunits. The different α subunits are differentially expressed in the CNS and the 
binding of autoantibodies to these different subunits could explain the range of spinal cord and 
brainstem symptoms observed in individuals with GlyR autoantibodies (GlyR-Abs). However, 
a recent study showed that the majority of sera from GlyR-Ab positive patients bind to α1β 
heteromers, and no correlation between different subunit binding affinities and clinical 
phenotype was found (Carvajal-González A et al. 2014). 
Under physiological condition, glycine-mediated activation of the GlyR leads to an 
influx of Cl- into the neurons and results in hyperpolarisation of the membrane potential with 
consequent reduced excitation (Legendre P, 2001). Indeed, incubation of HEK293 cells 
expressing GlyRs with IgG derived from individuals with GlyR-Abs resulted in internalisation 
and targeting of the receptors to lysosomes. Therefore, if a similar response occurs in vivo, the 
expected reduced glycinergic neurotransmission may explain the symptoms seen in patients 
with PERM.  
1.5.10 GAD antibody syndromes  
 
Highly raised antibodies against glutamic acid decarboxylase 65 (GAD-65) have been detected 
in 60-100% of patients with SPS (Costa M et al. 2002; Chang T, Alexopoulos H, McMenamin 
M et al. 2013) and at much lower titres in 80% of newly diagnosed type 1 diabetes mellitus 
(Baekkeskov S et al. 1990). GAD antibodies have also been detected in some patients with 
subacute cerebellar ataxia (Honnorat J et al. 1995; Saiz A et al. 1997; Abele M et al. 1999) and 




Pathogenic mechanisms of GAD-Abs 
GAD65 is a rate-limiting enzyme of GABA synthesis. Despite being an intracellular antigen, it 
is still unclear if these antibodies paly a pathogenic role. A loss of GAD activity may lead to 
decreased GABA synthesis and a reduction in inhibitory interneuron activity, resulting in 
hyperexcitability and epileptiform activity. However, it is not clear how the GAD antibodies 
can exert this effect on an intracellular enzyme. Specific and distinct staining of hippocampal 
neurons by sera from GAD-positive patients with drug-resistant epilepsy, ataxia and SPS has 
been demonstrated (Vianello M et al. 2006) and implies that the sera may contain additional 
specificities. In vitro studies have suggested that IgG from GAD-positive patients can be 
pathogenic, selectively suppressing GABA-mediated transmission on cerebellar Purkinje cells 
(Mitoma H et al. 2000), and a few patients have responded to IvIg treatment (Abele M et al. 
1999). It is unclear whether the pathogenicity lies in the GAD antibodies or in an additional 
unidentified antibody. The immunisation of experimental animals with GAD65 resulted in the 
production of antibodies that immunoprecipitated GAD and bound to GAD intracellularly but 
also to the surface of cerebellar neurons in culture. Immunised animals did not show any 
behavioral abnormality, but they showed immunoglobulin diffusion into the brainstem, and a 
partial loss of GAD-EGFP expressing GABAergic neurons in the brainstem, suggesting the 
possible existence of a humoral response to antigen expressed on the surface of these neurons 
(Chang T et al. 2013).    
 
1.5.11 Proposed criteria for the diagnosis of autoimmune encephalitis 
 
Until a few years ago, the most common cause of acute encephalitis was considered to be 
infectious. However, with the discovery of so many new antibody targets, it has become clear 
that autoimmune encephalitis is more common than previously thought. Given the importance 
of an early treatment in determining patients’ outcome however, it is clear that a prompt 
diagnosis cannot rely solely on the presence of antibodies. Moreover, despite the increasingly 
large number of targets, some CSF and sera are negative for known antibodies (“seronegative” 
autoimmune encephalitis). Recently a Consensus paper established guidelines to help the 
clinician in the early identification and treatment of patients with suspected autoimmune 
etiology (Graus F et al. 2016). 
A patient with new onset encephalitis should be considered as having a possible 
autoimmune encephalitis if all three of the criteria shown in Table 1.3 are met. Of course, this 




Table 1. 3 Diagnostic criteria of possible autoimmune encephalitis 
The diagnosis of POSSIBLE autoimmune encephalitis can be made if all the following 
criteria are met:  
1)  Subacute onset (rapid progression of less than 3 months) of working memory deficits 
(short term memory loss), altered mental status (defined as decreased or altered level of 
consciousness, lethargy, or personality change), or psychiatric symptoms; 
2)  At least one of the following: 
·      New focal CNS findings 
·      Seizures not explained by a previously known seizure disorder 
·      CSF pleocytosis (white cell count of more than five cells per mm3) 
·      MRI features suggestive of encephalitis (hyperintense signal in T2-weighted fluid 
attenuated inversion recovery sequences highly restricted to one or both medial temporal 
lobes, or in multifocal areas involving grey matter, white matter or both compatible with 
demyelination or inflammation) 
3)  Reasonable exclusion of other causes. 
 





Drug toxicity (including use of illicit drugs, direct neurotoxic effects of prescribed drugs or 
through induction of seizures, posterior reversible encephalopathy, idiosyncratic reaction, 



















to these guidelines, the diagnosis of definite autoimmune limbic encephalitis can be made when 
all four criteria listed in Table 1.5 are met. If one of the first three criteria is not met, a diagnosis 
of definite LE can be made with the detection of antibodies against cell-surface, synaptic, or 
onconeural proteins. Finally, if antibodies are negative, the diagnosis of autoantibody negative 
but probable autoimmune encephalitis can be made when all four of the criteria listed in Table 
1.6 have been met. 
1.6 NSA-Abs in “discrete” neurological disorders 
 
After the discovery of the NSA-Abs and their report in the classical syndromes described above, 
an increasing number of studies investigated the presence of these or other antibodies in 
neurological and psychiatric disorders, either because their presentation might involve some of 
the symptoms observed in autoimmune encephalopathies, or because their subacute onset and 
clinical course suggested an autoimmune etiology. The significance of these findings is still 
often unclear, but it has been suggested that these cases may represent a less severe form of 
limbic encephalitis.  
 
1.6.1 NSA-Abs in epilepsy 
 
Seizures are frequently observed in patients with NSA-Abs either in the course of the disease 
either at onset, and sometimes they represent the main clinical feature. Although the 
mechanisms of seizures in AE are unclear, the pathogenic role of the antibodies is likely.  
More recently, however, these antibodies have been reported also in unselected patients 
with recent onset and chronic forms of isolated epilepsies. McKnight et al. compared 139 
epilepsy patients, composed of 26 patients with definite concomitant autoimmune disorders 
(systemic lupus erythematosus, Hashimoto’s encephalopathy, antiphospholipid syndrome, 
etc.), 46 patients with suspected concomitant autoimmune disorders, and 67 patients with solely 
drug resistant epilepsy, to a control group of 150 patients. They reported VGKC complex 
antibodies in 11.5 % of the patients with epilepsy, spread across all 3 patient populations, vs 
0.5 % of the control subjects, as well as GAD65 antibodies in 3.6 % of the epilepsy patients 
and none of the controls. Among the group with VGKC-complex antibodies, 6 patients 
presented with a short duration of seizures and five of them were treated with immunotherapy 
and had a good response. By contrast, GAD65-positive patients presented with a long history 




Table 1. 5 Diagnostic criteria for defined limbic encephalitis 
The diagnosis of DEFINED limbic encephalitis can be made if all the following criteria 
are met:  
1) Subacute onset (rapid progression of less than 3 months) of working memory deficits, 
seizures, or psychiatric symptoms suggesting involvement of the limbic system; 
2) Bilateral brain abnormalities on T2-weighted fluid-attenuated inversion recovery MRI 
highly restricted to the medial temporal lobes (18Fluorodeoxyglucose (18F-FDG) PET can be 
used to fulfil this criterion); 
3) At least one of the following: 
• CSF pleocytosis;  
• EEG with epileptic or slow-wave activity involving the temporal lobes;  
4)  Reasonable exclusion of other causes (see table 1.4). 
 
Table 1. 6 Diagnostic criteria for possible autoimmune encephalitis 
The diagnosis of PROBABLE autoimmune encephalitis can be made if all the following 
criteria are met:  
1) Rapid progression (less than 3 months) of working memory deficits (short-term memory 
loss), altered mental status, psychiatric symptoms; 
2) Exclusion of well-defined syndromes od autoimmune encephalitis (e.g., typical limbic 
encephalitis, Bickerstaff’s brainstem encephalitis, acute disseminated encephalomyelitis)  
3) Absence of well characterised autoantibodies in serum and CSF, and at least two of the 
following criteria: 
• MRI abnormalities suggestive of autoimmune encephalitis; 
• CSF pleocytosis, CSF specific oligoclonal bands or elevated CSF IgG index, or both; 
• Brain biopsy showing inflammatory infiltrates and excluding other disorders (i.e. Tumour). 





Another study of 106 female patients with chronic epilepsy found VGKC-complex 
antibodies in 6.5% of the subjects. Only one patient was positive for voltage gated calcium 
channel (VGCC) and none for GAD65. Seizures were mainly generalised tonic-clonic (GTCS) 
and MRIs were normal in patients with VGKC-complex antibodies (Majoie HJ et al. 2006).  
Quek et al. retrospectively investigated 32 patients with refractory epilepsy and a 
suspected autoimmune aetiology, and found 18 with VGKC-complex antibodies, 7 with 
GAD65-antibodies, and one patient with NMDAR-antibodies. In this study, 81% of patients 
improved after immunotherapy, with 67% achieving seizure freedom within a period of 10 
months (Quek AM et al. 2012). Overall, patients with autoantibodies often had frequent, 
antiepileptic drug (AED)-refractory seizures with neuropsychiatric comorbidities.  
Another study, found 5 NMDAR antibody positive patients and 3 GAD65 antibody 
positive patients in a group of 19 female patients with new onset unexplained epilepsy 
(Niehusmann P et al. 2009). Brenner et al. reported the presence of neuronal antibodies in 46 
of 416 adult patients with epilepsy (11%). Among those patients, 21 (5%) had VGKC-complex 
Abs, 12 (3%) had GlyR-Abs, 7 (1.7%) had GAD65-Abs, and 7 (1.7%) had NMDAR-Abs 
(Brenner T et al. 2013). The presence of GlyR-Abs is of interest as these antibodies are usually 
associated with a completely different phenotype.  
Many of these studies have two particular limitations: 1) they are retrospective and 2) 
they include patients with suspected autoimmune etiology. To determine the prevalence of 
NSA-Abs associated with immune-mediated epilepsy, Dubey et al (2017) enrolled 112 
consecutive patients with epilepsy of unknown etiology. Serum Abs suggesting a potential 
autoimmune etiology were detected in 39 (34.8%) cases; 15 (13.4%) had thyroid peroxidase 
(TPO)-Ab, 14 (12.5%) had GAD65-Ab, 12 (10.7%) had VGKC-complex Ab (4 of whom were 
positive for LGI1-Ab), and 4 (3.6%) had NMDAR-Ab. The presence of GlyR-Abs was not 
investigated. More than one Ab was detected in 7 patients (6.3%): 3 (2.7%) had TPO-Ab and 
VGKC-complex Abs, 2 (1.8%) had GAD65-Ab and VGKC-complex Ab, 1 had TPO-Ab and 
GAD65-Ab, and 1 had Hu Ab and GAD65-Ab. Thirty-two patients (28.6%) had a single Ab 
marker. Even after excluding TPO-Ab and low-titre GAD65-Ab, Abs strongly suggesting an 
autoimmune cause of epilepsy were seen in 23 patients (20.5%). Certain clinical features, such 
as autonomic dysfunction, neuropsychiatric changes, viral prodrome, facio-brachial dystonic 
spells or facial dyskinesias, and mesial temporal sclerosis abnormality on magnetic resonance 
imaging, correlated with seropositivity (Dubey D et al. 2017). In patients who were 





 In another consecutive series, including 111 patients with mesial temporal lobe 
epilepsy with hippocampal sclerosis (MTLE-HS), 30 healthy volunteers and 50 patients with 
relapsing remitting multiple sclerosis, antibodies against CASPR2 were found in 11 patients, 
uncharacterised VGKC-complex antibodies in four patients, GlyR-Abs in 5 patients, NMDAR-
Abs in 4 patients and GABAAR in 1 patient; these antibodies were not found in controls. The 
history of status epilepticus, diagnosis of psychosis and positron emission tomography or 
single-photon emission computer tomography findings in temporal plus extratemporal regions 
were found significantly more frequently in the seropositive group (Vanli-Yavuz EN et al. 
2016). 
 A few studies investigated the presence of NSA-Abs in children with various forms 
of epilepsy, with a frequency of positivity around 10% (Dhamija R et al. 2011; Suleiman J et 
al. 2011; Suleiman J, Brilot F et al. 2013; Suleiman J et al. 2013; Wright S et al. 2016). 
Interestingly, Wright S et al. (2016) found neuronal antibodies at low levels in 9.5% of 178 
patients with new-onset pediatric epilepsy. However, these antibodies did not necessarily 
persist over time, and the development of antibodies de novo in later samples suggests they 
could be due to a secondary response to neuronal damage or inflammation.  
 Overall, these data suggest that these antibodies are present in increased numbers in 
the general epilepsy population, even when these patients do not present as typical limbic 
encephalitis. In those patients with a more abrupt onset of seizures, multiple studies provide 
consistent observational evidence to suggest a preferential response to immunotherapy over 
AEDs (Quek AM et al. 2012; Toledano M et al. 2014; Dubey D et al. 2017). However, the 
results of these studies are not conclusive and there are still unanswered questions such as the 
pathogenic role of the antibodies, the optimal methods used to identify patients with epilepsy 
and autoantibodies, and the rationale for immunotherapy. 
1.6.2 NSA-Ab in degenerative disorders 
 
Many NSA-Ab related syndromes associate with cognitive impairment and sometimes this is 
the first and prevalent manifestation. Case series have demonstrated that progressive dementia 
without delirium may represent an autoimmune neurological disorder (Geschwind MD et al. 
2008; McKeon A et al. 2007). Given the fact that these are potentially treatable disorders, 
several studies tried to identify the main features associated with an “autoimmune dementia”. 
These have been classically defined as: 1) subacute onset with a rapidly progressive course; 2) 




suggestive of an inflammatory process (McKeon A et al. 2010; Castillo P et al. 2006; 
Geschwind MD et al. 2008; McKeon A et al. 2007).  
In a setting when an autoimmune etiology for the dementia is strongly suspected, 
Flanagan et al. reported the presence of autoantibodies targeting the VGKC complex in 15% of 
cases. In the same cohort, 64% of cases responded to immunotherapy. A shorter delay from 
symptom onset to initiation of therapy for autoimmune dementia increased the likelihood of 
response (Flanagan EP et al. 2010). However, 41% of immunotherapy-responsive dementia 
patients had normal brain MRIs, and many patients showed normal CSF and EEG; almost 9% 
of the disorders had been initially diagnosed as Creutzfeldt-Jakob disease (CJD) (Flanagan EP 
et al. 2010).  
Despite the clear existence of cases of immunotherapy-responsive dementia associated 
with NSA-Ab, the presence of several neuronal antibodies has been reported in patients with 
ascertained prion disease (Mackay G et al. 2012; Fujita K et al. 2012; Angus-Leppan H et al. 
2013; Fujita K, Yuasa T, Takahashi Y et al. 2012; Rossi M et al. 2015), challenging the 
significance of this finding and further complicating this diagnostic dilemma in cases with more 
chronic presentations. In another study, 6.4% of patients with suspected CJD had autopsy 
findings of potentially treatable diseases, with immune-mediated disorders being the most 
frequent (Chitravas N et al. 2011). In a large cohort of 346 patients with suspected CJD 1.7% 
showed the presence of NSA-Ab in CSF versus none of 49 patients with definite CJD. The 
target antigens included CASPR2, LGI1, NMDAR, aquaporin 4 (AQ4), Tr (DNER [δ/notch-
like epidermal growth factor–related receptor]), and an unknown protein. All patients improved 
or stabilized after appropriate treatment (Grau-Rivera O et al. 2014). Indeed, most patients with 
well diagnosed CJD do not have these antibodies (Rossi M et al. 2015). 
However, not all patients with antibody-mediated dementia present with a rapidly 
evolving clinical picture. Autoimmune-mediated cognitive decline can progress slowly over 
many months, and therefore may be mistaken for a primary neurodegenerative disorder such as 
Alzheimer’s disease (AD) or frontotemporal dementia (FTD) (Castillo P et al. 2006; Geschwind 
MD et al. 2008; McKeon A et al. 2007). To explore the prevalence of NSA-Ab in patients with 
defined primary dementias, Coban A et al. (2004) investigated 50 patients finding NMDAR 
antibodies in one case presenting with dementia with Lewy body (DLB) phenotype. Despite 
the fact that this patient had some features suggestive of an autoimmune etiology, the presence 
of atypical features in the remaining cases failed to predict the presence of an NSA-Ab, 




The presence of NMDAR antibodies of the IgA isotype was initially described in a small 
cohort of patients with atypical dementia. A subgroup of positive patients partially responded 
to immunotherapy (Pruss H et al. 2012). Purified IgA containing NMDAR IgA antibodies 
caused substantial loss of NMDARs and further synaptic proteins in primary hippocampal 
cultures, resulting in marked changes of NMDAR-mediated currents (Pruss H et al. 2012). 
These results were further explored in a large series of 660 cases including different 
neurological disorders and controls.  Serum NMDAR antibodies of IgM, IgA, or IgG subtypes 
were detected in 16.1% of 286 dementia patients and in 2.8% of 217 cognitively healthy 
controls. Higher prevalence of serum antibodies was detected in patients with “unclassified 
dementia” followed by progressive supranuclear palsy (PSP), corticobasal syndrome (CBD), 
Parkinson’s disease-related dementia (PDD), and primary progressive aphasia (PPA). Among 
the unclassified dementia group, 60% of 20 patients had NMDAR antibodies, accompanied by 
higher frequency of CSF abnormalities, and subacute or fluctuating disease progression. 
Immunotherapy in selected prospective cases resulted in clinical stabilisation, loss of 
antibodies, and improvement of functional imaging parameters. Epitope mapping showed 
varied determinants in patients with NMDAR IgA-associated cognitive decline. However, 
antibodies were rarely found in CSF (Doss S et al. 2014), and therefore their role in the clinical 
manifestations is unclear. 
As emerged from this and other reports, not only dementias but also other 
neurodegenerative disease, mainly presenting with movement disorders, can be associated with 
the presence of NSA-Ab. Patients with LGI1, IgLON5, DPPX and GAD65 antibodies have 
been misdiagnosed with Parkinson’s disease, PSP or multisystem atrophy (MSA) (Pittock S et 
al. 2006; Tobin W et al. 2014; Kurtis MM et al. 2015; Sabater L et al. 2014; Kannoth S et al. 
2015). However, the prevalence of NSA-Ab in a population of patients with a diagnosis of 
parkinsonism has not yet been reported. REM sleep behavior disorder (RBD) is associated with 
neurodegeneration and can anticipate by decades the onset of a neurodegenerative disease, in 
particular MSA and PD. RBD has been reported in patients with LGI1-antibody-associated 
limbic encephalitis (Iranzo A et al. 2006; Irani SR et al. 2010) and with IgLON5-antibody 
linked neurodegeneration (Sabater L et al. 2014). Finally, status dissociatus, a complete 
breakdown of the boundaries of the different states of being, which are wakefulness, REM 
sleep, and non-REM sleep, with motor hyperactivity, which may be observed in the final phase 
of several different neurodegenerative disorders, has also been reported in patients with 




Abgrall G et al. 2015), widening the overlap between neurodegenerative and autoimmune 
conditions. 
Finally, the question of the relation between antibodies and neurodegeneration is made 
more complex by the description of IgLON5 antibodies. These were firstly described in a small 
group of patients with prominent sleep-related movement disorders, mainly characterised by a 
non-REM sleep parasomnia with simple or finalistic movements, resembling daytime activities 
such as eating, drinking or manipulating objects. Other sleep abnormalities included RBD and 
periodic limb movements of sleep. Breathing disorders, including obstructive sleep apnea 
(OSAS) and stridor, both in sleep and wakefulness, are almost a constant feature and are often 
associated with respiratory failure. Other clinical manifestations include ataxia, bulbar signs, 
abnormal eyes movements and dysautonomia (Sabater L et al. 2014). Over time other clinical 
manifestations were reported including dementia and chorea (Simabukuro MM et al. 2015; 
Brüggemann N et al. 2016; Haitao R et al. 2016). In the first case series, all eight patients 
reported received immunotherapy, but six of them died during the follow-up period (Sabater L 
et al. 2014). To date more than 60 patients have been reported and response to immunotherapy 
seems to occur in certain cases and to some extent (Bonello M et al. 2017; Simabukuro MM et 
al. 2015; Brüggemann N et al. 2016; Haitao R et al. 2016; Honorat JA et al. 2017; Montagna 
M et al. 2108). However, mortality remains high (Gaig C et al. 2017; Honorat JA et al. 2017). 
Neuropathology, intriguingly show the presence of hyperphosphorylated three- and four-repeat 
tau aggregates in neurons, and neuronal loss predominantly in the hypothalamus and the 
brainstem tegmentum, and absence of inflammatory infiltrates (Sabater L et al. 2014; Gelpi E 
et al. 2016). These findings suggest neurodegeneration as the primary disease mechanism, 
which would fit with the observed absence of a significant response to immunotherapy. 
However, all genotyped patients had HLA-DQB1*0501 and HLA-DRB1*1001 alleles, 
suggesting a genetic susceptibility for autoimmunity (Sabater L et al. 2014, 2016).  
The IgLON5 antibodies target the extracellular domain of the protein and are 
predominantly of the IgG4 subtype, and to a lesser extent IgG1. The latter are responsible for 
the internalisation of IgLON5 in neuronal cultures (Sabater L et al. 2016), whereas this effect 
was not seen with IgG4 antibodies, which are likely to act in a different way, and which may 
lead to secondary neurodegenerative changes. However, it is also possible that their presence 
is secondary to a primary tauopathy. Future studies have to address the link between 






1.6.3 NSA-Ab in Narcolepsy with cataplexy 
Narcolepsy is a chronic sleep disorder, characterised by excessive daytime sleepiness (EDS) 
and cataplexy, often in association with hallucinations at sleep onset (hypnagogic) or/and at 
awakening (hypnopompic) and sleep paralysis (Yoss RR and Daly DD, 1957); the presence or 
absence of cataplexy defines two groups of patients; narcolepsy with cataplexy (narcolepsy 
type 1, NT1) and narcolepsy without cataplexy (narcolepsy type 2, NT2) (AASM, 2005). The 
disease, and in particularly NT1, has been linked to the loss of a small group of neurons in the 
posterior lateral hypothalamus producing hypocretin 1 and 2 (HCRT-1 and 2) (also known as 
orexin A and B) (Scammell TE, 2003; Peyron C et al. 2000; Thannickal TC et al. 2000). Patients 
with narcolepsy and cataplexy have low concentrations of hypocretin in the CSF, typically 
below 100 ng/L and most often undetectable with conventional radioimmunoassays (Nishino S 
et al. 2000; Nishino S et al. 2001). Although it is clear that the loss of orexin neurons is 
responsible for many of the symptoms observed in NT1 patients, the cause of this loss in 
unknown. The specific and highly selective depletion of hypocretin-secreting neurons and the 
strong association with the HLA DRB1*06:02 (Mignot E et al. 1997) led to the hypothesis that 
narcolepsy is an autoimmune driven process within the hypothalamus. However, to date, many 
observations supporting this hypothesis are circumstantial and clear evidence of an ongoing 
autoimmune process are missing, although, recently, autoreactive T cells clones directed 
against hypocretin were found in narcolepsy patients (Latorre D et al. 2018), supporting an 
autoimmune T cell-mediated disorder. It remains to be established if these T cells are primary 
or if they are secondary to the destruction of hypocretin neurons produced by other mechanisms.  
 Immunohistochemical studies screening for hypothalamic antibody binding (Knudsen 
S et al. 2007; Martinez-Rodriguez JE et al. 2007; Overeem S et al. 2006), as well as antibody 
studies screening for specific antigens such as the hypocretin precursor-peptide (Black JL III et 
al. 2005), HCRT1 and 2, hypocretin receptors 1 and 2 (HCRTR1 and 2) (Tanaka S et al. 2006) 
and other neuronal and non-neuronal autoantigens in narcoleptic patients (Black JL III et al. 
2002) gave negative or inconclusive results. A possible explanation for these inconclusive 
findings is the fact that in many cases the studies were performed on patients with symptoms 
of an unspecified or lengthy duration, which could result in a negative study if the antibodies 
are only transiently present. The relevance of timing in the autoimmune process related to 
narcolepsy is suggested by the observation that a better, though insufficient, control of 
symptoms could be obtained by human IvIg administered within a few months from disease 




and normalization of HCRT-1 CSF levels when the IvIg was administered within the first 15 
days from onset (Dauvilliers Y et al. 2009). 
 Sleep disturbances are common in patients with autoimmune encephalitis (Vincent A et 
al. 2011), who often present with low levels of orexin A in the CSF (Mignot E et al. 2002; 
Küçükali Cİ et al. 2014). LGI1 antibodies, associated with limbic encephalitis, appear to co-
localise with orexin neurons (among other neurons; Irani SR et al. 2012). Also, NMDAR 
antibodies were recently found in three orexin-deficient NT1 patients who presented with 
psychiatric disturbances (Tsutsui K et al. 2012). However, although 4/13 patents stained on rat 
brain sections, screening for antibodies associated with encephalitis (i.e. CASPR2, LGI1, 
NMDAR) was negative in post vaccine (Pandemrix®) narcolepsy cases (Thebault S et al. 
2015). Moreover, the association between narcolepsy, psychosis and presence of NMDAR-Ab 
was not confirmed by a small subsequent study (Dauvilliers Y et al. 2016). Finally, new 
interesting clues about antibody-mediated pathogenic mechanisms in narcolepsy came from 
Ahmed and colleagues, who found antibodies against the HCRTR2 in 85% of post-Pandemrix® 
narcolepsy cases as well as in 35% of controls (Ahmed SS et al. 2015). The significance of this 
finding is unknown, and HCRTR2-antibodies were only rarely found in patients with idiopathic 
narcolepsy (Giannoccaro MP et al. 2017).  
 
1.7 Open questions 
 
Despite their relative rarity, antibody-mediated CNS diseases have been one of the most 
intriguing and research-driving fields in neurology over the last 15 years. However, several 
questions remain unanswered. Among these, is the site of production and distribution of the 
antibodies. To cause symptoms the antibodies must access the brain. Are they produced in the 
periphery and gain access to the brain when or where the BBB is less efficient, or are they 
produced locally in the brain? These two scenarios are not mutually exclusive, and their 
importance may change during the course of the disease. In NMDAR encephalitis the 
autoantibodies are present in patients’ serum and CSF, the latter usually showing intrathecal 
synthesis and high antibody concentrations (Dalmau J et al. 2008). B-cells are able to cross the 
BBB where they are believed to undergo antigen driven re-stimulation, clonal expansion and 
differentiation into antibody producing plasma cells (Hauser SL et al. 2008). Indeed, NMDAR 
encephalitis responds to cyclophosphamide and rituximab therapies, both able to deplete B cell 




In some diseases, it may be essential for CNS symptoms, as implied in cases of CASPR2-Abs 
(Joubert B et al. 2016), or the antibodies in the CSF may just reflect higher serum levels.   
Very little is known about the origin of these antibodies. The role of tumours in paraneoplastic 
syndromes is well accepted, and the role of infections in precipitating the disease is also 
common, with clear relationship between HSV and NMDAR-Ab encephalitis. However, the 
role of triggering infections in other forms of autoimmune encephalitis or of other 
environmental factors have not been explored and epidemiological studies are missing. Genetic 
factors may also contribute to the pathogenesis of these disorders. Indeed, distinctive HLA 
associations are linked to clinical features and antibody subtypes in myasthenia (reviewed in 
Nacu A et al. 2015) and a recent study showed a strong association between LGI1 antibodies 
and HLA II DRB1*07:01–DQB1*02:02 haplotype (Kim TJ et al. 2016). The strong association 
of LG1 antibodies to HLA-DRB1*07:01 was confirmed in another study, which also found an 
association between CASPR2 antibodies and the HLA-DRB1*11:01 (Binks S et al. 2018). 
 Similarly, autoimmune encephalopathy with the IgLON5 autoantibody appears to be 
associated with specific HLA genotypes (Sabater L et al. 2014). However, the presence of a 
specific HLA locus association in other NSA-Abs syndromes is still unknown. In the future, 
more studies will be oriented in exploring the influence of genetic and environmental factors.  
Another major question relates to how these antibodies can produce specific syndromes 
when the antigens are often expressed throughout the CNS. Epitope differences may play a role 
as well as the site of access of the antibodies into the CNS. Also, the relevance of different Ig 
classes and whether they cause disease requires further study. High frequency of IgM and IgA 
have been found in patients with dementia or different psychiatric disorders (Doss S et al. 2014; 
reviewed by Pollak TA et al. 2016). A recent study showed that, independently from the Ig 
class and the associated clinical condition, all NMDAR-Abs directed against the GluN1 subunit 
are able to provoke NMDAR1 internalisation in human-induced pluripotent stem cell-derived 
neurons and reduction of glutamate-evoked currents in NR1-1b/NR2A-expressing Xenopus 
oocytes; these results showed that all antibodies had pathogenic potential (Castillo-Gómez E et 
al. 2016). If this is confirmed and expanded to other antibodies, the diagnostic significance of 
this finding needs to be revised.  
To be considered as pathogenetic some line of evidence needs to be satisfied. For 
antibodies the most compelling line of evidence derives from passive transfer studies of the 
human antibody into an animal model. This has been accomplished for some antibodies, i.e. 
NMDAR given intraventricularly (Planagumà J et al. 2015; Wright S et al. 2015), but for many 




associated with specific and recognisable clinical syndromes, there can be problems about their 
significance. This occurs when they are found in cases where the clinical expression of disease 
and a particular autoantibody have not been previously described, or in cases with a very 
restricted clinical phenotype such as epileptic syndromes or neurodegenerative disorders. 
Moreover, there is insufficient data regarding the prevalence of these antibodies in the general 
population. From a recent revision of the literature (Lang K and Pruss H, 2017) it emerged that 
NSA-Ab are overall rarely found in the healthy controls (HC) (mean 0.23%), however this 
result was variable for different antibodies and HC population size. Indeed, in a cohort of 1,703 
HC samples analyzed for antibodies against AMPAR1/2, AQP4, DNER, DPPX, GABABR, 
GlyR, mGluR5, myelin oligodendrocytes glycoprotein (MOG), NMDAR/NR1, CASPR2, and 
LGI1, no positive samples were found for AQP4, DNER, GABABR, and mGluR5. The most 
frequent antibody was that against the NMDAR/NR1 in 20 cases (1.2%) (Dahm L et al. 2014). 
On the other hand, the same study revealed that NSA-Ab were present in 1.5% of disease 
controls, with frequencies varying among different subgroups from 0.25% to 3.46% (Lang K 
and Pruss H, 2017). These findings, together with the possibility of antibodies in epilepsy, 
narcolepsy or neurodegenerative cases raises several questions on the utility of antibody 
screening in cases without an obvious autoimmune suspicion, and on the clinical significance 
of positive findings. One could speculate that at least some of these positives in patients as well 
as controls could be “false positive”.  
The other possibility is that these antibodies are often present in the sera but do not cause 
disease because they are unable to reach their target. Therefore, in these cases, a “second hit”, 
like disruption of the BBB, could be necessary to allow the manifestation of the disease and 
access of B cells into the cerebral compartment. Indeed, in many diseases and healthy controls, 
the positive finding of serum antibody has not been accompanied by CSF testing.   
Another possible scenario is that the antibodies in healthy individuals are pathogenic 
but do not cause an obvious clinical phenotype because the changes induced go undetected – 
that is they are not sufficient to cause neurological symptoms. It is also possible that functional 
differences (i.e. affinity) in the antibodies play a role in their pathogenic potential. Finally, a 
positive neuronal antibody in a patient not initially suspected to have an antibody-mediated 
disease can still be “true-positive” and represent the further expanding phenotypic spectrum 
seen in most antibody-specific syndromes. Investigations into these restricted clinical 





1.8 Aims of this PhD 
 
The aim of this PhD was to investigate the presence and pathogenic role of antibodies directed 
against neuronal surface antigens in different neurological conditions. Methods are described 
in Chapter 2. At first, the presence and frequency of these antibodies were explored in three 
different cohorts of patients. These included those (1) for which an autoimmune aetiology is 
strongly suspected (narcolepsy type 1), (2) patients with chronic neurological conditions with 
unknown or not primarily an immunologically-related aetiology (patients with temporal lobe 
epilepsy and patients with neurodegenerative disorders), and (3) healthy and disease 
(seronegative myasthenia gravis patients) controls. The presence of the antibodies was related 
to patients’ clinical features (results are presented in Chapter 3). Finally, the pathogenic effects 
of antibodies against neuronal surface antigens in vivo were examined by a passive transfer 
animal model, using lipopolysaccharide (LPS) to open the blood-brain barrier. For this 
experiment, CASPR2 antibodies were chosen for several reasons: (1) they were one of the most 
common antibodies found in our cohorts; (2) they are some of the most commonly observed 
antibodies in patients with autoimmune encephalitis; (3) there are no previous studies 
attempting to model their CNS effects; (4) most importantly, plasma derived from the 
plasmapheresis of a patient with CASPR2 related encephalitis was available for the study. In 
this animal model, the behavioural and neuropathological effects of the antibodies were 















Chapter 2: Materials and Methods  
2.1 Antibody screening in human cohorts  
The CNS disorders cohorts were provided from the UOC Clinica Neurologica of the IRCCS 
Istituto delle Scienze Neurologiche di Bologna. Population controls from elderly individuals 
(age over 60 years) and serum samples from patients with seronegative myasthenia gravis 
(SNMG), which served as disease controls, were kindly provided by the Nuffield Department 
of Clinical Neurosciences. It is important to note that all this work was retrospective, and no 
patients or controls were prospectically included in the study. The initial work included the 
search for antibodies in different cohorts in order to assess their frequency in specific 
neurological disorders and their association with specific phenotypes. In a second step the 
frequency of antibodies among patients with different neurological disorders and healthy 
controls were compared.  
 
2.1.1 Narcolepsy type 1 cohort  
 
Narcolepsy type 1 (NT1) patients’ sera were collected at the Sleep Centre of the IRCCS Istituto 
delle Scienze Neurologiche di Bologna. Inclusion criteria were diagnosis of narcolepsy with 
cataplexy on unknown etiology or related to infections and vaccination (i.e. Pandemrix); 
patients were excluded if brain imaging documented the presence of brain lesions potentially 
responsible for secondary narcolepsy. Both children and adults could participate to the study. 
According to these criteria, sera from 59 consecutive patients (22 F, 37 M) diagnosed with NT1 
accordingly to the ICSD, 2nd edition (AASM, 2005) were included. All patients underwent 
MSLT the day after a complete polysomnography and protracted EEG monitoring. CSF HCRT-
1 levels and HLA status at locus DQB1*0602 were available in all patients.  
 
2.1.2 Epilepsy cohort  
 
Patients were collected by different adult and pediatric epilepsy centers in the Bologna area. 
Inclusion criteria was an ascertained diagnosis of temporal lobe epilepsy, with or without 
family history, and with or without mesial temporal sclerosis. Exclusion criteria were history 
and/or imaging evidence of stroke, tumor, trauma, vascular malformation, abscess or 
infectious lesion. No age limits were established. On the basis of these criteria, this cohort 




2.1.3 Neurodegenerative cohort  
Patients consecutively admitted for a neurodegenerative disorder to our clinic were included 
in this study if they satisfied the following inclusion criteria: parkinsonism or cognitive 
impairment/dementia of suspected neurodegenerative aetiology in absence of other causes 
(i.e. vascular dementia, drugs, syphilis). Patients with family history or mutations in genes 
associated to parkinsonism and/or dementia could be included. Patients with abnormal 
complete blood count, blood biochemistry analyses, thyroid function tests, sedimentation rate, 
vasculitic/rheumatological antibody screening, and cranial MRI were included only if these 
alterations were not considered responsible for the clinical picture. Sixty-one patients (21 F, 
40 M), diagnosed with different neurodegenerative conditions, on the basis of current clinical 
criteria, were included.  
2.1.4 Control cohorts 
 
These included 50 population controls aged over 60 years (from a study started in the 1990s 
and used in Vincent A et al. 2004) and 159 patients with SNMG collected from 2000-2003. As 
specific ethics were not available for these samples to be used as controls, they were 




2.2.1 Cell-based assays (CBAs) 
 
Proteins that are expressed on the neuronal surface and relevant for neurological disorders were 
chosen for the screening of the cohorts using human embryonic kidney (HEK) 293 T cells after 
transfection with the plasmid of interest.   
 HEK 293 cells were cultured in Dulbecco’s modified eagle’s medium (DMEM) media 
supplemented with 10% foetal calf serum (FCS) (Biowest®) and 1% each of penicillin G and 
streptomycin 1 in 175 cm 3 plastic flasks at 37°C 5% CO2. After 3-4 days, cells were collected 
after 1-minute incubation with trypsin (GIBCO®, 0.5% diluted in PBS) and centrifuged (1100 
RCF, 5 min) at room temperature (RT). Pellets were resuspended in 10 ml of HEK culture 
medium and counted on a hemocytometer using Tryptan blue to stain dead cells to exclude in 




coverslips (13 mm, VWR) and coated with poly-L-lysine (PLL). 24 hours after seeding, cells 
were transiently transacted with the plasmid encoding for the protein of interest associated in 
some cases with the enhanced green fluorescent protein (EGFP) encoding plasmid. A total of 3 
or 3.2 µg of DNA respectively was diluted in 50 µL DMEM, 0.82 µL of 20% glucose and 1.5 
µL of polyethylenimine (9 mM, PEI) per well. After 12-16 hours of incubation (37°C) the 
media was replaced, and cells cultured for a further 24 hours (hr). EGFP was used as a marker 
of the successful transfection.  
 
Indirect immunofluorescence 
Sera antibodies were diluted in DMEM supplemented with N-(2-hydroxyethyl)piperazine-N’-
2-thanesulphonic acid (HEPES) buffer (4.6 mg/ml) and 1% bovine serum albumin (BSA) and 
incubated with coverslips transferred to individual well on a 24 wells plate (1 hr, RT). For 
NMDAR, LGI1, AMPAR, IgLON5 and HCRTR2 constructs, sera were screened at 1:20 
dilution; GABAAR antibodies were screened at 1:50 dilution; GlyR, GABABR and CASPR2 
were screened at 1:100. These dilutions were those in use by the routine laboratory.  
 After incubation, coverslips were washed 3 times in DMEM/HEPES and fixed in 
paraformaldehyde (PFA) (4%, TAAB®). After a further three washes, secondary antibodies 
(usually Alexa Fluor™ 568 anti-human IgG H&L chain rises in goat) were incubated in the 
dark (1 hr, RT). Finally, cells were washed in DMEM/HEPES (x3) and phosphate buffered 
saline (PBS) (x3) and the coverslips were mounted onto glass microscope slides (VWR®) using 
mounting medium (Dako®) containing a 1:1000 dilution of 4’,6’-diaminidino-2-
phenlindoledichloride (DAPI) in order to stain cells nuclei. This protocol was subjected to 
minor changes due to the use of different secondary antibodies, as described in the appropriate 
sections. 
 Antibody binding to the expressed antigen was observed using a fluorescence 
microscope (Leica DM 2500™). Successful transfection and antibody binding were usually 
confirmed by green (EGFP) and red (secondary antibody against human IgG) fluorescence 
respectively. A subjective visual scoring system was adopted to assess the presence and the 
intensity of the antibody binding to the cells of each coverslip (adapted from Leite I et al. 2008). 
In all experiments, positive and negative controls were included. The scoring system was the 
following: 0= no labelling; 1= weak, considered as a low positive; 2= moderate; 3= moderate-
strong; 4= strong. Also, intermediate scores were possible and therefore 0.5 point could be 
added at each number when the observed staining was in between two scores. For instance, a 




did not satisfy criteria for score 2. Any result with observed reactivity (score ≥0.5) was 
reassessed by repeat assay. As anti H&L chain secondaries can bind IgG as well as IgM, to 
further confirm the positivity and the relevance of the observed staining, secondary antibodies 
against the human IgG Fc fragment were used to confirm that the antibodies were IgG. In 
positive cases, serum dilutions were performed, when possible, to assess the antibody titre. All 
samples were tested blind to the serum identify and retested on HEK cells transfected with a 
different construct to exclude non-specific binding to the cells.  
 Pictures were taken using an Imaging Rolera XR™ camera or with Leica Confocal 
microscope under the same conditions. No specific features within any image was enhanced, 
obscured, removed or introduced unless explicitly stated.  
 
2.2.2 Screening approaches 
 
2.2.2.1 Immunostaining on rat and mouse brain sections 
 
Rat brain collection and preparation 
Sprague Dawley rats were decapitated, and their brains removed by careful dissection, cut 
sagittally and immediately immersed for 1 hour in 4% PFA at RT. After fixation, the half brains 
were transferred in a sucrose solution at 40% and stored at 4 °C. The passage in sucrose solution 
ensure cryoprotection of the tissue. Brains were left in the solution for 24-48 hours and then 
embedded in optimum citing temperature (OCT) compound (Tissue-Tek®) and snap-frozen in 
dry-ice cooled isopentane. Frozen brains were wrapped in foil and stored at -80°C. Frozen tissue 
was mounted with OCT compound and cut on a cryostat (10 µm) (ThermoScientific 
Cryotome® FSE) sagittally. Cut section were transferred onto SuperFrost® Plus slides, dried 
overnight and stored at -20°C wrapped in aluminum foil.  
 
Immunohistochemistry (IHC) 
Slides were allowed to dry at RT and hydrophobic wells were created around each section using 
a Dako® delimiting pen. All procedures were performed at RT if not otherwise specified. After 
a rinse in cold tris-buffered saline (TBS) solution, endogenous peroxidase blocking was 
achieved by submersion in a solution of TBS-0.3% H2O2 for 15 min RT. Slides were than 
washed with TBS (3 x 5 min) and unspecific binding was blocked in normal goat serum (NGS) 
(10% in TBS for 1 hr). Sections were rinsed in TBS and then incubated in primary antibodies 




slides were washed with TBS (3 x 5 min) and incubated with secondary antibodies (Biotinylated 
Goat Anti-Human IgG Antibody, Vector lab,1:1000 in TBS) for 2 hours. After washing with 
TBS (3 x5 min), in order to amplify the signal of the secondary antibody, a further incubation 
was performed with the avidin-biotin complex (ABC, Vectastain Elite ABC Kit Standard) 
(1:100 in TBS, 1 hr). Sections were further washed with TBS (3 x 5 min) and the reaction 
developed using brown 3,3’-diaminobenzidine DAB (ImmPACT DAB Peroxidase (HRP) 
Substrate, Vector lab) prepared as per manufactures instructions. Slides were left to dry in the 
fume hood before proceeding with dehydration procedure by immersion in progressive 
concentration of ETOOH solutions followed by p-Xylene. Slides were mounted with DPX 
mountant for histology (Sigma-Aldrich®) and viewed using a light Microscope (Nikon Eclipse 
E400). Section location was identified by comparison with a rat brain atlas (Paxinos G and 
Watson C, 2007).  
 Screening of patient sera binding to sagittal sections was assessed in the hippocampus, 
cortex, thalamus and cerebellum. Binding to these areas was scored using a subjective scoring 
system (0= no binding, 0.5= weak/questionable binding, 1=weak definitive binding, 2= 
moderate, 3= strong) in each brain area and appearance of binding. All patients showing a score 
≥ 0.5 in at least 1 brain area was repeated and the final score was the mean value.  
 
2.2.2.2 Immunostaining on primary hippocampal neuronal cultures  
 
Neuronal cultures 
The protocol for neuronal cultures was adapted from Kaech S and Banker G (2006). Following 
sacrifice of the pregnant dam, E17-19 fetuses were removed from the uterus and placed on ice. 
Brains were removed and immersed in ice cold antibiotic-antimycotic (AA) supplemented 
Hanks’s Buffered Saline Solution (HBSS) (Gibco®). After midline sagittal bisection of the 
brain and involution of the cortex, the hippocampus was identified and dissected from each 
side. When all of the hippocampi had been removed, they were gently transferred with a Pasteur 
pipette to a Falcon tube containing 5 ml of a solution of HBSS-0.5% trypsin and incubated for 
20 min at 37°C. After removal of the trypsin solution, the tissue was resuspended in complete 
minimum essential medium (MEM) (1X MEM alpha, Gibco®, supplemented with 10% FCS, 
1% AA solution), triturated by repeatedly pipetting up and down and then centrifuged (1000 
RCF for 10 minutes) before being re-suspended in complete MEM. Dissociated cells were 
plated-out in complete Neurobasal medium (NBS) (Neurobasal media 1 X, Gibco®, 




6 well-plates containing 5-9 borosilicate glass coverslips (12 or 10 mm, VWR) previously 
coated with PLL. One third of media was replaced with fresh NBS medium every 5 days and 
maintained in culture for 12 days. Three days after plating, cytosine arabinoside was added at 
a concentration of 5 µM to curb glial proliferation.   
 
Indirect immunofluorescence  
After 12 days in culture, antibody binding studies to neurons were performed. Coverslips were 
transferred to individual wells on a 24 well plate and incubated with serum (1:100) diluted in 
NBS medium supplemented with HEPES buffer (4.6 mg/ml) and 1% BSA. Coverslips were 
then washed 3 times (NBS-HEPES) and fixed with PFA 3% in PBS (10 min, RT). After 3 
additional washes with PBS, neurons were incubated with Alexa Fluor® Goat anti-human IgG 
H&L 488 secondary antibody (1:1000 in complete NBS-1%BSA) (45 min, RT). After further 
washing with PBS (3x), cells were permeabilised with PBS-T 0.3% (15 min, RT) prior to 
incubation with anti-microtubule associated protein 2 (MAP2) commercial antibodies (1:1000 
in PBS-T 0.1%-5% NGS) (1 h, RT). Following PBS washes, appropriate secondary antibodies 
were added (Alexa Fluor® Goat anti Mouse 568) (45 min, RT). After final PBS washes, 
coverslips were mounted with DAPI and visualised using a fluorescence microscope (Leica 
DM 2500™) or a confocal microscope (Zeiss® LSM 710 TM).  
 Binding of patients’ IgG to neurons was considered positive only if MAP2 staining was 
present, showing the neurons to have been healthy. The binding was scored subjectively on a 
scale of 0-3 (0= no binding, 1=weak definitive binding, 2= moderate, 3= strong). In the case of 
repeated experiments, the final score was the mean of the previous scores.  
 
2.3 Passive transfer animal model 
 
2.3.1 IgG purification  
 
The plasma from the CASPR2-Ab positive patient and the serum form the healthy donor were 
centrifuged, diluted 1:1 with Hartmann’s solution and incubated with Protein G Sepharose 
column beads (Sigma-Aldrich, Inc.) overnight at 4°C on a roller. The Sepharose-IgG mixture 
was then percolated trough a chromatography column before elution of IgG with 0.1M glycine 
solution (pH 2.3); the eluate was immediately neutralised with 100 μl of 1M Tris pH 8. The 




USA). The eluted fractions were pooled, dialysed against 2 liters of Hartmann’s physiological 
solution two times over 24 hours at 4°C, concentrated by dialysis against polyethylene glycol 
and filter-sterilized. The concentration was determined using NanoDrop 3300 
(ThermoScientific, UK), and IgG was stored at 4°C. The specificity of the binding and the 
antibody titre of the CASPR2-IgG in the original plasma were already reported  (Coutinho E et 
al. 2017). Absence of other antibodies in the plasma of the patient with CASPR2-Ab related 
encephalitis was demonstrated by showing the absence of binding to CASPR2-null neurons and 




Nineteen C57Bl6 male mice aged 6 weeks (18-22 g) were purchased from a licensed breeding 
establishment (Charles River). The animals were housed in group of four or five under standard 
laboratory conditions (ad libitum access to food and water; 12:12 light:dark cycle, with lights 
on at 7:00) and monitored daily during the experimental period. Mice were tagged and 
randomly assigned to each experimental group. All in vivo experiments were performed in the 
Biomedical Services Unit at the John Radcliffe Hospital in accordance with the United 
Kingdom Home Office Animals in Scientific Procedures Act (1986) and in accordance with 
institutional guidelines. 
 
2.3.3 Intraperitoneal injections 
 
Two cohorts of mice were injected intraperitoneally (IP) with purified IgG from either a patient 
with CASPR2-antibodies (CASPR2-IgG, n=10 mice) related encephalitis or a healthy control 
(HC-IgG, n= 9). Animals were injected daily for 8 days. At day 3 all mice were injected IP with 
lipopolysaccharide (LPS, 1 mg/Kg). Further details are provided in results.  
 
2.3.4 Behavioural testing 
Behavioural testing was done during the light phase. The animals were brought to the 
experimental room approximately 15 minutes before testing. A rest period of at least 2 hours 
was allowed between a test and the following one. Between mice the walls and the floor of the 
different apparatus were cleaned with 70% ethanol and water and dried with a dry tissue. All 




allow animals to recover after the LPS injection, which could have affected behaviour. The 
olfaction test and the reciprocal social interaction test were performed only after the IgG 
administration. 
 
2.3.4.1 Accelerating rotarod (AR) 
Accelerating rotarod was used to assess motor coordination (Deacon R, 2013). The mice were 
placed place on the rotating rod, facing away from the direction of rotation. The rotarod was 
initially set with a speed of 4 rpm for the initial 10 seconds after which an acceleration of 20 
rpm/minute was applied. Time to fall was recorded. If the mouse had fallen off during the initial 
10 seconds it would have another try, to a maximum of 3 trials (Figure 2.1).  
 
2.3.4.2 Kondziela’s inverted screen test (IS) or grip test 
This test was used to assess muscle strength. The inverted screen consisted of a 43 caesurae of 
wire mesh consisting of 12 mm squares of 1 mm diameter wire, surrounded by a 4 cm deep 
wooden beading to prevent the mice from climbing to the other side. At the beginning of the 
test the mouse was placed in the centre of the apparatus on the deeper side and the screen was 
quickly inverted while the timer was started. The inverted screen was held 50 cm above a 
padded surface for a maximum of 5 minutes. The time to fall was recorded. The average of 
three trials was taken as a final result (Figure 2.1).   
 
2.3.4.3 Narrow beams (NB) 
Narrow beams or static rods were used as another test of coordination (Deacon R, 2013). For 
this test three wooden rods of varying thickness (35 (rod 1), 22 (rod 2) and 9 (rod 3) mm 
diameter) each 60 cm long were fixed to a laboratory shelf such that the rods horizontally 
protrude into space at a height of about 60 cm from a padded floor. The end of the rod near the 
bench has a mark 10 cm from the end, to denote the finishing line. The mouse was placed at 
the far end of the widest rod and the timer was started. The orientation time (time taken to 
orientate 180° from the starting position towards the shelf) and transit time (the time taken to 
travel to the shelf end) were recorded for a maximum of 5 minutes. If the mouse had not fallen 
and had arrived at the end of the rod, was transferred on the next smaller rod. If the mouse had 
not reached the end by this time the test was ended, and the mouse transferred to the next rod 






2.3.4.4 Marble burying test (MBT) 
This test was used to assess the presence of repetitive, compulsive-like behaviors (Angoa-Pérez 
M et al. 2013). Standard polycarbonate mouse cages with fitted filter-top covers were fitted 
with fresh mouse bedding to a depth of 5 cm and its surface leveled by inserting another cage 
of the same size onto the surface of the bedding. Ten standard glass toy marbles (assorted styles 
and colors, 14 mm diameter) were placed on the surface of the bedding in 2 rows of 5 marbles. 
The mouse was placed into a corner of the cage containing the marbles and left undisturbed for 
30 min. Food and water access was allowed during the test. At the end of the test the mouse 
was returned to its home cage and the marbles buried were counted and the number expressed 
as percentage. A marble was scored as buried if two-thirds of its surface area was covered by 
bedding (Figure 2.1).  
 
2.3.4.5 Open field (OF) 
The open field was used to assess motricity but also anxiety. The apparatus consisted of a dark 
closed arena of 50 x 50 cm divided into 10 cm squares illuminated with a 60 W lamp posed 45 
cm above the centre of the floor of the box. The mouse was placed in a corner square facing the 
wall and its movement recorded on camera for 5 minutes. The latency to move, the number of 
peripheral and central square entered (four paws), the number of rears (both back paws on the 
ground but not part of grooming), the number of grooming and time spent grooming, the time 
spent in the peripheral and in the central squares, the time spent moving and the time spent 
freezing were recorded. The number of faecal boli and the presence/absence of urine were also 
recorded (Figure 2.1).  
 
2.3.4.6 Light-dark box (LDb) 
The LD box test was used to assess anxiety. The apparatus consisted of an open white 
compartment 30 x 20 x 20 cm joined by a 3 x 3 cm opening to a dark box 15 x 20 x 20 cm. The 
white compartment was illuminated by a 60 W lamp placed 45 cm above the centre of the floor. 
One side of the white compliment of the box was transparent allowing detection of the mouse 
movement. The mouse was placed in the middle of the light side facing away from the opening 
and a count-down timer for 5 min started. The latency to cross with all four feet to the dark 
side, the latency to cross with all four feet to go back for the first time to the light side, the total 
time spent on the light side and on the dark side and the number of transitions through the 
opening were registered for the test. The number of faecal boli and the presence/absence of 





























A) Accelerating rotarod; B) Inverted screen; C) Narrow beams; D) Marble burying 










2.3.4.7 Forced alternation test (FA) or spatial preference test  
This test was considered as a short memory test. The apparatus was a Y-maze constructed from 
transparent Perspex and mounted on an opaque square Perspex board (64.5 cm x 56.5 cm). The 
walls of the Y-maze were 20 cm high and 0.5 cm thick. Each arm was 30 cm long and 8 cm 
wide. The test consisted of 3 periods: a habituation period (5 minutes), a delay period (1 minute) 
and a test period (2 minutes). During the exposure training trials, the entrance to one arm (the 
Novel arm) was blocked using a rectangular piece of Perspex. The Novel arm (NA) was 
counterbalanced in each group between right and left side. At the start of a trial the mouse was 
placed at the end of the Start arm (which was always considered as the one closest to the 
experimenter) and allowed to explore the Start arm and the Other arm. During this period the 
time spent in each arm and the number of entries to each arm were recorded. An arm entry was 
defined as when a mouse had placed all four paws into an arm. At the end of the trial the mouse 
was removed from the maze and returned to its home cage for 1 minute during which the maze 
was cleaned and the block to the Novel arm removed. At the beginning of the test period the 
mouse was returned at the end of the Start arm and now allowed to explore the Start, Other, and 
Novel arms and exploratory behavior assessed for 2 minutes. During the test the time spent in 
each arm and the number of entries into each arm were recorded. Preference for the Novel arm 
was calculated as a Preference Index (entries/time in the new-entries/time in the old 
arm)/(entries/time in the new + entries/time in the old arm) for both the time in arms and number 
of arm entries (Rubovitch V et al. 2010). Scores greater than 0.5 indicate a preference for the 
Novel arm (Figure 2.2). 
 
2.3.4.8 Continuous spontaneous alternation (CSA) test 
The continuous spontaneous alternation test was used as a test of working memory. The test 
was conducted in the same Y-maze as described above and it consisted of a single 5 min trial, 
in which the mouse was allowed to explore all three arms of the Y-maze. The start arm was 
varied between animals to avoid placement bias. CSA was assessed by scoring the pattern of 
entries into each arm during the 5 min of the test. Spontaneous alternation performance (SAP) 
was defined as successive entries into each of the three arms as on overlapping triplet sets (i.e., 
ABC, BCA, . . .) and scored as percentage of spontaneous alternation (total alternations/total 
arm entries - 2* 100) (Wietrzych M et al. 2005). The percentage of alternate arm returns (AARs) 
(i.e. ABA) and same arm returns (SARs) (i.e. AAB) were also scored for each animal in order 
to assess aspects of attention within spontaneous working memory (Wall PM and Messier C, 









A) Forced alternation test: in the habituation period the mouse could explore only two arms 
of the Y-maze for 5 minutes before being returned to its home cage; after 1 minute delay, 
the mouse was returned in the Y-maze and allowed to explore all arms; B) Continuous 
spontaneous alternation test; C) Novel object recognition test: in the familiarization phase 
the mouse was left to explore two identical objects; after 24 hours one of the object was 









2.3.4.9 Novel object recognition (NOR) test 
The novel object recognition test was used to evaluate long term memory (Antunes M and Biala 
G, 2012). The open field arena was used in order to benefit from previous habituation. Towers 
of Lego bricks (X-cm high and X-cm wide) and Falcon tissue culture flasks filled with bedding 
(9.5 cm high, 2.5 cm deep and 5.5 cm wide, transparent plastic) were used as objects. Animals 
were randomly assigned one of those pairs of object for the familiarization phase. The test 
comprised two phases: a familiarization phase and a test phase performed 24 h later. During the 
familiarization session two identical objects (either towers of Lego bricks or Falcon tissue 
culture flasks) were placed in the open field arena, 5 cm away from the walls. The mouse was 
placed in the open field, its head positioned opposite the objects, and left free to explore for 5 
minutes. The test phase was identical to the familiarization phase but one of the familiar object 
was replaced in the same position with a new object. The position of the novel object (left or 
right) was randomized between each mouse. The test was video recorded and subsequently 
analysed for number of visit and time spent with each object during both the familiarization and 
the test phase. The object exploration was scored whenever the mouse sniffed the object or 
touched the object while looking at it (i.e., when the distance between the nose and the object 
was less than 2 cm). Climbing onto the object (unless the mouse sniffs the object it has climbed 
on) or chewing the object did not qualify as exploration. If an animal had a total objects 
exploration time < 5 sec during any phase it was excluded from the analysis. The preference 
for the new object was expressed as Preference index [PI= (time new object - time familiar 
object)/(time new object + time familiar object)]. This result can varies from +1 to -1 with a 
positive score indicating preference for the novel object (Antunes M and Biala G, 2012) 
(Figure 2.2).  
 
2.3.4.10 Reciprocal social interaction test (RSI) 
This is a social interaction test where two mice of the same treatment group, unknown to each 
other, are allowed to interact freely (Barkus C et al. 2012). The apparatus was the same used 
for the open field as the mice were already habituated to it. Two animals from the same 
treatment group but housed in different cages, tightly matched for weight (within 5% 
difference), were exposed to each other for 5 minutes. The test was video recorded and scored 
offline for the latency to start the interaction and for time spent in social and non-social 
behaviours and number of social and non-social events. Social behaviours included sniffing, 
grooming and following closely; non-social behaviours included self-grooming, rearing and 




2.3.4.11 Olfaction test (OT) 
An olfaction test was performed in order to assess olfaction deficits that could interfere with 
the results from the social interaction tests. The open field arena was used in order to benefit 
from previous habituation. A small plastic container with an odour (1 mL of vanilla or citrus 
food flavouring) was placed at two corners. The test comprised 3 phases: a sample phase (5 
minutes), a delay period (5 minutes) and a test phase (5 minutes). During the first phase, the 
same odour was placed in both containers (half of the mice for treatment group would smell 
one odour, while the other half would smell the other). After this, the mice would return to the 
home cage for 5 minutes. During the test phase, a container with the alternate (new) odour was 
placed in one of the corners. The location of the new odour was counterbalanced across 
treatment groups. The test was video recorded and subsequently analysed for number of visit 
and time spent with each odour.  
2.3.5 Blood and brain tissue processing 
 
At day 11, eleven animals (6 CASPR2-IgG and 5 HC-IgG injected) were randomly selected 
and sacrificed by CO2. Blood samples were collected by cardiac puncture from 10 animals, 
centrifuged and sera stored at -20 °C. Brains were harvested and split sagittally. For each animal 
half brain was embedded with freezing media and snap frozen in chilled isopentane for 
histological analysis whereas the other half-brain was snap frozen without embedding for 
protein extraction. The remaining eight animals (4/group) were used for morphological and 
immunofluorescence analysis of the brain. Mice were deeply anesthetized with isoflurane 
followed by pentobarbital injection (100 mg kg−1 i.p) and transcardially perfused with 50 ml 
of phosphate-buffered saline (PBS) followed by 50 ml of ice-cold 4% paraformaldehyde (PFA) 
in 0.1 M phosphate buffer. Brains were removed and post-fixed for 24 hours (h) at room 
temperature (RT), cryoprotected with 30% sucrose in PBS and snap frozen in ice-cold 
isopentane. All brains were stored at -80°C. 
 
2.3.6 Morphological and immunofluorescence analysis of the brain and image processing 
 
For morphological and immunofluorescence analysis, perfused fixed brains were cut at 50 µm 
thickness using a Leica CM1900 cryostat in 10 series of free-floating sections. Confocal images 
were taken of immunofluorescently labeled brain sections using a Zeiss LSM 710 confocal 




2.3.6.1 IgG deposition in the brain and CASPR2 expression 
To look at the similarity between CAPSR2 staining and IgG staining, two consecutive series 
were fixed with 4% PFA, washed 3 times in PBS, blocked for 1 hr in PBS 10% NGS and 
incubated respectively with anti-human IgG antibodies (Biotium, USA, 20022, 1:500) and with 
rabbit monoclonal anti-CASPR2 antibodies (Abcam, EPR8738, ab137052, 1:500) in blocking 
solution overnight at 4°C. We used two consecutive sections instead of a single one to avoid 
the interactions between secondaries we noted in preliminary experiments. In the same 
experiments, we also excluded the presence of interactions between the rabbit CASPR2 
antibodies, the secondary anti rabbit antibodies and the human IgG already present in the tissue 
(data not shown). The day after, the latter sections were washed 3 times in PBS and incubated 
with goat anti-rabbit Alexa Fluor® 568 secondary (1:500) for 1 hr at RT. All sections, included 
the one incubated with anti-IgG, were washed 3 times in PBS and coverslips were mounted 
using fluorescent mounting media containing DAPI (1:1000). For each staining, images were 
acquired using a confocal microscope. For quantitative analysis of the mean fluorescent 
intensity, 32 single plain pictures (4 from the dentate gyrus, 4 from the CA3, 6 from the CA1 
areas of the hippocampus, 6 from the somatosensory cortex, 6 from the thalamus, 6 from the 
cerebellum) were taken from 2 sections per animal. Mean fluorescence intensity was analysed 
with FiJi software (Open Source HR Software) and results plotted with GraphPad 6 as the mean 
of the intensity per each area per mouse.  
 
2.3.6.2 Morphometric studies  
The presence of gross morphological alterations was evaluated on Nissl-stained sections. The 
cresyl violet solution (Sigma C5042) that stains Nissl bodies (granular endoplasmic reticulum 
and ribosomes) allows observation of neuronal soma. Sections were mounted on super frost 
plus slides (vWR), left to dry at RT, fixed with 4% PFA for 10 minutes, rinsed twice in PBS 
and once in deionized water for 5 minutes and immersed in cresyl violet solution (Sigma 
C5042) for 10 minutes. Slides were than dehydrated by immersion in ethanol solutions of 
increasing concentrations until 100%, cleared with xylene and coverslipped with DPX 
mounting medium. Slides were scanned with the Aperio AT2 scanner and analysed with the e-
pathology Aperio ImageScope image analysis system from Leica Biosystems. The sums of the 
area of a series of sections (12 sections), from the appearance of the frontal pole cortex to the 




of the section (50 µm) to obtain the total brain volume on the coronal plain. The same formula 
was used to calculate the cerebellum and hippocampus volumes (at least 4 sections). Thickness 
of the following structures were measured (25-50 measurements per area): anterior cingulate, 
motor, piriform and somatosensory cortices, neuronal layers of dentate gyrus, CA3 and CA1, 
CA4, CA3 and CA1 fields, granular and molecular layer of the cerebellum. 
2.3.6.3 Neuron and astrocyte counts 
Neurons and astrocytes were identified by immunofluorescence using a mouse anti-NeuN 
(Chemicon, MAB377; 1:500) and a polyclonal rabbit anti-glial fibrillary acidic protein (GFAP) 
antibody (Dako, Z0334; 1:500) respectively. Free-floating sections were fixed with 4% PFA, 
washed with PBS then blocked with 10% NGS in PBS-Triton-X-100 (0.3%) for an hour then 
incubated overnight with primary antibodies at 4°C. The next day the sections were washed in 
PBS then incubated for two hours at RT with goat anti-mouse (568) and goat anti-rabbit (488) 
Alexa-Fluor secondary antibodies from life technologies at 1:500 dilutions in blocking solution. 
Sections were subsequently washed in PBS, mounted on slides after a brief wash in TNS (pH 
= 7.4) and counterstained with DAPI mounting medium, left to dry then sealed and stored 
protected from the light at 4°C for confocal imaging. Cerebellar sections were stained similarly. 
In this case, however, primary antibodies included also guinea pig anti-calbindin D28K 
antibody (Millipore, AB1778; 1:200) for the identification of Purkinje cells. Secondaries 
antibodies included goat anti-mouse (648), goat anti-rabbit (488/568), goat anti-guinea pig 
(555). Neuronal and astrocyte cell densities were determined in the hippocampal fields (CA4, 
CA3, CA1), the somatosensory cortex and the piriform cortex. Confocal images were taken 
across the z-plane spanning the entire hippocampus in all cases in both hemispheres. Six images 
were taken per hemisphere for each cortical region. Eighteen stacks were taken every 2 μm z-
plane for the hippocampus. For the neuronal density, cells were counted in every fifth image in 
the same stack. For astrocytes density, images were z-projected, cells counted, and the density 
calculated as number of cells per volume of area. In the cerebellum, confocal images were taken 
across the cerebellar lobules. Fifteen stacks were taken for each case every 3 μm z-plane. To 
avoid bias related to the different distribution of Purkinje cells across photographs the Purkinje 
cell density was calculated as linear density (number of calbindin positive cells per mm). At 
least 100 cells were counted for each case over 5,3 mm length. Astrocytes density was assessed 
in the molecular layer of the cerebellum as mean fluorescence intensity of the GFAP staining. 
For the neuronal density in the molecular layer, images were z-projected on FiJi and NeuN 




2.3.6.4 C-fos expression 
To assess the expression of neuronal c-fos, free flowing sections were rinsed in TNS, fixed with 
4% PFA for 15 minutes than washed 3 times in PBS, blocked for one hour in 10% NGS 0.3% 
PBS-T and incubated with rabbit anti-c-fos (Abcam, ab190289; 1:100) and mouse anti-NeuN 
(Chemicon, MAB377; 1:500) in blocking solution overnight at 4°C. The day after sections were 
washed and incubated with goat anti-rabbit (488) and goat anti-mouse (568) Alexa-Fluor® 
secondary antibodies at 1:500 dilution in blocking solution in the dark at room temperature for 
two hours. Sections were subsequently washed in PBS, mounted on slides after a brief TNS 
wash (pH = 7.4) and counterstained with DAPI mounting medium, left to dry then sealed and 
stored at -20°C for confocal imaging. Quantification of c-fos expressing neurons (defined as c-
fos/NeuN positive cells) was performed in the somatosensory, entorhinal and piriform cortex, 
the CA4, CA3 and CA1 fields of the hippocampus, the amygdala, the torso-medial and lateral 
nuclei of the hypothalamus. For each hemisphere, twelve z-stacks were taken in the 
hippocampus (3 for the CA4, 4 for the CA3 and 6 for the CA1), four in the somatosensory area, 
3 in the piriform cortex, 4 in the amygdala, 2 in the entorhinal and 4 z-stacks (2 per subarea) 
were taken in the hypothalamus. The z-step interval was 2 µm within a 50 µm depth. An 
average density was obtained (cells/mm3) for each area. 
2.3.6.5 Microglia counts and morphological analysis 
Microglial cells were identified by the combined expression of Iba1 and CD68 markers. Free 
floating sections were fixed with 4% PFA, washed with PBS then blocked with 10% NGS in 
PBS-T 0.3% for an hour then incubated overnight with a rat anti-CD68 (BioRad, MCA1957; 
1:400) and a rabbit anti-Iba1 (Wako chemicals, 019-19741) primary antibodies in blocking 
solution at 4°C. The sections were washed the next day with PBS-T 0.3% then incubated for 
two hours at room temperature with goat anti-rat (488) and goat anti-rabbit (568) Alexa-Fluor® 
secondary antibodies at 1:500 dilution in blocking solution in the dark. Sections were 
subsequently washed in PBS, mounted on slides after a brief TNS wash (pH = 7.4) and 
counterstained with DAPI mounting medium, left to dry then sealed and stored at -20°C for 
confocal imaging. Quantification of reactive microglia (defined as CD68/Iba-1 positive cells) 
was performed in the somatosensory and piriform cortex, the CA4, CA3 and CA1 fields of the 
hippocampus and in the granular and molecular layers of the cerebellum. For each hemisphere, 
seventeen z-stacks were taken in the hippocampus (3 for the CA4, 4 for the CA3 and 10 for the 




taken in the cerebellum. The z-step interval was 2 µm and microglial cells were counted within 
a 50 µm depth. An average density was obtained (cells/mm3) for each area. 
Microglial morphology was assessed in confocal z-stacks detecting fluorescence on Iba-1 
expressing cells in the hippocampus and in the molecular layer of the cerebellum as previously 
described (Coutinho E et al. 2017). Soma size (μm2) and total cell body size (μm2) were 
measured and the soma/total cell body size ratio calculated and used as a marker of microglia 
activation. The length of the longest ramification (max ramification length) was recorded 
manually in Fiji. 
 
2.3.6.6 Astrocyte complement C3 expression and morphology 
Double staining for complement C3 fraction and GFAP was used to evaluate astrocytes 
activation. Free floating brain sections were mounted on SuperFrost plus slides. When dry, 
sections were washed with TNS, immersed for 10 minutes in a boiled solution of citrate EDTA 
buffer and then left in the same solution for 20 minutes on ice. Sections were washed three 
times in PBS-T 0.3% and incubate with rat anti-C3 (Abcam, EPR19394, ab200999, 1:100) and 
rabbit anti-GFAP (Dako, 1:500) primary antibodies overnight at 4°C. The day after, sections 
were washed in PBS-T 0.3% and incubated with goat anti-rat (488) and goat anti-rabbit (568) 
Alexa-Fluor secondary antibodies at 1:500 dilution in 5% NGS PBS-T 0.3% solution in the 
dark at room temperature for one hour. Slides were than washed in PBS-T 0.3% and TBS, 
counterstained with DAPI mounting medium, left to dry then sealed and stored at -20°C for 
confocal imaging. For each hemisphere, three z-stacks were taken in the hippocampus, 
somatosensory cortex and cerebellum at 40X magnification with a z-step of 2 µm within a 
50 µm depth. Images were analyzed using Fiji. After z-projecting and automatic thresholding, 
the composed images were split in three channels. Images were magnified. Single astrocyte 
cells were manually selected, and for each cell the area on the GFAP and on the C3 channels 
measured. For each cells the C3 expression was calculated as C3/GFAP stained cell areas ratio. 
200 cells/group were analyzed in the hippocampus, 81 cells/group in the somatosensory cortex 
and 100 cells/group in the cerebellum, and the results plotted as both cells average and 4 
animals/group average. Astrocytes morphology was assessed on the same z-stacks detecting 
fluorescence in GFAP expressing cells using the same script as for assessing microglia 
morphology (Coutinho E at al. 2017). The total cell body size (μm2) was measured and the 
number of ramifications and the length of the longest ramification (max ramification length) 





2.3.7 Immunoblot analysis  
For total brain protein extraction, frozen brain tissue (3 brains and cerebellar hemispheres per 
mice/group) was homogenate in lysis buffer (50 mM TRIS-HCL, 150 mM NaCl, 0.1% SDS, 
1% triton-X 100, pH 7.4) supplemented with protease inhibitors (1:100) with a mechanical 
homogenizer. The homogenate was than spinned at 17000 rpm for 20 minutes at 4°C. 
Supernatant was collected and protein concentration measured by a PierceTM BCA protein assay 
kit (23225). 
 
2.3.7.1 Western blot analysis of CASPR2 expression 
For western blot (WB) analysis, NuPAGE sample reducing agent (10x; Invitrogen, NP0009) 
and LDS sample buffer (4x; Invitrogen, NP0008) were added to 10 to 30 µg of an appropriate 
amount of solubilized tissue, boiled for 10 minutes and the proteins separated into 3-8%Tris 
acetate SDS polyacrylamide gels (Invitrogen, NP0322) and transferred with dry blotting on 
nitrocellulose membranes. Membranes were blocked in 5% non-fat skimmed milk in PBS 0.1% 
Tween 20 solution and incubated overnight at 4°C with rabbit anti CASPR2 (Abcam, EPR8738, 
ab137052, 1:1000) and anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibodies 
(Abcam, [EPR16891] ab181602 1:2000). Membranes were washed in PBS-Tween 0.1% and 
incubated with secondary antibodies in blocking solution for 1 h at room temperature (anti-
rabbit IgG HRP 1:1000). Signals were detected by enhanced chemiluminescence (Amersham 
GE Healthcare) and captured on autoradiography film (GE Healthcare). All studies were done 
in duplicate or triplicate. Films were digitally scanned, and signals quantified using Fiji ImageJ 
software. The signal intensity of each antigen was normalized to that of GAPDH in the same 
lane. The mean OD intensity of signal in CASPR2-IgG and HC-IgG treated animals was 
compared in GraphPad Prism 6. 
 
2.3.7.2 Cytokine and chemokine array 
Brain cytokine expression was analyzed using a Mouse Cytokine Antibody Array (22 Targets) 
(Abcam, ab133993) as per manufacturer instructions. Briefly, membranes were blocked in 
blocking buffer for 30 minutes at room temperature than incubated with 250 µg of proteins 
from the brain lysates in blocking buffer overnight at 4°C. The day after, membranes were 
thoroughly washed and incubated with biotin-conjugated anti-cytokines antibodies overnight 




Immunoreactivity was then visualized using enhanced chemiluminescence reagent. X-ray film 
was than scanned and densitometric analysis performed using Fiji. Positive controls were 
included on each membrane and used for results normalization. The mean intensity of the 
normalized signal in HC-IgG injected mice was defined as 1 and the other intensities expressed 
relatively to this value.  
 
2.4 Statistics  
 
A student’s t test or a Mann-Whitney was used to compare the mean of two groups, depending 
if the data distribution was normal or not respectively. Holm–Sidak correction was applied to 
correct for multiple comparisons. Chi square or Fisher’s exact test were applied to determinate 
the relations between categorical data. One-way ANOVA was performed when more than two 
groups were compared. For weight changes over time a two-way ANOVA was used with post 
hoc analysis. Behavioural data were analyzed by one-way ANCOVA, using the baseline 
behavior as a covariate. Post hoc analysis was performed when appropriate. Significance for 
all experiments was placed at p<0.05. Statistical tests were carried with GraphPad prism version 
6 (GraphPad software, San Diego, California, USA) or IBM SPSS statistics version 20.0 (SPSS 
Inc., Chicago, USA). Graphs were plotted using Graph Pad prism version 6. Data is shown as 





Chapter 3. Antibodies in cohorts of patients with central nervous system 
disorders and controls 
 
3.1 Introduction 
As discussed in the Introduction, the discovery of syndromes associated with the presence of 
antibodies directed against neuronal surface antigens (NSA-Abs) has helped to define a clear 
aetiology and a rationale for a specific therapy in several cases of autoimmune encephalitis. 
However, patients with “a minora” phenotypes, with a more restricted clinical presentation, 
have been reported in every neurological field from epilepsy to neurodegenerative disorders. 
As a result, an effort has been made to identify the clinical features that may suggest an 
antibody-mediated disorder in those cases which do not have a “classical” presentation but 
could still benefit from the immunotherapy.  
On the other hand, the search for antibodies has also been extended to several disorders for 
which the aetiology is still obscure but in which an autoimmune aetiology is strongly suggested 
by circumstantial evidences (i.e. Narcolepsy type 1). These efforts, have, as a counterpart, 
raised new questions, particularly about the role and relevance of the antibodies in “discrete” 
neurological syndromes, their pathogenicity and, of course, their pathophysiological 
mechanisms. Moreover, the discovery of antibodies against neuronal-surface antigens (NSA) 
in a small proportion of healthy controls (Dahm L et al. 2014) or patients with other confirmed 
neurological diagnosis (Rossi M et al. 2015) or transiently during the course of a neurological 
disease (Wright S et al. 2016), has led to the hypothesis that these antibodies might be clinically 
irrelevant or a secondary phenomenon.      
The purpose of this study was, therefore, to evaluate the frequencies of NSA-Abs in 
different CNS neurological disorders and in controls with PNS disorders or none, and to try to 
establish a correlation with specific clinical phenotypes and, thereby, shed light on their 
significance. Three groups of patients were studied: narcolepsy type 1 (NT1) as an example of 
a highly specific disease, epilepsy patients representing a potentially diverse group, mostly with 
unknown and possibly autoimmune aetiologies, and patients with neurodegeneration who 
represented a diverse group of patients with brain pathology of other primary causes. For 
antibody screening, three approaches were used: two screening approaches combining search 
for unknown antigens by immunohistochemistry (IHC) on rat brain sections and 
immunofluorescence on dissociated neurons cultures, and a candidate antigen approach using 




from medical records available at the UOC Clinica Neurologica di Bologna. All methods are 
available in Chapter 2.   
3.2 Screening of antibodies in narcolepsy type 1  
 
This cohort included 59 patients (22 F, 37 M), aged 31.10  17.71 years (range 8-69) at 
sampling. Data are summarised in Table 3.1. Based on the age at sampling, the cohort included 
22 children (age < 17 years). The typical association of reduced CSF HCRT1 levels and 
positivity for the allele DQB1*0602 was observed in 54 patients, whereas one was HLA 
negative with normal HCRT-1 levels, two were HLA negative with reduced HCRT-1, and two 
were HLA positive with normal HCRT-1 in the CSF. Patients’ age at excessive daytime 
sleepiness (EDS) onset was 20.4  13.7 years (range 6-62) and age of cataplexy onset was 22 
 14.4 years (range 6-62). Patients with age at onset over 40 years were considered as late onset 
(n=6). EDS usually presented before cataplexy and the time gap between EDS and cataplexy 
onset was 28.9  51.8 months (range 0-276). On the basis of the time lapse between EDS and 
cataplexy onset, we divided NT1 patients into subjects with acute onset (cases with gap between 
symptoms ≤ 6 months) and those with a more chronic evolution (progressive). Twenty-eight 
patients (15 children) were considered as acute onset. 
 The timing of sampling in relation to symptom onset was highly variable (time lapse 
from EDS onset 128.3  131.6 months, range 0-528; time lapse from cataplexy onset 108.9  
133.6 months, range 1-504) but 22 patients (11 acute) were sampled within 1 year from onset.  
 After antibody screening, more detailed clinical information regarding additional 
symptoms, brain imaging, and CSF analysis were collected and correlation with the antibody 
status performed. First, we screened for the presence of general reactivity, subsequently we 
looked for specific antigens by CBAs. 
 
3.2.1 Screening for unknown antigens  
 
Immunohistochemistry (IHC) on sagittal rat brain sections showed the presence of antibody 
binding to the neuropil in 10 (16.9%) NT1 patients (Figure 3.1). The binding was generally 
diffuse and concentrated on the hippocampus, cortex, cerebellum and thalamus; no new 





Table 3. 1 Demographic and clinical features of the NT1 cohort 
 
N. of subjects 59 
   
Female:Male 22:37       
Children:adults 22:37       
Age at sampling (mean ± SD) 
(years) 
31.1 ± 17.7       
Age EDS onset (mean ± SD) 
(years) 
20.4  13.7        
Age cataplexy onset (mean ± SD) 
(years) 
22  14.4    
Time lapse between EDS onset-
sampling (mean ± SD) (months) 
128.3  131.6        
Time lapse between cataplexy onset-
sampling (mean ± SD) (months) 
108.9  133.6    
Acute:progressive 29:30       
Late onset (>50 y)  6       
Sampled close to onset (1 year) 22       
Post-vaccine/H1N1 cases 2       
HCRT-1 levels Reduced Reduced Normal Normal 
HLA-DQB1*0602 + - - + 
Number 55 1 1 2 


















A) Representative images of immunohistochemistry (IHC) from a healthy control 
(HC) and a patient with NT1 showing neuropilar reactivity. B) Representative images 

























Immunofluorescence on rat hippocampal neurons showed punctate staining, suggestive 
of the presence of an antibody against a neuronal surface antigen, in 8 patients (13.5%) (Figure 
3.1). Among these reactive sera, 5 (8.4%) were positive on both tissue and neurons, 5 (8.4%) 
were positive only on tissue and 3 (5%) positive only on neuronal cultures.  
 
3.2.2 Antibody screening for known antigens on CBAs 
 
The 59 samples from this cohort were screened by CBA for NMDAR, CASPR2, LGI1, 
AMPAR, GABABR, GABAAR, D2R, GlyR, Neurexin 1α (NRX1) (Zandian A et al. 2017) and 
HCRTR2 (Giannoccaro MP et al. 2017) antibodies. Overall, 15 patients had positive antibodies: 
8 against NMDAR, 1 against LGI1, 1 against GlyR, 1 against GABAAR, 1 against NRX1 and 
3 against HCRTR2. Titres were generally low: 1:20 (n=6), 1:100 (n=1) to 1:500 (n=1) for 
NMDAR, 1:200 for GlyR, 1:500 for NRX1, 1:100 to 1:200 for HCRTR2 (Figure 3.2). Titres 
were not determined for GABAAR and LGI1 antibodies. Among the CBA positive patients 3 
(1 LGI1-, 1 GlyR- and 1 GABAAR-Abs) were positive also on brain sections and neuronal 
cultures, 1 (NMDAR) was positive also on neuronal cultures and 2 (NMDAR) were positive 
also on immunohistochemistry. The absence of a perfect correspondence between the three 
different techniques is not surprising as CBAs are known to be more sensitive for most neuronal 
antibodies. Overall, only 2 patients showed reactivity on both neurons and brain sections in the 
absence of antibodies against known antigens on CBAs.  
 Patients with NMDAR antibodies (5 M, 3 F) included 4 adults and 4 children. Age at 
EDS (P=0.4) and cataplexy onset (P=0.37), age at sampling (P=0.40), time lapse between EDS 
(P=0.7) and cataplexy onset (P=0.88) and sampling, Epworth sleepiness scale (ESS) (P=0.26) 
and HCRT-1 CSF levels (P=0.81) were not different from the rest of the patients (independent 
samples t test; Table 3.2). However, the presence of NMDAR antibodies was associated with 
an acute onset of the disease (P= 0.022, Fisher’s exact test, two tailed) and unexpectedly, these 
antibodies were inversely associated with the presence of hypnagogic hallucinations (P=0.019, 
Fisher’s exact test, two tailed) (Table 3.3 A and B).  
Patients with HCRTR2 antibodies were 2 M and 1 F, and all three had prominent 
psychiatric symptoms. One male patient, aged 38 years, HLA positive, with undetectable CSF 
HCRT-1, presented at age 15 years with EDS; cataplexy onset was at 27 years. Since disease 
onset he had an associated psychosis. The female patient, aged 23 years, HLA negative and 
with normal CSF HCRT-1, presented with EDS onset at age 16 years followed 2 years later by 




   
A) Score results for different antigens; B) Representative images of a CBA from a 
negative (HC) and a positive (NT1) patient. 
. 











Gender (M, F) 5,3 32,19 >0.999 $ 
Age EDS onset (years) 16.6 ± 8.1 21 ± 14.14 0.40 ^ 
Age cataplexy onset (years) 17.7 ± 9.2 22.6 ± 15 0.37 ^ 
Time lapse EDS-cataplexy 
onset (months) 
13.6 ± 38.1 31.3 ± 53.5 0.37 ^ 
Age at sampling (years) 26.5 ± 17.5 31.8 ± 17.7 0.40 ^ 
Time lapse EDS onset-
sampling (months) 
115.5 ± 134.5 130.3 ± 132.4 0.77 ^ 
Time lapse cataplexy onset-
sampling (months) 
102.2 ± 123.6 110 ± 136.3 0.88 ^ 
HCRT-1 CSF levels 27.1 ± 41.4 32.7 ± 65.7 0.81 ^ 
ESS 18.1 ± 3.6 16.4 ± 3.9 0.26 ^ 
$: Fisher’s exact test, two tailed; ^: independent samples t-test; CSF: cerebrospinal fluid; 
EDS: excessive daytime sleepiness; Seaworth Sleepiness Scale; F: female; HCRT-1: 
hypocretin 1; M: male. 
 
         
Table 3. 3 Association between NMDAR-positivity in the CBA and acute onset of 
narcolepsy symptoms (A) and absence of hypnagogic hallucinations (B). 
A) Association between NMDAR positivity  
and acute onset 
NMDAR CBA (Fc)  
Positive: Negative 
Acute onset (n=28) 7 : 21  
Progressive onset(n=31) 1 : 30  
P= 0.022 Fisher's exact test, two tailed 
B) Association between NMDAR positivity  
and absence of hypnagogic hallucinations 
NMDAR CBA (Fc)  
Positive: Negative 
Hypnagogic hallucinations (n=38) 6 : 15  
No hallucinations (n=21) 2 : 36  










was a 17-year old male, HLA positive but with normal CSF HCRT-1 levels. He presented an 
acute onset of EDS and cataplexy at age 16 years; recently he reported a worsening of auditory 
hallucinations and mild behavioural problems. No patients had H1N1 infection/vaccination; all 
had elevated anti-streptolysin O (ASO) titres.  
 
3.2.3 Clinical features of NT1 patients showing any antibody reactivity 
 
Overall 22 patients (37.3%) showed the presence of some reactivity (found either by CBAs, 
immunohistochemistry or immunofluorescence on neurons). We than analysed if patients with 
antibody reactivity showed any specific clinical feature. Examined clinical features are 
described in Table 3.4.  
No differences were found in demographics between patients with or without any 
reactivity (Table 3.5). However, the presence of any antibody reactivity was more frequent in 
patients with an altered blood-brain barrier (BBB) (P=0.048, Fisher’s exact test, two tailed), as 
expressed by an altered CSF/sera albumin concentration ratio, and less frequent hypnagogic 
hallucinations (P=0.050, Fisher’s exact test, two tailed). The association with an altered BBB 
was even stronger after exclusion of patients showing isolated reactivity (i.e. only on neurons 
or tissue) (P=0.018, Fisher’s exact test, two tailed). No other associations were found with acute 
onset, other clinical features (presence of sleep paralysis, other sleep disturbances, psychiatric 
disorders, other immunological disorders), brain MRI features or other CSF alterations (Table 
3.6).  
The cohort included 9 patients with NT1 and psychosis. Clinical features are 
summarised in table (Table 3.7). Surprisingly, none of them had NMDAR-Abs, but, although 
the frequency of antibody reactivities was not different from the rest of the cohort, 4/9 cases 
with psychosis showed some evidence of antibody reactivity (1 on immunohistochemistry, 1 
for LGI1 and 2 for HCRTR2, as already discussed).  
3.3 Screening for antibodies in the Epilepsy cohort  
 
This cohort included 73 patients (6 children) (34 F, 39 M), with clearly defined temporal lobe 
epilepsy, with or without family history. Age at sampling was 31.7  14.6 years (range 4-82); 
the age at onset and, therefore, the time lapse between sampling and onset, was not available. 
After screening for antibodies, clinical information about family history, response to 




Table 3. 4 Examined clinical features in NT1 patients 
Clinical features N. of data available N. of patients (%) 
Sleep features  
ESS 58 n.a. 
Paralysis 59 34 (57.6) 
Hypnagogic Hallucinations 59 38 (64.4) 
• visual  55 31 (56.4) 
• auditory  55 14 (25.5) 
• somesthetic 55 14 (25.5) 
• multimodal 55 19 (34.5) 
RBD 59 21 (35.6) 
Other sleep disorders 59 21 (35.6) 
Psychiatric disorders 
Psychosis 59 9 (15.3) 
Depression 59 18 (30.5) 
Anxiety  59 6 (10.2) 
Anti streptolysin O titre 48 18 (37.5) 
MRI  
  
Altered 49 10 (20.4) 
• white matter abnormalities 49 5 (10.2) 
• other lesions 49 5 (10.2) 
CSF data 
  
altered proteins 44 12 (27.3) 
altered white cells 43 3 (7) 
altered IgGs CSF index 35 8 (22.9) 
altered blood-brain barrier index 34 6 (17.6) 
OBs 
  
• absent 42 32 (76.6) 
• present 42 5 (11.9) 
• mirror pattern 42 4 (9.5) 
• mixed 42 1 (2.4) 
ESS: Epworth Sleepiness Scale; RBD: REM sleep behaviour disorder; MRI: magnetic 













Gender (M:F) 13:9 24:13 0.78 $ 
Age EDS onset (years) 21.4 ± 14.7 19.8 ± 13.3 0.67 ^ 
Age cataplexy onset (years) 23.9 ± 15.5 20.8 ± 13.8 0.47 ^ 
Time lapse EDS-cataplexy onset (months) 35.5 ± 66.3 24.9 ± 41.4 0.45 ^ 
Age at sampling (years) 31.5 ± 18.8 30.8 ± 17.2 0.87 ^ 
Time lapse EDS onset-sampling (months) 122.1 ± 143.2 132 ± 126.1 0.78 ^ 
Time lapse cataplexy onset-sampling 
(months) 
91.2 ± 133.7 119.4 ± 134.3 0.43 ^ 
HCRT-1 CSF levels 47.8 ± 91.2 22.2 ± 33.9 0.21 ^ 
ESS 17.5 ± 4.1 16 ± 3.8 0.16 ^ 
$: Fisher’s exact test, two tailed; ^: independent samples t-test; CSF: cerebrospinal fluid; 
EDS: excessive daytime sleepiness; ESS: Epworth Sleepiness Scale; F: female; HCRT-1: 
hypocretin 1; M: male. 
 
 







HCRT-1 CSF levels (low:normal) 20:2  36:1 0.54 
HLA DQB1*06:02 20:2  36:1 0.54 
Onset (acute:progressive) 10:12 16:21 0.43 
Sampling from onset (close:far) 10:12 12:25 0.40 
Hypnagogic hallucinations (yes:no)  8:13 23:11 0.050 
Sleep paralysis (yes:no) 9:13 25:12 0.059 
RBD (yes:no) 8:14 13:24 > 0.999 
Psychiatric disorders (yes:no) 13:9 17:20 0.42 
Other autoimmune diseases 
(yes:no) 
4:18 4:33 0.45 
Brain MRI (altered:normal) 6:14  4:25 0.27 
CSF analysis data    
Blood brain barrier (altered:normal) 4:6 2:22 0.048* 
CSF proteins (increased:normal) 5:11 7:21 0.73 
CSF WBC (increased:normal) 0:16 3:24 0.28 
CSF IgGs index (altered:normal) 0:10 8:17 0.073 










Table 3. 7 Clinical features of patients with NT1 and psychosis 




















22 13 15 38 15 12 22 14 23 
Sex M F M M F M M M F 
Age EDS 
onset (y) 









7 1 1 
month 
11 1 3 7 1 6 




0 10.2 10.8 0 13.3 0 0 23.1 410 
HLA-
DQB1*0602 
+ + + + - + + + - 








+ + - + + + + - - 




21 12 15 16 13 11 21 16 25 















IHC + - - - + - - - - 
Neurons - - - - + - - - - 
CBAs - - - HCRTR2 LGI1 - - - HCRTR2 
Any 
reactivity 
+ - - + + - - - + 
CSF: cerebrospinal fluid; EDS: excessive daytime sleepiness; IHC: immunohistochemistry;  m: months; 






(MTS) on brain MRI were retrieved and correlated with the antibody status. These data are 
presented below. No information on the specific type or frequency of seizures, EEGs or CSF 
data were available. 
 
3.3.1 Screening for unknown antigens  
 
Neuropil binding was observed by immunohistochemistry in 14 patients (19.1%). The pattern 
of staining was diffuse and did not suggest a specific reactivity for this cohort. Neuronal cell 
binding was observed with 11 sera (15.1%) (Figure 3.3). Among these reactive sera, 7 (10.1%) 
were positive on both tissue and neurons, 7 (10.1%) were positive only on tissue and 5 (5.8%) 
only on neuronal cultures.  
 
3.3.2 Antibody screening for known antigens  
 
The 73 samples were screened by CBA for NMDAR, CASPR2, LGI1, AMPAR, GABABR, 
GABAAR, GlyR, IgLON5 and HCRTR2 antibodies. Given the reported association between 
GAD65 antibodies and epilepsy, these were also tested by radioimmunoassay (RIA). Fourteen 
patients (19.1%) had specific antibodies: 2 to GAD65, 2 to GlyR, 5 to CASPR2, 4 to GABAAR, 
3 to GABABR (Figure 3.3). Two showed multiple reactivities: 1 to CASPR2 and GAD65 and 
1 to GABAAR and GABABR. Overall, 4 patients (1 GlyR, 1 CASPR2, 2 GABAAR) showed 
reactivity on neurons and tissue, and 4 (1 GlyR, 1 CASPR2, 1 GABABR, 1 GAD65) also by 
immunohistochemistry. Only three patients had undetermined reactivities on both tissue and 
neurons.  
Features of positive patients are described in Table 3.8. No difference in age at sampling 
were found between patients with different specific antibodies (F (4, 11)=2.064, P= 0.15, one-
way ANOVA). No specific features were associated with specific antibodies (Table 3.8). 
However, the presence of GABABR antibodies was associated with AED resistance (P=0.026, 











Table 3. 8 Clinical features of Epilepsy patients with specific antibodies 
 
CASPR2 + GABAAR + GABABR + GlyR + GAD65 + 
Number of patients (%) 5 (6.8) 4 (5.4) 3 (4.1) 2 (2.7) 2 (2.7) 
Sex (F:M) 3:2 1:3 1:2 1:1 1:1 
Age at sampling 24.6 ± 10.4 44.2 ± 7.4 31.3 ± 15.8 34 ± 9.8 27.5 ± 4.9 
Family history (n of patients) 1 0 2 0 0 
MTS (n of patients) 2 1 2 0 1 
Temporal lesion (n of 
patients) 
2 1 2 0 0 
AED resistance (n of patients) 3 3 3 0 2 
AED: antiepileptic drugs; MTS: medial temporal sclerosis. 
 
Table 3. 8B Association between GABABR antibodies and resistance to anti-epileptic 
therapies (AEDs) 
 
Association between GABABR positivity 
and AED resistance 
GABABR CBA (Fc) Positive: 
Negative 
AEDs resistance (n=22) 3 : 19  
AEDs response (n=50) 0 : 50 






















A) IHC and neuronal score results; B) Representative images of a low positive on 
neuronal cultures; C) Score results of CBAs.  
 
 




3.3.3 Clinical features of patients showing any antibody reactivity 
 
Overall, 24 patients (32.9%) demonstrated some antibody reactivity (either on CBAs, RIA, 
immunohistochemistry on rat brain tissue or immunofluorescence on neurons).  
Epilepsy patients’ clinical features are described in Table 3.9. Patients with a family 
history were significantly younger at sampling than other patients (t(68)=2, P=0.048, 
independent samples t-test). The presence of temporal lesions was more common in female 
patients (P= 0.014, Fishers’ exact test, two-tailed) and, as expected, mesial temporal sclerosis 
(MTS) associated closely with other temporal lesions on the brain MRI (P < 0.0001, Fishers’ 
exact test, two-tailed). 
 Patients with antibody reactivity were significantly younger at sampling compared to 
seronegative patients (t(71)=2, P=0.04, independent samples t-test) (Table 3.10), and again, 
antibody reactivity was correlated with resistance to AEDs (P=0.016, Fisher’s exact test, two 
tailed) (Table 3.10), and this association remained after excluding patients with only single, 
undefined, reactivities (P=0.028, Fisher’s exact test, two tailed) (i.e. positive only on tissue or 
neurons). 
There were no differences in other clinical features, including gender distribution, 
presence of temporal lesions or mesial temporal sclerosis (MTS) on brain MRI between 
seropositive and seronegative patients (Table 3.10).  
 
5.4. Screening for antibodies in the Neurodegeneration cohort  
 
This cohort included serum samples from 61 patients (21 F, 40 M), aged 67.9  10.1 years 
(range 46-84) at sampling, diagnosed with a broad range of neurodegenerative disorders (Figure 
3.4), according to current clinical diagnostic criteria. If the clinical criteria for a specific disease 
were not met, the patients were defined as undetermined dementia (UD) or undetermined 
parkinsonism (UP). The diagnoses included progressive supranuclear palsy (PSP, n= 5), 
cortico-basal degeneration (CBD, n= 4), multiple system atrophy (MSA, n= 3), Parkinson’s 
disease (PD, n= 2), PD with dementia (PDD, n= 7), PD with dysautonomia (PDDy, n= 2), 
Alzheimer’s disease (AD, n = 6), Creutzfeldt-Jakob disease (CJD, n= 3), behavioral variant 
fronto-temporal dementia (FTD, n= 4), dementia with Lewy body (DLB, n=3), UD, n= 14 and 
UP, n=7. Age at onset was 62.5  13.4 years (range 16-81) and the time lapse between onset 




Table 3. 9 Demographic and clinical features of Epilepsy cohort patients 


















      
Yes (n = 24) 12:12 26.8 ± 12.4 - 8:16 3:16 7:17 
No (n = 46) 26:20 34.1 ± 15.4 - 17:29 18:27 15:31 
p-value  0.62 $ 0.048*^ - 0.79 $ 0.082 $ >0.999 $ 
AEDs resistency  
      
AEDs resistant (n= 22) 14:8 30.9 ± 15.3 7:15 8:14 9:9 - 
AEDs responders 
 (n = 50) 
24:26 32.2 ± 14.5 17:31 17:33 12:36 - 
p-value  0.30 $ 0.73 ^ >0.999 $ >0.999 $ 0.075 $ - 
Temporal lesions  
     
Yes (n = 25) 8:17 33.2 ± 14.2 8:17 - 17:5 8:17 
No (n = 47) 30:17 31.1 ± 15 16:29 - 4:40 14:33 
p-value  0.014*$ 0.56 ^ 0.79 $ 
 
<0.0001*$ >0.999 $ 
MST 
      
Yes (n = 21) 7:14 34.6 ± 14.7 3:18 17:4 - 9:12 
No (n = 45) 27:18 32.2 ± 14.9 16:27 5:40 - 9:36 
p-value  0.064 $ 0.54 $ 0.082 $ <0.0001*$ - 0.075 $ 
*: significant value; $: Fishers’ exact test, two tailed; ^: independent samples t test; AEDs: 
antiepileptic drugs; MST: mesial temporal sclerosis.  
 
 
Table 3. 10 Contingency table correlating clinical features and antibody positivity 
 
Seropositive (n=24) Seronegative (n=49) p-value 
Gender (M:F) 13:11 26:23 > 0.999 $ 
Age at sampling 26.7 ± 12.6 34.1 ± 15 0.040* ^ 
Family history (yes:no) 8:15 16:31 > 0.999 $ 
MTS (yes:no) 6:14 15:31 > 0.999 $ 
Temporal lesion (yes:no) 8:16 17:31 > 0.999 $ 
Resistency to AEDs (yes:no) 12:12 10:38 0.016* $ 
*:significant value; $:Fishers’ exact test, two tailed; ^: independent samples t test; AEDs: 






After screening for antibodies, detailed clinical information about disease onset, clinical 
presentation, additional features and results of imaging, CSF, neuropsychological and 
neurophysiological testing were collected for associations with the antibody status.  
 
3.4.1 Screening for unknown antigens  
 
Immunohistochemistry on rat brain sections showed a pattern compatible with the presence of 
antibodies against neuronal antigens in 9 (14.8%) cases. Neuronal punctate binding was 
observed with 14 (23%) sera (Figure 3.4). Of these positive sera, 5 (8.2%) were positive with 
both methods, 9 (14.8%) bound only live neurons in cultures and 4 (6.6%) only on tissue.  
 
3.4.2 Antibody screening for known antigens  
 
Samples were screened by CBA for NMDAR, CASPR2, LGI1, AMPAR, GABABR, GABAAR, 
GlyR and IgLON5 antibodies. We identified 11 patients (18%) with specific antibodies (Figure 
3.4): 4 to GlyR, 1 to CASPR2, 2 LGI1, 3 to GABAAR, one of whom positive also for AMPAR-
Abs, 1 to GABABR. Overall, 3 patients (1 LGI1, 2 GABAAR) showed reactivity on neurons 
and tissue and 1 (GABAAR) on neurons. Two patients (3.3%) had undetermined reactivities on 
both tissue and neurons. Four patients (6.6%) remained positive only on tissue and 8 (13.1%) 
only on neurons. Demographic and clinical data of patients with specific antibodies are in given 
in Table 3.11.  
 
3.4.3 Clinical features of patients showing any antibody reactivity 
 
Overall 25 patients (40.9%) showed the presence of some reactivity (either on CBAs, 
immunohistochemistry or immunofluorescence on neurons). The diagnoses of positive patients 
were: PSP (n=3), MSA (n=1), PD (n=1), PDD (n=2), PDDy (n=1), CJD (n=2), FTD (n=1), 
DLB (n=3), UD (n=8), UP (n=3). Clinical diagnosis and demographic data are described in 
Table 3.12. No associations were found between diagnosis at discharge and antibody presence 
(P=0.15, Pearson Chi-Square), after dichotomizing patients between defined vs undefined 
diagnoses (P=0.27, Fishers’ exact test, two tailed), or between prevalent parkinsonism or 
cognitive impairment (P>0.999, Fishers’ exact test, two tailed). However, the presence of 
antibody reactivity was associated with subacute onset in patients with prevalent dementia 







A) Pie-chart of diagnosis at admission (top); pie-chart of diagnosis at discharge 
(bottom); B) results of antibody screening by immunohistochemistry (IHC) on rat brain 
tissue and immunofluorescence on hippocampal rat neurons (left) and representative 
image of a serum showing reactivity towards an antigen expressed on the surface of 






























Brain MRI CSF EEG MMSE Other 
features 
F, 68 CASPR2 PSP 64 Chronic Yes, 
hypersomnia 
Parkinsonism Yes Normal Normal N.D. 25 RLS 
F, 76 GABAAR PSP and 
dementia 
66 Chronic No, but step-
down 
Parkinsonism Partial White matter 
hyperintensity 
and atrophy 
Normal N.D. 25 RLS, 
RBD 
F, 75 GABAAR Rapidly 
evolving 
dementia 
71 Subacute No Cognitive and 
behavioural 
impairment 




; OBs (mirror 
pattern) 


























No White matter 
hyperintensity 
and atrophy 





M, 66 LGI1 Rapidly 
evolving 
dementia 















M, 65 GlyR PDD 63 Chronic No Cognitive and 
behavioural 
impairment 
N.A. White matter 
hyperintensity 
and atrophy 







Continuation of Table 3.11 
F, 59 GlyR Undefined 
dementia 








M, 70 GlyR PDD 65 Chronic No Cognitive and 
behavioural 
impairment 
N.A. Normal Lymphocytosis Normal 29 RBD 
F, 77 GlyR Undefined 
parkinsonism 
16 Chronic No Parkinsonism Yes White matter 
hyperintensity 
and atrophy 
Normal N.D. 29 - 
F, 53 GABABR Undefined 
dementia 














ADLD: autosomal dominant leukodystrophy; BBB: blood brain barrier; CJD: Creutzfeldt-Jakob disease; DLB: dementia with Lewy bodies; EEG: electroencephalogram; GTC: 
generalized tonic-clonic; MG: myasthenia gravis; MMSE: Mini mental State Evaluation; N.A.: Not available; N.D.: Not done; OBs: oligoclonal bands; PDD: Parkinson’s disease and 







  97 
  
 parkinsonism (P > 0.999, Fishers’ exact test, two tailed) (Table 3.13 B).  
Overall, irrespective of the clinical diagnosis, the presence of antibody reactivity was 
associated with a subacute onset or a sudden worsening of symptoms (P=0.005, Fisher’s exact 
test, two-tailed), with the positivity of other antibodies (i.e. anti-nuclear antibodies) (P=0.038, 
Fisher’s exact test, two-tailed) and the presence of sleep disorders (P=0.036, Fisher’s exact test, 
two-tailed). Patients with any reactivity had significantly higher levels of CSF beta-amyloid 
compared to seronegative cases (P= 0.001, independent sample t test) and lower CSF tau/a-beta 
ratio IgG (P=0.04, independent sample t test) (Table 3.14 and 3.15).  
After exclusion of patients with single undetermined reactivity (i.e. positive only on 
neurons or tissue), 13 patients (21.3%) still showed Ab-reactivity. This was found to be 
associated with the presence of cognitive impairment (P=0.006, Chi-square test, two-tailed).  
3.5 Control cohorts 
The controls included 50 sera from elderly healthy subjects (EHC) over 60 years of age and 
159 sera from patients with seronegative myasthenia gravis (SNMG). All sera were anonymised 
and no information about demographic data were available.  
 
3.5.1 Screening for unknown antigens  
 
No patients from the EHC cohort showed reactivity on tissue or neurons (Figure 3.8). Among 
the SNMG patients 16 (10%) bound to rat brain sections and 12 (7.5%) bound neurons. Of these 
only 1 bound both tissue and neurons (Figure 3.5). 13 (8.1%) patients remained positive only 
on tissue and 10 (6.2%) only on neurons. 
 
 3.5.2 Screening for known antigens by CBAs 
 
The control samples were screened by CBA for NMDAR, CASPR2, LGI1, AMPAR, 
GABABR, GABAAR and GlyR antibodies. Among the EHC, only 1 was positive for NDMAR 
(Figure 3.5). This serum was not positive on tissue or neurons. Among the SNMG, 5 sera were 
positive: 1 to CASPR2, 2 for GABAAR, 1 for GlyR and 1 for GABABR. Of these 2 were 
positive also by IHC (GlyR and CASPR2-Abs) and 1 was positive also on neurons (GABAAR) 
(Figure 3.5). No patients were positive by all methods. Overall in the SNMG cohort only 1 
serum presented an undefined reactivity on both tissue and neurons. 
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Table 3. 12 Clinical diagnosis and demographic data of Neurodegenerative patients 
Diagnosis at 
discharge 
Sex (M:F) Age at sampling (y) 
(mean ± SD) 
Age at onset (y) 
(mean ± SD) 
Time lapse onset-
sampling (m) 
(mean ± SD) 
PSP 2:3 73.2 ± 7.3 68.6 ± 6.9 57.6 ± 36.3 
CBD 1:3 74 ± 5.2 72 ± 5 24.7 ± 15.5 
MSA 3:1 63 ± 4.9 58.2 ± 3.4 57 ± 38.4 
PD 1:1 69.5 ± 7.7 64.5 ± 4.9 60 ± 33.9 
PDD 5:2 69.4 ± 12.8 67.8 ± 8.1 92.5 ± 70.5 
PDDy 2:0 77.5 ± 3.5 61.5 ± 23.3 132 ± 152.7 
AD 6:0 67.8 ± 7.9 64.8 ± 7.9 36 ± 25.1 
CJD 2:1 71.6 ± 6.5 71.3 ± 7 5.3 ± 5.7 
FTD 4:0 58.5 ± 9 55.7 ± 6.1 36 ± 34.9 
DLB 2:1 78.6 ± 2.5 76.6 ± 3.2 24 ± 12 
UD 8:6 60.5 ± 9.9 55.2 ± 15 64.2 ± 104.6 
UP 3:4 72.7 ± 9.3 56.7 ± 23.2 192 ± 255 
Total 39:22 67.9 ± 10.1 62.5 ± 13.4 71.1 ± 112.7 
Y: years; m: months; PSP, progressive supranuclear palsy; CBD, corticobasal degeneration; 
MSA, multiple system atrophy; PD, Parkinson’s disease; PDD, Parkinson’s disease and 
dementia; PDD, Parkinson’s disease and dysautonomia; AD, Alzheimer’s disease; CJD, 
Creutzfeldt-Jakob disease; FTD, fronto-temporal dementia; DLB, dementia with Lewy bodies; 
UD, undefined dementia; UP, undefined parkinsonism. 
 
 
Table 3. 13 Association between subacute onset and antibody reactivity in patients with 
prevalent parkinsonism (A) or dementia (B) 
A) 
 
Association between subacute onset and antibody 
reactivity in patients with prevalent 
parkinsonism 
Antibody Positive: Negative 
Subacute onset (n =11) 1 : 2 
Chronic progression (n=17) 10 : 15 




Association between subacute onset and antibody 
reactivity in patients with prevalent dementia 
Antibody Positive: Negative 
Subacute onset (n =13) 9 : 4 
Chronic progression (n=20) 5 : 15 
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Table 3. 14 Clinical features of seropositive and seronegative Neurodegenerative 
patients 
 
Seropositive (n=25) Seronegative 
(n=36) 
p-value 
Gender (M:F) 14:11 26:10 0.27 $ 
Age at sampling (y)(mean ± SD) 68.5 ± 11.1 67.5 ± 9.4 0.70 ^ 
Age at onset (y)(mean ± SD) 61.9 ± 17.1 63 ± 10.3 0.75 ^ 
Time lapse onset-sampling (m) 
(mean ± SD) 
82 ± 157.2 63.5 ± 68.3 0.53 ^ 
Family history (yes:no) 6:19 14:22 0.27 $ 
Subacute onset/acute worsening 13:12 6:30 0.005* $ 
          Main presentation (onset) 
  
Parkinsonism (yes:no) 7:18 13:23 0.58 $ 
Seizures (yes:no) 2:23 1:35 0.56 $ 
Mood disorders (yes:no) 6:19 7:29 0.75 $ 
Cognitive impairment (yes:no) 10:15 17:19 0.61 $ 
          Neurological examination   
 
Myoclonus (yes:no) 4: 20 11:24 0.23 $ 
Ataxia (yes:no) 5:19 3:32 0.25 $ 
Altered ocular movement 
(yes:no) 
10:14 16:19 0.79 $ 
Parkinsonism (yes:no) 17:7 25:10 > 0.999 $ 
Postural instability (yes:no) 4:20 8:27 0.74 $ 
Pyramidal signs (yes:no) 6:18 6:29 0.52 $ 
Neuropathy (yes:no) 3:21 1:34 0.29 $ 
Other clinical features    
Other autoimmune diseases 
(yes:no) 
4:21 6:30 > 0.999 $ 
History of tumour (yes: no) 3:20 3:32 0.67 $ 
Sleep disorders 16:9 12:23 0.036* $ 
Hallucinations (yes:no) 3:22 7:29 0.50 $ 
*: statistically significant; $: Fishers’ exact test, two tailed; ^: independent samples t test; 
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Table 3. 15 Laboratory, imaging, neurophysiological and neuropsychological features of 
seropositive and seronegative Neurodegenerative patients 
 
Seropositive (n=25) Seronegative (n=36) p-value 
Presence of other antibodies 
(yes:no) 
6:2 5:13 0.038*$ 
          CSF findings 
   
OBs (yes:no:mirror) 2:0:9 1:2:20 0.27 $ 
Lymphocytosis (yes:no)    
(mean value ± SD) 
3:15         
 9.5 ± 28.8 
5:28             
7.4 ± 25.1 
0.78 ^ 
Increased proteins (yes:no)                    
(mean value ± SD) 
5:13                 
44.8 ± 15 
6:26           
43.7 ± 15.3 
0.82 ^ 
Increased IgGs (yes:no)  
 (mean value ± SD) 
8:7                     
4.5 ± 1.8 
11:13           
3.5 ±  1.9 
0.13 ^ 
Altered CSF index (yes:no)    
(mean value ± SD) 
2: 11             
0.59 ± 0.07 
5:18          
0.68 ±0.43 
0.46 ^ 
Altered BBB (yes:no)                
(mean value ± SD) 
6:6                
7.8 ± 3.9 
8:15             
7.1 ± 4.3 
0.64 ^ 
Increased tau protein (yes:no) 
(mean value ± SD) 
6:13          
356.5 ± 360.5 
10:21       
381.9 ± 457.3 
0.83 ^ 
A-beta (mean value ± SD) 808.6 ± 232.2 457.8 ± 209 0.001*^ 
Altered tau/a-beta ratio (yes:no) 
(mean value ± SD) 
3:7             
0.38 ± 0.31 
7:11           
0.77 ± 0.70 
0.40* ^ 
14.3.3 (yes:no) 2:15 1:29 0.54 $ 
         Brain MRI findings 
   
White matter hyperintensities 
(yes:no) 
15:9 19:17 0.59 $ 
Atrophy (yes:no) 13:9 21:15 0.47 $ 
Inflammatory changes (yes:no) 5:17 2:34 0.092 $ 
other features (yes:no) 0:22 2:34 0.52 $ 
         EEG findings 
   
slowing 7:4 8:11 > 0.999 $ 
aspecific 9:4 8:11 0.16 $ 
epileptic  2:10 1:18 0.54 $ 
         Neuropsychological testing 
 
MMSE (mean value ± SD) 23.7 ± 5.5 23 ± 5 0.64^ 
BBMD (mean value ± SD) 0.16 ± 0.9 0.32 ± 1.5 0.69^ 
*: statistically significant; $: Fishers’ exact test, two tailed; ^: independent samples t test. 
BBMD: brief battery for mental deterioration; CSF: cerebrospinal fluid; EEG: 
electroencephalogram; MMSE: Mini-Mental State Examination; MRI: magnetic resonance 
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A) Immunohistochemistry, immunofluorescence on neuronal culture (left) and CBAs results 
(right) in the elderly healthy controls population; B) Immunohistochemistry, 
immunofluorescence on neuronal culture (left) and CBAs results (right) in the seronegative 












Figure 3.5 Antibody testing results in control cohorts 
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3.6 Frequency of antibody distribution between cohorts of patients versus controls 
The frequency of seropositive cases was compared between patients with CNS disorders (NT1, 
epilepsy, neurodegenerative) and controls (EHC and SNMG). Results are shown in Table 3.16. 
The overall frequency of reactivity was higher in the CNS disorders (all patients, n= 193) than 
in controls (all controls, n= 209) (P < 0.0001, Fisher’s exact test, two tailed). Irrespective of 
CBA positivity, positivity on tissue (IHC) (P=0.006, Fisher’s exact test, two tailed) or neurons 
(P < 0.0001, Fisher’s exact test, two tailed) were both associated with CNS disorders, but single 
positivity on either tissue or neurons were not different between groups. Positivity on CBAs 
alone (P < 0.0001, Fisher’s exact test, two tailed) or combined positivity on one or both 
screening assays were more frequent in CNS patients than controls (P=0.031, Fisher’s exact 
test, two tailed). The analysis was, therefore, repeated excluding cases with single undetermined 
reactivities. The frequency of seropositivity remained significantly higher in the CNS diseases 
group (P< 0.001, Fisher’s exact test, two tailed) and binary logistic regression analysis showed 
a significant predictive value of this variable (Table 3.17).   
The frequency of antibodies between each cohort of CNS disorders and controls were 
then compared. The EHC were compared only with the neurodegenerative patients due to the 
similar age distribution. Results are in Table 3.18. 
NT1 patients were significantly more seropositive (after excluding single reactivities) 
than SNMG patients (P < 0.0001, Fisher’s exact test, two tailed) and showed more frequent 
positivity for NMDAR antibodies (P < 0.0001, Fisher’s exact test, two tailed).  
Epilepsy patients showed more reactivity (after excluding single reactivities) than 
SNMG patients (P < 0.0001, Fisher’s exact test, two tailed) and more frequent positivity for 
CASPR2 antibodies (P = 0.01, Fisher’s exact test, two tailed) and GABAAR (P = 0.009, Fisher’s 
exact test, two tailed).  
Patients with neurodegenerative disorders displayed more reactivity than both EHC and 
SNMG (Table 5.18) and more frequent positivity for GABAAR (P = 0.02, Fisher’s exact test, 
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N. of positive on tissue (IHC) (%) 33 (17.5) 16 (7.8) 0.006* 
N. of positive on neurons (IF) (%) 33 (17.5) 12 (5.7) 0.000* 
N. of isolated positivity on tissue (IHC) (%) 11 (5.7) 13 (6.2) 0.83 
N. of isolated positivity on neurons (IF) (%) 14 (7.3) 10 (4.8) 0.40 
N. of combined positivity on tissue and 
neurons (%) 
7 (3.6) 1 (0.5) 0.031* 
N. of isolated positivity on CBAs (%) 26 (13.5) 3 (1.4) <0.0001* 
N. of combined positivity by all assays (%) 10 (5.2) 0 0.001* 
N. of cases with any positivity (%) 66 (34.2) 30 (14.4) <0.0001* 
N. of cases with any double positivity (%) 46 (23.8) 7 (3.3) <0.0001* 
N. of CASPR2 positive cases (%) 6 (3.1) 1 (0.5) 0.058 
N. of LGI1 positive cases (%) 3 (1.6) 0 0.10 
N. of AMPAR positive cases (%) 1 (0.5) 0 0.47 
N. of GABAAR positive cases (%) 8 (4.1) 2 (1) 0.054 
N. of GABABR positive cases (%) 4 (2.1) 1 (0.5) 0.20 
N. of NMDAR positive cases (%) 8 (4.1) 1 (0.5) 0.016* 
N. of GlyR positive cases (%) 7 (3.6) 1 (0.5) 0.031* 
*: statistically significant; $: Fisher’s exact test, two tailed; CBAs: cell-based assays; IHC; 
immunohistochemistry; IF: immunofluorescence; N: number. 
 
 
Table 3. 17 Logistic regression analysis 
Variable Sig.  Odds ratio Confidence interval (95%) 
IHC only 0.68 1.24 0.53-2.86 
Neurons only 0.094 2.05 0.88-4.77 
CBA only 0.50 1.73 0.34-8.64 
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N. of positive 
on tissue 
(IHC) 
12 0 10 0.07* 14 0.01* 9 0.13 0.003* 
N. of positive 
on neurons 
(IF) 
12 0 8 0.19* 11 0.09 14 0.004* 0.0002* 
N. of isolated 
positivity on 
tissue (IHC) 
13 0 3 0.56 4 0.59 4 0.78 0.12 
N. of isolated 
positivity on 
neurons (IF) 
10 0 2 0.52 4 >0.999 8 0.10 0.007* 
N. of isolated 
positivity on 
CBAs 





N. of cases 
with any 
positivity 
29 1 22 0.01* 24 0.01* 25 0.0008* <0.0001
* 












1 0 0 >0.999 5 0.01* 1 0.48 >0.999 
N. of LGI1 
positive cases 
















0 1 8 <0.0001
* 
0 >0.999 0 >0.999 0.45 
N. of GlyR 
positive cases 
1 0 1 0.46 1 0.2 4 0.02* 0.12 
$: comparison with SNMG cohort, Fisher’s exact test, two tailed; §: comparison with EHC cohort, Fisher’s exact 
test, two tailed; *: significant value CBAs: cell-based assays; EHC: elderly healthy controls; IHC; 
immunohistochemistry; IF: immunofluorescence; N: number; NT1: narcolepsy type 1; SNMG: 
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3.7 Frequency of antibody distribution between cohorts of patients with CNS disorders  
There were no differences in gender distribution between the cohorts, but age at sampling was 
different (F(2)=132, P<0.0001, one-way ANOVA). Post hoc analysis (Bonferroni) showed that 
NT1 (P<0.0001) and Epilepsy (P<0.0001) patients were significantly younger at sampling than 
Neurogenerative patients, as expected. No differences were found between NT1 and epilepsy 
patients (Table 3.19).   
There were no differences in terms of frequency of general seropositivity among cohorts 
as found by reactivity on IHC, neurons or CBAs. Surprisingly, NT1 patients showed higher 
frequencies of NMDAR antibodies compared to epilepsy (P = 0.001, Fisher’s exact test, two 
tailed) and neurodegenerative patients (P = 0.002, Fisher’s exact test, two tailed) (Table 3.20).  
 
3.8 Features of all patients with antibody reactivity  
 
Clinical features of all patients with CNS disorders showing antibody positivity are summarized 
in Table 3.21. There were no differences in gender distribution between seropositive and 
seronegative cases nor difference in mean age. This did not change after exclusion of cases with 
single unspecified reactivities (Table 3.21). 
Clinical features of patients showing specific antibody reactivity at CBAs are 
summarised in Table 3.22. There were no differences in gender distribution among different 
antibodies. However, age at sampling was significantly different between patients with 
different antibodies (F(5,31)=0.29, P=0.008, one-way ANOVA). Post hoc analysis showed that 
patients with NMDAR antibodies were significantly younger than patients with GABAAR-Abs 
(P=0.001) or GlyR-Abs (P=0.004).  The median age at onset is shown in Table 3.23. Compared 
to literature data, there was a tendency towards a different age and gender distribution for some 
antigens.  
Among the patients with identified antibody reactivities, for which this information was 
available, none showed MRI or CSF evidence of inflammation. Overall, only 5 patients, 4 from 
the neurodegeneration cohort, and 1 from the NT1 met the criteria for possible AE (3 LGI1, 1 
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Table 3. 19 Demographic data of patients with CNS disorders 
 
NT1 Epilepsy Neurodegenerative p-value 
Sex (M:F) 40:21 39:34 37:22 0.31$ 
Age at sampling 31.1 ± 17.7 31.7 ± 14.6 67.9 ± 10.1 <0.0001*^ 
$ Fisher’s exact test; ^: one-way ANOVA; *: significant value.  
 
 
















N. of positive on 
tissue (IHC) 
10 14 0.65 9 0.80 0.49 
N. of positive on 
neurons (IF) 
8 11 0.80 14 0.23 0.37 
N. of isolated 
positivity on tissue 
(IHC) 
3 4 >0.999 4 0.78 >0.999 
N. of isolated 
positivity on 
neurons (IF) 
2 4 0.69 8 0.10 0.007* 
N. of isolated 
positivity on CBAs 
9 13 0.81 11 0.80 >0.999 
N. of cases with any 
positivity 
22 24 0.85 25 0.46 0.37 
N. of cases with any 
double positivity 
17 16 0.42 13 0.4 >0.999 
N. of CASPR2 
positive cases 
0 5 0.06 1 >0.999 0.21 
N. of LGI1 positive 
cases 
1 0 0.45 2 >0.999 0.21 
N. of AMPAR 
positive cases 
0 0 >0.999 1 >0.999 0.45 
N. of GABAAR 
positive cases 
1 4 0.37 3 0.61 >0.999 
N. of GABABR 
positive cases 
1 3 0.25 1 >0.999 0.62 
N. of NMDAR 
positive cases 
8 0 0.01* 0 >0.999 0.41 
N. of GlyR positive 
cases 
1 1 >0.999 4 0.36 >0.999 
N. of HCRTR2 
positive cases 
3 0 0.05 - - - 
* significant value; Fisher’s exact test; $: against NT1 patients; §: against Epilepsy patients; CBAs: cell-
based assays; IHC; immunohistochemistry; IF: immunofluorescence; N: number. 
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Table 3. 21 Demographic data of seropositive and seronegative patients with CNS 
disorders 
 




Seropositive (n=66) 38:28 43.8 ± 23.9 
Seronegative (n=127) 78:49 42.5 ± 21.4 
p-value 0.64 0.68 
Any reactivity excluding undetermined single reactivities 
Seropositive (n=46) 23:23 42.8 ± 22.2 
Seronegative (n=147) 93:54 43 ± 22.3 
p-value 0.12 0.95 
 
 
Table 3. 22 Demographic data of patients with different specific antibodies reactivities 
 
Sex (F,M) Mean age at sampling ± SD 
CASPR2 (n=6) 4,2 31.8 ± 20 
LGI1 (n=3) 1,2 53.3 ± 33.8 
GABAAR (n=8) 4,4 58.3 ± 16.2 
GABABR (n=4) 2,2 36.7 ± 16.9 
NMDAR (n=8) 3,5 26.2 ± 17.5*§ 
AMPAR (n=1) 0,1 78 
GlyR (n= 7) 3,4 57.2± 17.4 






Table 3. 23 Comparison between present study’s data and literature data 
 
Present study data Literature data  










CASPR2 (n=6) 24.5 68 17 66 77 25 
LGI1 (n=3) 66 79 15 64 84 31 
GABAAR (n=8) 51 78 36 53 80 2 
GABABR (n=4) 40.5 53 13 70 75 51 
NMDAR (n=8) 23.5 56 9 25 33 16 
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Table 3. 24 AE criteria in patients with specific antibody positivity 
Antibody Acute 
onset 
CSF feature MRI features Other features AE 
criteria 
NMDAR Yes Normal Normal - No 
NMDAR No OBs Normal - No 
NMDAR Yes Normal Normal - No 
NMDAR Yes Altered BBB 
and increased 
proteins 
N.A. - No 




NMDAR Yes N.A. n.a. - No 
NMDAR Yes N.A. Normal - No 
NMDAR Yes N.A. Normal - No 
LGI1 Yes N.A. Normal Multimodal hallucinations, 
including olfactive, and 
psychosis 
Possible 
LGI1 Yes Normal White matter 
hyperintensities 
Parkinsonism, cognitive and 
psychiatric features 
Possible 





Cognitive and behavioural 
impairment; GTC seizures 
Possible 
GlyR No Normal White matter 
hyperintensities 
- No 
GlyR No Altered BBB White matter 
hyperintensities 
Cognitive and behavioural 
impairment 
No 
GlyR No N.A. Leukodystrophy Ataxia and dysautonomia No 
GlyR No Lymphocytosis Normal Cognitive and behavioural 
impairment 
No 
GlyR No Normal White matter 
hyperintensities 
Parkinsonism No 
GABAAR No OBs White matter 
hyperintensities 
- No 
GABAAR No Normal White matters 
hyperintensities 
and atrophy 
Cognitive impairment No 
GABAAR Yes Lymphocytosis White matters 
hyperintensities 
and atrophy 
Cognitive impairment Possible 
GABAAR 
+AMPAR 
Yes Normal Diffuse cortical 
hyperintensities 
Ataxia and parkinsonism No 
CASPR2 No but 
acute 
worsening 
Normal Normal Parkinsonism, hypersomnia No 
GABABR Yes Lymphocytosis 




Cognitive and mood disorders; 
insomnia 
Possible 
AE: autoimmune encephalitis; GTC: generalized tonic-clonic; OBs: oligoclonal bands; N.A.: not available. 
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3.9 Discussion  
In this Chapter, the frequency of neuronal antibodies in patients with different CNS disorders 
and in both healthy and disease controls was assessed. For each disorder the results were 
compared with the clinical features in order to see which could predict the seropositive status. 
Moreover, the frequencies of antibodies between different cohorts were compared.  
Several studies have tried to identify specific antibodies in patients with Narcolepsy 
type 1 with results that indicate the presence of specific reactivities in a variable, and usually 
small, percentage of cases (Bergman P et al. 2014; Thebault S et al. 2015; Cvetkovic-Lopes V 
et al. 2010; Ahmed SS et al. 2015). Here, antibodies were found against heterogeneous targets, 
in 16.9% of NT1 patients. HCRTR2 antibodies had been previously reported in a high 
proportion of NT1 patients who developed the disease after Pandemrix® vaccination (Ahmed 
SS et al. 2015). In a previous study, we showed that the frequency of these antibodies in 
idiopathic NT1 patients was very low (3%; Giannoccaro MP et al. 2017). Here one new case 
was added, and the previous cases followed up, which confirmed the low frequency of these 
antibodies in NT1, but interestingly, also the association with atypical clinical features, such as 
normal HCRT-1 CSF levels and psychiatric disorders. Surprisingly, although the most common 
antibodies found in this cohort were directed against NMDAR, and their presence was 
associated with an acute onset of the disease, there were no other distinctive clinical features. 
These observations suggest a secondary phenomenon occurring as a bystander effect during the 
neuronal destruction caused by another, possibly T-cell mediated, immune process.  
The presence of NMDAR antibodies has previously been described in a few patients 
with NT1 and associated psychosis (Tsutsui K et al. 2012) but this finding was not replicated 
in a later study (Dauvilliers Y et al. 2016). Indeed, not only did the NDMAR patients studied 
here not have psychotic symptoms but the presence of NDMAR antibodies was inversely 
correlated with the presence of hypnagogic hallucinations.  
On the other hand, this cohort included 9 patients with NT1 and psychosis and 4/9 cases 
showed antibody reactivity (1 by immunohistochemistry, 1 for LGI1 and 2 for HCRTR2, as 
already discussed). This suggests that antibody screening could be appropriate in patients with 
atypical features. This is further supported by the fact that other atypical features were observed 
in these patients, including negative HLA and/or normal HCRT-1 CSF levels.  
In the Epileptic cohort antibodies were detected in 32.8% of cases, but specific 
antibodies were only observed in 13.6%, a percentage lower than other cohorts where the 
frequency was between 20 and 22% (Dubey D et al. 2017; Vanli-Yavuz EN et al. 2016). As 
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expected from previous studies (Quek AM et al. 2012; Barajas RF et al. 2010), the seropositive 
status was associated with AED resistance, particularly in the case of GABABR antibodies. This 
observation is consistent with a pathogenic role for these antibodies at least in some cases. 
However, the occurrence of seropositivity also in cases with a positive family history for 
epilepsy and in a patient with an ascertained genetic form of epilepsy due to CASPR2 mutations 
(GAD65 positive), point to a likely secondary phenomenon.  
Due to the limited clinical information available for this cohort, it was not possible to 
establish other possible relationships that might help identify seropositive cases. Interestingly, 
seropositive patients were younger than the rest of the population, which is an unexpected 
finding considering the general increase in antibody reactivity with aging, and the fact that the 
majority of antibodies against neuronal surface antigens occur in older subjects. This finding, 
if confirmed, suggests that younger patients with refractory epilepsy of unknown aetiology 
could be the ones who would benefit the most from an immunotherapy trial.  
The most commonly observed antibody in our Epilepsy cohort was CASPR2 (6.8%). 
This is similar to what observed in a previous study reporting a prevalence of 10% for CASPR2 
antibodies in a cohort of 111 patients with mesial temporal lobe epilepsy and hippocampal 
sclerosis (Vanli-Yavuz EN et al. 2016). However, in our cases CASPR2 antibodies were not 
associated with temporal lobe lesions or mesial temporal sclerosis.  
The highest frequency of reactivity was observed in the Neurodegenerative cohort 
patients (40.9%), mostly related to the high proportion of sera binding only to neurons. Indeed, 
only 18% of patients presented specific antibody reactivities. Nevertheless, the proportion of 
positive cases was higher than previously reported. This could be related to the use of live-cell 
CBA, which is known to be a more sensitive method than commercial assays using fixed cells 
(Coban A et al. 2014) or to the use of sera instead of CSFs (Grau-Rivera O et al. 2014).  
The most frequently encountered antibodies in this cohort were directed against GlyR. 
All patients with these antibodies had a chronic disease course and variable clinical phenotypes. 
Most of the previous studies concentrated on patients with rapidly evolving dementia, as this is 
one of the most common differential diagnosis of autoimmune encephalitis in elderly patients 
(Coban A et al. 2014; Grau-Rivera O et al. 2014; Flanagan EP et al. 2010). This cohort included 
a large range of different neurological conditions and no differences in antibody frequencies 
were found in patients presenting with prominent dementia compared to patients presenting 
with prominent parkinsonism. Seropositive status, however, was associated with an acute onset 
of symptoms and the presence of sleep disorders. Sleep disorders, like hypersomnia, insomnia, 
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status dissociatus or agrypnia excitata, are common features of patients with autoimmune 
encephalitis (Liguori R e al. 2001; Stamelou M et al. 2012).  
Not surprisingly, seropositivity was also associated with the presence of other 
antibodies, such as anti-nuclear antibodies, irrespectively of the presence of another 
autoimmune disease. Interestingly, seropositive patients showed significantly higher levels of 
A-beta protein in the CSF as well as a lower tau/A-beta ratio, a profile that has been previously 
associated with Alzheimer’s disease (AD) (Tapiola T et al. 2009). However, recently the same 
findings, with normal levels of CSF total-tau protein, have been reported in patients with 
chronic insomnia (Chen Dw et al. 2018). Whether our findings correlate with the sleep disorders 
observed in these patients needs to be investigated. This observation might also have clinical 
utility, particularly in the context of the differential diagnosis between an autoimmune dementia 
and AD. This is even more relevant considering that the majority of cases with specific 
reactivities did not show inflammatory changes either on brain MRI or in the CSF, as previously 
reported (Escudero D et al. 2017). 
Overall, patients with CNS disorders showed more frequently the presence of antibodies 
against neuronal surface antigens compared to elderly healthy controls and SNMG patients. 
The differences in antibody reactivities, however, were similar among all cohorts when 
considering single uncharacterised reactivities found with only one method (i.e. isolated 
reactivity on tissue or on neurons). These findings are in line with a previous retrospective study 
comparing the frequency of antibodies in patients and healthy controls reported in the literature 
(Lang K and Pruss H, 2017) and suggests that, in screening cohorts for the presence of 
antibodies, positive findings should concentrate on cases showing reactivity on at least two 
different assays to support their specificity.  
Given the small numbers involved, no differences were observed in the frequencies of 
antibody reactivities among CNS disorder patients, although some specific antibodies were 
more common in some cohorts, such as NMDAR antibodies in NT1 patients. This suggests that 
in several neurological conditions at least a proportion of patients might have an autoimmune 
aetiology. Of course, the role of these antibodies remains unclear. Few sera bound strongly on 
tissue, neurons or CBAs and CSFs were not available. Moreover, not all cases with positive 
antibodies on CBAs bound to neurons or tissue. This could reflect the low titres of the 
antibodies as well as the different serum dilutions used on these assays and the different 
concentration of the antigens.  
Only a few patients in our cohorts met the criteria for possible autoimmune encephalitis. 
These cases may represent misdiagnosis. The other cases might represent cases with a 
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“restricted” or “atypical” phenotype. Antibody-associated phenotypes might change in relation 
with the age of patients. For example, for LGI1 antibodies the typical facio-brachial dystonic 
seizures were not described in children (López-Chiriboga AS et al. 2018). Indeed, in our 
cohorts, compared to literature data, there was a tendency towards a different age and gender 
distribution for some antigens. For example, CASPR2 antibodies were more frequent in female 
and in younger patients, whereas GABABR and GlyR antibodies were observed in older patients 
compared to the cases reported in the literature.  
Antibodies might also be a secondary phenomenon. However, it is important to note 
that patients with a previous different neurological condition could develop antibodies in the 
course of their disease, as shown by cases presenting a sudden worsening of symptoms, and 
they could still benefit from immunotherapy in this situation.  
Our study has several limitations. Clinical data were not homogenous among cohorts 
and in some cases very limited (i.e. for the Epilepsy cohort), and demographic data were not 
available for the controls. Moreover, the lack of systematic titrations and of CSFs hampered 
our ability to understand better the role of these antibodies in these patients. Finally, it is 
important, of course, that in this essentially exploratory study, none of the clinical associations 
were corrected for multiple comparisons. Despite these limitations, we have shown that 
antibodies against neuronal surface antigens are more common in patients with CNS conditions 
than in controls and that some clinical features might help to identify those cases that could 
benefit for immunotherapy.   
In order, to prove pathogenicity of antibodies, it is necessary to perform both in vitro 
and in vivo experiments. With the availability of plasma from plasma exchange from a patient 
with an atypical limbic encephalitis/Morvan syndrome, it was possible to investigate the 












  113 
  
Chapter 4: Behavioural findings in CASPR2-antibody injected mice  
 
4.1 Introduction 
As discussed in Chapter 1, antibodies to CASPR2 (CASPR2-Abs) have been associated with 
limbic encephalitis and a wide range of central and peripheral nervous system disorders. Passive 
transfer of antibodies to experimental animals is considered the best way to prove pathogenicity 
of an antibody, but this has not yet been done by the peripheral route for any of the recently-
described antibodies to neuronal surface antigens (NSAs).  
CASPR2-Abs are typically at higher titres in serum than in CSF. Intraperitoneal injection 
of purified IgG from two CASPR2-Ab positive patients to mice over 18 days, without attempt 
to breach the blood-brain barrier (BBB), reduced the thresholds for mechanical stimuli and 
enhanced the excitability of dorsal root ganglia (DRG) neurons through reductions in Kv1 
channel expression, but in that study brain pathology was only marginally investigated (Dawes 
JM et al. 2018). To explore the effects of CASPR2-Ab in the CNS, we used a similar protocol 
with 8 daily injections of IgG purified from one patient with autoimmune encephalitis and from 
one healthy control (as used in previous studies: Coutinho E et al. 2017; Dawes JM et al. 2018). 
We added a single dose of lipopolysaccharide (LPS) at day 3 to disrupt the BBB. We evaluated 
the effects of the antibody on mouse behaviors from day 5 of the injections and for three days 
following the last injection, and then looked for evidence of brain pathology.  
 
4.2 Purification of IgG from CASPR2-Ab patient and healthy individual 
 
Plasma obtained from a patient who underwent plasma exchange during the course of his 
disease was used in this animal model. The serum of a sex- and age-matched healthy individual 
was used as control. All methods are described in Chapter 2. Human IgG was purified using 
the Protein G Sepharose beads, and concentrations measured using a NanoDrop 
spectrophotometer. The patient with CASPR2-Ab encephalitis was a 70-year old man who 
presented with cerebellar ataxia and neuropathic pain in his feet and hands, memory complaints 
(short- and long-term memory, and particularly word-finding difficulties) and short episodes of 
lack of perception with “goosebumps” suggestive of temporal seizures. Oncological screening 
excluded the presence of a tumour. A cell-based assay revealed the presence of very high titres 
of CASPR2 antibodies (1:62500) and he partially responded to plasmapheresis and 
immunosuppression. The absence of other, concomitant, antibodies and the specificity of the 
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reactivity against CASPR2 was previously ascertained by Coutinho E et al. (2017), who showed 
that the binding of this IgG to mouse brain tissue was lost on brain sections from CASPR2 K.O. 
mice. The healthy control serum was negative for all known antigenic targets. 
For the purpose of this thesis, purified IgG from this patient with CASPR2-Ab 
encephalitis, and from the healthy control, will be designated CASPR2-IgG and HC-IgG, 
respectively.  
4.3 Experimental design  
The experimental design is summarised in Figure 4.1. Nineteen C57Bl6 male mice aged 6 
weeks (18-22 g) were daily injected intraperitoneally (i.p.) with either CASPR2-IgG (10 mice) 
or HC-IgG (9 mice) (20 mg/ml on day 0; 12-6 mg/ml afterwards; volume 1-2 ml) for 8 days. 
At day 3 all animals were injected i.p. with lipopolysaccharide (LPS, E. Coli, 1 mg/Kg). 
Behavioural testing, including tasks assessing locomotion (open field), strength (inverted 
screen) and coordination (accelerating rotarod and narrow beam), working memory (continuous 
spontaneous alternation), short- (forced alternation and) and long-term memory (novel object 
recognition), anxiety (light-dark box), compulsive-like behaviour (marble burying test), social 
behavior (reciprocal social interaction tests) and olfaction (olfaction test) was then performed 
from day 5 to 10. At day 11 animals were sacrificed and sera and brains collected for analysis 
(details in Chapter 2). 
4.3 Weight 
 
Animals were weighted daily during the course of the experiment as a general assessment of 
well-being. No differences were observed between CASPR2- and HC-IgG injected mice (group 
P=0.83, time x status P=0.35, repeated measure ANOVA with Greenhouse-Geisser correction, 
Figure 4.1).  
 
4.4 Tests of strength and coordination 
 
Strength was assessed by the inverted screen. No difference was observed in the time to fall 
between groups (F(1,16)=3.8, P=0.06, one-way ANCOVA), although CASPR2-IgG injected 
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B) Weights       C) Accellerating rotarod D) Inverted screen 




 A) Experimental design.  AR= accelerating rotarod; OF= open field; IS= inverted screen; 
NORf= novel object recognition, familiarization phase; NORt= NOR, test phase; LDb= 
light-dark box; FA= forced alternation test; NR= narrow beams; MB: marbles burying 
test; CSA= continuous spontaneous alternation test; OT= olfaction test; RSI= reciprocal 
social interaction test B) Weights changes over time. Accelerating rotarod (C), inverted 
screen (D) and narrow beams tests results (E). No differences were observed between 
HC-IgG and CASPR2-IgG injected mice. Data are expressed as mean ± SEM. 
 
Figure 4.1 Experimental design and locomotor tests results 
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Coordination was evaluated by two tests, the accelerating rotarod and the successive 
narrow beams test. During the accelerating rotarod no differences were observed in the time to 
fall between groups (F(1,16)=0.26, P=0.61, one-way ANCOVA). For the narrow beams we 
evaluated the results obtained using the smallest rod as no animals fell from the wider ones. No 
differences were observed between groups in orientation time (F(1,16)=1.71, P=0.20, one-way 
ANCOVA) or in transit time (F(1,16)=1.79, P=0.20, one-way ANCOVA) (Figure 4.1). 
 
4.6 Open field test 
 
The open field test was used to evaluate different behaviours including locomotor activity, 
anxiety and repetitive behaviour. Locomotor activity was evaluated by the total number of 
entries in each square, the number of rearing and the total time spent active. No differences 
were observed between CASPR2- and HC-IgG injected mice in the total number of entries 
(F(1,16)=0.48, P=0.49, one-way ANCOVA), number of rearings (F(1,16)=2.5, P=0.13, one-
way ANCOVA) or total time spent active (F(1,16)=0.85, P=0.36, one-way ANCOVA). 
Anxiety-like behaviour was evaluated by counting the number of entries in peripheral vs central 
squares, the total time spent in the periphery or in the center of the arena, and counting the 
number of foecal boli which signify stress. No difference was observed between groups in the 
number of peripheral entries (F(1,16)=0.77, P=0.39, one-way ANCOVA), central entries 
(F(1,16)=0.11, P=0.73, one-way ANCOVA), time spent in the periphery (F(1,16)=0.24, 
P=0.62, one-way ANCOVA) or in the center of the arena (F(1,16)=0.24, P=0.62, one-way 
ANCOVA) and number of foecal boli (F(1,16)=0.40, P=0.53, one-way ANCOVA). Finally, 
repetitive behaviour was assessed by analysis of grooming. No differences were observed 
between groups in the number of grooming events (F(1,16)=0.39, P=0.54, one-way ANCOVA) 
or in the time spent grooming (F(1,16)=1.8, P=0.19, one-way ANCOVA) between the two 
groups (Figure 4.2). 
 
4.7 Test of anxiety  
 
Beside the open field, anxiety was specifically evaluated by the light-dark box test, which 
explores the innate preference of mice to explore dark areas. There were no differences between 
groups in latency to move to the dark side of the box (F(1,16)=1.05, P=0.32, one-way 
ANCOVA), time spent in the dark (F(1,16)=0.13, P=0.71, one-way ANCOVA) or number of 
crossings between the two chambers (F(1,16)=0.14, P=0.71, one-way ANCOVA) (Figure 4.3). 
 







N. total entries        N. of rearing                Time active 
N. peripheral entries        N. central entries        Time in periphery     Time in center 
N. foecal boli      N. grooming events      Time grooming 
  
No differences were observed between HC-IgG and CASPR2-IgG injected mice in 
any of the parameters analysed during the open field test. Data are expressed as 
mean ± SEM. 
  
 Figure 4.2 Open field test results 
 




                        
 
No differences were observed between HC-IgG and CASPR2-IgG injected 
mice in anxiety (A) or compulsive-like behaviour (B). Data are expressed 
as mean ± SEM. 
 
A) Light-dark box test 
 
                        
B) Marbles burying test 
Figure 4.3 Light-dark box and marbles burying test 
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4.8 Test of compulsive-like behavior  
 
Compulsive-like behaviour was assessed using the marble burying test (MBT). No differences 
were observed between groups in the percentage of marbles buried (F(1,16)=0.52, P=0.47, one-
way ANCOVA) (Figure 4.3). 
4.9 Tests of memory 
Different memory subtypes were explored using three tests. Both the forced alternation and the 
novel object recognition tests are based on the innate tendency of mice to prefer novelty. The 
forced alternation was used as a test of short-term memory. Although CASPR2-IgG injected 
mice showed a trend towards a reduced preference index for number of entries (F(1,16) = 3.36, 
P=0.085, one-way ANCOVA) in the novel arm (NA), no differences were observed between 
groups in the time spent (F(1,16)=0.26, P=0.61, one-way ANCOVA) in the new arm. The novel 
object recognition test was used to evaluate long-term memory. No differences between groups 
were observed in the preference index for the novel object (NO) (F(1,16)=2.45, P=0.14, one-
way ANCOVA). However, a significant reduction was observed in the percentage of 
spontaneous alternations (F(1,16)=5.04, P = 0.039, one-way ANCOVA) in the CASPR2-IgG 
injected animals compared to controls, despite a similar number of total arms entries between 
groups (F(1,16)=0.37, P=0.55, one-way ANCOVA), suggesting a possible working memory 
impairment in CASPR2-IgG exposed mice. In the same test, there was no difference in the 
percentage of alternate arm re-entries (F(1,16)=0.93, P=0.34, one-way ANCOVA) or in the 
percentage of same arm re-entries (F(1,16)=3.66, P = 0.074, one-way ANCOVA) (Figure 4.4).  
 
4.10 Olfaction test  
As mice rely heavily on smell for orientation and for their social interactions, an olfaction test 
was performed once at the end of the protocol as a control for the memory test and social 
interaction experiment. This experiment consisted of a sampling phase, where the same odour 
was placed in 2 containers and the test mouse allowed to freely explore, a delay period and a 
test phase, when the mouse was allowed to choose between the old or a novel odour. The mouse 
was expected to preferentially explore a novel odour, if its olfaction sense was intact. No 
differences were observed between groups in the time spent (P=0.36, independent samples t-
test) or in the number of visit to the new odour (NO) (P=0.67; independent samples t-test) 
(Figure 4.4). 
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Figure 4.4 Memory tests and olfaction test results 
A) In forced alternation, there were no differences in the preference index for number of 
entries or time spent in the novel arm (NA). B) Novel object recognition test did not show 
differences between the two groups in the preference index for the novel object (NO) 
although there was a trend to reduced preference in CASPR2-IgG injected mice. C) 
Alternations were reduced in CASPR2-IgG injected mice compared with HC-IgG injected 
mice. D) The olfaction test showed no differences between groups in the time spent or in the 
number of visits to the novel odour (NO). Data are expressed as mean ± SEM. 
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4.11 Reciprocal social interaction test 
 
Social behaviour was investigated by the reciprocal social interaction test in pairs of animals of 
the same group. The animals were tightly matched according to weight (within 5% of the 
weight), so any variation resulting from this factor was avoided. This meant that only 6 pairs 
per group could be tested, in order to avoid repeating the test in each animal more than twice. 
Since this test is based on the interaction between mice that have not been in contact before and 
given the limited number of animals, the test could only be done once, after the injections. 
During the test phase, a pair of animals was allowed to interact freely while the interaction was 
video recorded; later on, both social (licking, sniffing, grooming and following closely the other 
animal) and non-social behaviours (time spent inactive, number of rearing, self-grooming) were 
scored offline.  
CASPR2-IgG injected mice showed longer latency to start interacting compared to HC-
IgG injected mice (U= 5.5, P=0.04; Mann-Whitney U test) but similar interaction time (P=0.58; 
Mann-Whitney U test) and number of interactions (P=0.18; Mann-Whitney U test). Concerning 
non-social activities, CASPR2-IgG injected animals showed less exploratory behaviour as 
indicated by less rearing events (t(22)=3.01, P=0.006; independent samples t-test) and longer 
time spent immobile (t(22)=3.42, P=0.002; independent samples t-test), compared to HC-IgG 
injected animals. No differences, however, were observed between groups in the time spent 
self-grooming (P=0.97; Mann-Whitney U test) but HC-IgG injected mice showed a higher 
number of grooming actions (t(22)=2.61, P=0.015; independent samples t-test), corresponding 
to a longer duration of each self-grooming bout in CASPR2-IgG injected mice (t(22)=2.48, 
P=0.002; independent samples t-test) (Figure 4.5). It is noteworthy that all these non-social 
behaviours were assessed also during the open field and no differences were observed between 
groups, suggesting a specific influence of the social context. 
4.12 Discussion  
In this Chapter, the in vivo behavioural outcomes of mice injected with CASPR2 IgG were 
described. In patients with CASPR2 antibodies, there are a wide range of CNS behavioural 
changes from anxiety and depression to memory impairment, seizures and sleep disorders, 
representing limbic encephalitis or Morvan Syndrome spectra. Ataxia has also been described 
in some patients. In addition, genetic defects of CNTNAP2, the gene encoding for CASPR2, 
have been reported in patients with autism and epilepsy (Friedman JI et al. 2008).  
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Figure 4.5 Reciprocal social interaction test 
 
In the reciprocal social interaction test there was reduced latency to interact but no differences 
in the interaction time, or number of interactions between CASPR2-IgG and HC-IgG injected 
mice. However, in the non-social aspects of the test, CASPR2-IgG injected mice showed 
increased time spent immobile, reduced rearing, reduced grooming and longer duration of 
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Given the difficulty in anticipating the specific deficits that might be caused by CASPR2-Abs 
in a mouse model, a broad range of functions and behaviours were studied in an exploratory 
model. 
No differences were observed in total body weight, motor tasks, anxiety tests and 
compulsive-like behavior between groups. However, mice injected with CASPR2-IgG showed 
less alternation in the continuous spontaneous alternation tests, with similar trends in the forced 
alternation and novel object recognition tests, suggestive of memory impairment. During the 
social interaction test CASPR2-IgG injected mice showed longer latency to interact and 
increased immobility suggestive of anxiety-like behaviour. Since the same non-social activities 
were normal during other tests (i.e. open field) they are likely to be related to the social novelty 
context (Meeker H et al. 2013). This interpretation is also supported by the longer grooming 
bouts during the same test (Kalueff AV and Tuohimaa P, 2004). This needs to be explored in 
more detail in the future.  
Two previous studies assessed the effects of CASPR2 antibodies in different passive 
transfer animal models. The first one, showed that in utero CASPR2-IgG exposed mice 
displayed pronounced social interaction defects and increased repetitive behaviours such as 
grooming and digging in the absence of alterations of locomotor or anxiety behaviours. In this 
model memory or cognitive deficits were not extensively explored, but there was a strong trend 
for an impairment of working memory in CASPR2-IgG exposed mice, when assessed by 
spontaneous alternation in the T-maze (Coutinho E et al. 2017). However, this study used a 
placental passive transfer model, so the mice were exposed to the antibodies early in their 
neurodevelopment and this is expected to cause different and wider effects compared to the 
exposure of adult mice. In this respect, indeed, that approach might be expected to recapitulate 
more closely the effects of CASPR2 mutations.    
The second model was focused on the peripheral effects, specifically the presence of 
pain, of CASPR2-Abs in adult mice and used peripheral CASPR2-IgG injections, very similar 
to that used here, but in the absence of LPS to open the blood-brain barrier (Dawes JM et al. 
2018). Therefore, the authors explored the presence of pain and the presence of alterations in 
locomotor activity and coordination without exploring CNS functions. Mice exposed to 
CASPR2-IgG showed mechanical pain-related hypersensitivity. Reassuringly, no differences 
were observed between groups in the open field and in the accelerating rotarod in that model, 
similar to the results described here. 
Interestingly, the same study compared the effects induced by the antibodies on pain 
sensitivity with those observed in knockout mice (KO) lacking CASPR2 (CNTNPA2−/−). 
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These mice demonstrated enhanced pain-related hypersensitivity to noxious mechanical 
stimuli, although more severe than that obtained with the antibodies, and that was extended to 
heat and algogens. Nevertheless, either immune or genetic-mediated ablation of CASPR2 
enhanced the excitability of dorsal root ganaglia (DRG) neurons through regulation of Kv1 
channel expression at the soma membrane. These findings imply that in adult mice, antibodies 
can recapitulate the effects induced by genetic mutation but in a more limited and less severe 
manner. CNTNAP2 KO mice were shown to have social deficits, abnormal motor activity, 
cognitive deficits and seizures (Penagarikano O et al. 2011). More recently, a model showed 
also the presence of hypoactivity and wake fragmentation with a flattened diurnal activity 
rhythm (Thomas AM et al. 2017). Performance in memory tasks have shown contrasting results 
suggesting a lack of spatial learning and memory impairments but a significant impairment in 
learning (Peñagarikano O et al. 2011), or the presence of significant deficits in spatial working 
and reference memory (Rendall AR et al. 2016). The reasons for these different findings might 
be related to the tests used and to the different difficulty of the tasks. However, this suggests 
that CASPR2 KO mice do not display obvious memory impairment, like the CASPR2-IgG 
injected mice, which showed only modest changes. 
Our approach has some limitations. It is always difficult to establish correlations 
between animal phenotypes and human disorders and this might explain why we observed such 
mild changes in our model. The fact that the major differences in behaviour were observed in 
tests performed at day 10 suggest as well that behavioural changes may need a longer period to 
fully develop. Indeed, in previous passive transfer models the maximal behavioural effect was 
observed after 14 days of injections (Dawes JM et al. 2018; Planagumà J et al. 2015). In our 
study, the limited amount of plasma available for CASPR2-IgG purification did not allowed a 
longer period of IgG administration.  
In conclusion, CASPR2-IgG injected mice showed clear although mild behavioural 
alterations in the tests performed. A wider and more targeted range of tests needs to be 
established for further studies. As it stands, it is difficult to interpret the results in the light of 
the clinical implications but to look further into the effects of the antibodies in vivo, we 
evaluated the presence of neuropathological changes that might relate to these alterations. The 
results of behavioural and histological changes will be integrated in the general discussion. 
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Chapter 5. IgG transfer and pathological changes in CASPR2-antibody 
injected animals 
5.1 Introduction 
A detailed analysis of the brain was conducted in a randomly selected subgroup of animals at 
the end of the experiment, in order to look for IgG deposition in the brain and provide a 
histological substrate for the behaviour abnormalities found in the CASPR2 IgG-injected mice. 
Firstly, the presence of CASPR2-IgG was assessed in the sera and brain parenchyma of 
CASPR2-IgG inject animals versus controls. Subsequently, a general morphometric study was 
conducted. Afterwards, a hypothesis-driven analysis looked for similarities with the 
histological abnormalities described in the few neuropathological cases of patients with 
CASPR2-Ab encephalitis reported in the literature; for example, reduced expression of 
CASPR2, neuronal loss and microglia activation (Sundal C et al. 2017; Liguori R et al. 2001; 
Kortvelyessy P et al. 2015), as well as the findings of previous animal models such as increased 
neuronal activity, using c-fos as a surrogate marker (Dawes JM et al. 2018). In addition, changes 
of CASPR2 expression and levels of cytokines and chemokines were evaluated in brain protein 
extracts. 
5.2 Overview on sera and brain processing  
Eleven animals (6 CASPR2-IgG and 5 HC-IgG injected) were randomly selected and sacrificed 
by CO2. Blood samples were collected by cardiac puncture, centrifuged and the sera used for 
testing by cell-based assay for CASPR2-IgG (see Chapter 2). Brains from the same animals 
were harvested and snap-frozen for protein extraction. Eight animals (4/group) were perfused 
with phosphate-buffered saline (PBS) followed by ice-cold 4% paraformaldehyde (PFA). 
Histological studies were performed on PFA-fixed, free-floating, 50 m coronal sections of the 
brain. Nissl staining was conducted to assess gross morphological abnormalities and to 
determine volume and/or thickness of total brain or specific brain regions. The remaining 
studies were done by immunofluorescence. Protein analysis was conducted on 3 brains per 
group by western blot for CASPR2 expression and by a commercial array for 
cytokine/chemokine expression. The statistical analysis compared the results between CASPR2 
and HC IgG-injected animals using an N number of 4, if not otherwise specified. All 
experiments were coded for treatment groups.  
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5.3 Serum CASPR2 antibodies and brain human IgG deposition  
A cell-based assay for CASPR2-Abs confirmed high levels in the CASPR2-IgG injected mice 
even on Day 11, 4 days after the last IgG injection (Figure 5.1).  
The distribution of human IgG was investigated in different brain regions by 
immunofluorescence (Figure 5.1). Both CASPR2- and HC-IgG injected animals showed the 
presence of IgG in the brain. However, the level of deposited IgG, as evaluated by fluorescence 
intensity, was higher in the cortex (t(6)=2.71, P=0.03, independent samples t-test), 
hippocampus (t(6)= 3.03, P=0.023, independent samples t-test) and thalamus (t(6)= 7.14, 
P=0.0004, independent samples t-test ) of CASPR2-IgG injected mice compared to controls 
(Figure 5.1). No differences between groups were observed in the cerebellar cortex which was 
analysed overall, without distinguishing the different layers (t(6)=1.57, P=0.16, independent 
samples t-test). 
5.4 CASPR2 expression  
To look at the similarity between CAPSR2 and IgG staining, two consecutive series were 
incubated with anti-human IgG antibodies and with rabbit monoclonal anti-CASPR2 antibodies 
respectively. We used two consecutive sections instead of a single one to avoid the interactions 
between secondary anti-human and anti-rabbit antibodies we noted in preliminary experiments. 
In the same experiments, we also excluded the presence of interactions between the rabbit anti-
CASPR2 antibodies, the secondary anti-rabbit antibodies and the human IgG already present 
in the tissue.  
We would have expected a reduction of CASPR2 expression as a consequence of the 
IgG binding. Nevertheless, there were no apparent differences in CASPR2 expression, 
measured by mean fluorescence intensity between the two groups in the cortex (t(6)=1.04, 
P=0.33, independent samples t-test), hippocampus (t(6)= 1.23, P=0.26, independent samples t-
test), thalamus (t(6)=0.23, P=0.82, independent samples t-test) or cerebellum (t(6)=0.34, 
P=0.74, independent samples t-test) (Figure 5.1). Similar results were obtained when total 
CASPR2 protein was quantified by western blot (WB) in whole brain lysates (t(4)=1.65, 
P=0.17, independent samples t-test) (Figure 5.2); indeed, CASPR2 expression showed a trend 
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Figure 5.1 Sera and brain IgG and CASPR2 expression 
A) Representative images of cell-based assays showing CASPR2-Ab in the serum from a 
CASPR2-IgG injected mouse but not in the serum from a HC-IgG injected mouse. 63X, scale 
bar 10 µm. B) Representative images of IgG and CASPR2 expression in perfused fixed 
brains. C) CASPR2-IgG injected animals had higher levels of IgG in the cortex (Cx), 
hippocampus (Hip) and thalamus (Th) compared to HC-IgG injected mice, but not in the 
cerebellum (Cb). No differences were observed in the levels of CASPR2 expression in the 
same areas (C). 40X, scale bar, hippocampus 200 µm, cerebellum 50 µm. Data are expressed 






















Figure 5.2 Western blot analysis of CASPR2 expression 
Western blots of the whole brains from CASPR2-IgG injected mice (C2) showed a trend 
towards increased CASPR2 expression, normalized by GAPDH, compared to HC-IgG 
injected mice (HC) (3 brains/group; means of 4 replicates for each brain). Data are expressed 
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5.5 Morphometric analysis  
No gross morphological changes were observed on Nissl-stained sections between the two 
groups. In particular, there were similar hippocampal (t(6)=0.5, P=0.63, independent samples 
t-test), cerebellar (t(4)=1.19, P=0.29, independent samples t-test) and total brain volumes 
(t(4)=1.5, P=0.20, independent samples t-test) between the two groups. Likewise, there were 
no differences in the thickness of the anterior cingulate (t(6)=0.25, P=0.80, independent 
samples t-test), primary motor (t(6)=0.11, P=0.91, independent samples t-test), piriform 
(t(6)=2, P=0.07, independent samples t-test) or somatosensory cortex (overall: t(6)=0.2, 
P=0.82; layer I t(6)=0.7, P=0.46, layers II-IV t(6)=0.2, P=0.83, layers V-VI t(6)=0.19, P=0.84, 
independent samples t-test). No differences were observed in the thickness of the hippocampal 
cell body layers (dentate gyrus t(6)=0.04, P=0.96, CA3 t(6)=0.24, P=0.81, CA1 t(6)=0.77, 
P=0.46; independent samples t-test) or fields (CA4 t(6)=1.2, P=0.27, CA3 t(6)=0.37, P=0.72, 
CA1 t(6)=1.9, P=0.10, independent samples t-test). The thickness of the cerebellar molecular 
(t(6)=1.5, P=0.16, independent samples t-test) and granular (t(6)=0.77, P= 0.46, independent 
samples t-test) layers was also not different (Figure 5.3).  
5.6 Neuronal counts and neuronal activation  
To evaluate if CASPR2-Abs were able to cause neuronal death we measured the density of 
neurons, stained by the NeuN marker. No evidence of neuronal loss was found in the CASPR2-
IgG compared to the HC-IgG injected mice in the somatosensory cortex (t(6)= 1.12, P=0.30, 
independent samples t-test), in the piriform cortex (t(6)= 0.54, P=0.60, independent samples t-
test) or in the hippocampus (overall t(6)=1.6, P=0.15; CA4 t(6)= 0.13, P= 0.89; CA3 t(6)=0.27, 
P= 0.79; CA1 t(6)=1.60, P= 0.16; independent samples t-test). In the cerebellum, however, 
despite no difference in the count of NeuN positive cells in the molecular layer (t(6)= 0.86, 
P=0.42, independent samples t-test), there was a 14.6% reduction in the number of calbindin-
positive Purkinje cells (t(6)=2.45, P=0.049, independent samples t-test) (Figure 5.4).  
 We used c-fos expression on NeuN stained neurons as a marker of neuronal activity. 
Compared to the HC-injected mice, mice injected with CASPR2-IgG showed a higher density 
of c-fos expressing neurons in the entorhinal-piriform cortex (t(6)=3.11, P=0.020), dorsomedial 
(t(6)=2.67, P=0.036) and lateral (t(6)=2.79, P=0.031, independent samples t-test) 
hypothalamus. No differences between groups in the density of c-fos expressing neurons were 
detected in the hippocampus (overall: t(4)=0.77, P= 0.48; DG t(6)=0.87, P=0.41; CA3 t(6)= 
1.77, P=0.12; CA1 t(6)=0.96, P=0.37; independent samples t-test), somatosensory cortex 
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(t(6)=1.2, P=0.26, independent samples t-test) and amygdala (t(6)=1.03, P=0.34, independent 
samples t-test) (Figure 5.5). 
5.7 Microglia analysis  
Microglia are the resident tissue macrophages of the CNS. These cells can transform from a 
surveillance state to an activated phenotype in response to brain injury. Under normal 
conditions they are characterised by a small cell body with fine, ramified processes and low 
expression of surface antigens. In response to brain injury, ischemia and inflammatory stimuli, 
microglia rapidly transform into an activated phenotype associated with proliferation, migration 
to the site of injury, elaboration of both neurotoxic and neurotrophic factors and phagocytosis 
of cellular debris (Garden GA and Moller T, 2006; Hanisch UK and Kettenmann H, 2007; Streit 
WJ, 2002). Activated microglial cells, as identified by expression of Iba1 and CD68, were 
measured in the somatosensory and piriform cortices, the hippocampus and the cerebellum. 
Microglial density was increased in the somatosensory cortex of CASPR2-IgG injected mice 
(t(6)=2.63, P=0.038, independent samples t-test) and molecular layer of the cerebellum 
(t(6)=4.99, P=0.002, independent samples t-test) but not in the piriform cortex (t(6)= 1.31, 
P=0.23, independent samples t-test), the hippocampus (overall t(6)=1.34, P=0.22, CA4 
t(6)=0.86, P=0.41, CA3 t(6)=0.59, P= 0.57, CA1 t(6)=1.92, P= 0.10, independent samples t-
test) or the granular layer (t(6)= 0.27, P=0.79, independent samples t-test) of the cerebellum 
(Figure 5.6). 
Analysis of microglial morphology was performed on Iba1 positive cells (Figure 5.6) in 
the hippocampus and in the molecular layer of the cerebellum. When activated, microglia 
assume an ameboid morphology characterised by a larger soma body and shorter processes. In 
the hippocampus, microglia from CASPR2-IgG injected mice showed a higher cell soma/cell 
total body size ratio (t(6)=4.74, P=0.0032, independent samples t-test), less (t(6)=3.27, 
P=0.017, independent samples t-test) and shorter (t(6)=3.68, P=0.010, independent samples t-
test) ramifications than HC-IgG injected mice, compatible with an activated phenotype. Similar 
results were found in the molecular layer of the cerebellum, with a higher soma/total body area 
size ratio (t(6)=7.35, P=0.0003, independent samples t-test) and shorter ramification maximal 
length (t(6)=3.68, P=0.008, independent samples t-test) in CASPR2-IgG than in HC-IgG 






























A) Photograph showing the cresyl violet staining of a brain serie (left panel) and volumetric 
measurements. B) Cortical thickness measurements. C) Photograph showing an example of 
cortical layers measurement in the somatosensory cortex and quantification of the layers 
thickness. D) Photograph showing an example of hippocampal cell body layers and fields 
measurements and their quantification. E) Quantification of the thickness of cerebellar layers. 
No differences were observed in any parameter between HC-IgG and CASPR2-IgG injected 








































































































































































































































Figure 5.3 Nissl staining 
 








Figure 5.4 Analysis of neuronal count in mouse brains 
A) Representative pictures of NeuN expression and quantification of NeuN positive cell 
densities in three brain regions. There were no differences between CASPR2-IgG and HC-
IgG injected brains. B) Calbindin expressing Purkinje cells (PC), but not NeuN expressing 
neurons, were reduced in the cerebellum of CASPR-IgG injected mice. Data are expressed as 
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Figure 5.5 C-fos expression 
C-fos expression in the entorhinal-piriform cortex, dorsomedial hypothalamus (DMH) and 
lateral hypothalamus (LH) was higher in the CASPR2-IgG injected compared to the HC-IgG 
injected mice (Representative images are shown from the entorhinal-piriform cortex). DG= 

























Figure 5.6 Microglial density and morphological analysis 
 
A) Representative images of the molecular layer of the cerebellum showing microglia 
staining. 40X, scale bar 20 µm. B) CASPR2-IgG injected mice showed higher microglia 
densities in the somatosensory cortex and in the molecular layer (ML) of the cerebellum but 
not in the granular layer (GL) or in the hippocampus. N= 4 animals/group. C) Representative 
images of the z-stack projected Iba1 staining used for morphological analysis. 40X, 10 µm. 
D) Quantification of morphological data in the hippocampus and molecular layer of the 
cerebellum showed that microglia from CASPR2-IgG injected mice had a higher cell 
soma/cell total body size ratio and shorter ramifications than HC-IgG injected mice, 
compatible with an activated phenotype in both the hippocampus and the cerebellum. N=200 
cells from 4 animals/groups were analysed from the hippocampus and 100 from the cerebellar 
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5.8 Astrocyte analysis  
 
The presence of astrocytosis was assessed by measuring the density of GFAP positive cells. 
We did not observe an increased density of astrocytes in the somatosensory (t(6)= 0.46, P= 
0.66, independent samples t-test) and piriform cortices (t(6)=0.45, P=0.66, independent 
samples t-test) or hippocampus (overall: t(6)=1.44, P=0.19, CA4 t(6)=1.69, P=0.14, CA3 
t(6)=0.32, P=0.75, CA1 t(6)=1.06, P=0.32, independent samples t-test). However, mean 
fluorescence intensity for GFAP in the molecular layer of the cerebellum showed increased 
GFAP staining (t(6)= 2.5, P=0.043, independent samples t-test) in the CASPR2-IgG injected 
compared to control mice compatible with the presence of a mild reactive gliosis (Figure 5.7). 
 Since the presence of activated microglia is often associated with a shift of astrocyte 
morphology towards an activated profile, we investigated the presence of reactive astrocytes 
by complement C3 expression in the hippocampus, somatosensory cortex and molecular layer 
of the cerebellum and by morphological analysis. The C3/GFAP co-stained area was raised in 
CASPR2-IgG injected mice in the hippocampus (t(398)=4.87, P < 0.0001, 200/cells per group, 
independent samples t-test), somatosensory cortex (t(160)=2.41, P=0.01, 81/cells per group, 
independent samples t-test) and cerebellum (t(204)=7.14, P < 0.0001, 103/cells per group, 
independent samples t-test) (Figure 5.7). The morphological analysis on GFAP stained cells 
showed that astrocytes from CASPR2-IgG injected mice also presented a smaller cell total body 
size (U=22052, P= 0.0051, Mann Whitney test U) and shorter (U=19946, P< 0.0001, Mann 
Whitney test U) maximal ramification length than HC-IgG injected mice, compatible with an 
activated phenotype, in the hippocampus (Figure 5.7). 
 
5.9 Cytokine and chemokine expression 
As these microglial and astrocyte changes suggested a state of mild neuroinflammation in the 
CASPR2-IgG injected mice, a commercial cytokine/chemokine array was performed on three 
whole brain lysates from each group to look for changes in neuroinflammatory markers. A trend 
towards increased levels was noted for several cytokines and chemokines, and particularly for 
interleukin (IL)-10, stem cell factor (SCF), and vascular endothelial growth factor (VEGF), but 
also for granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte-colony 
stimulating factor (GCSF), IL2 and monocyte chemotactic protein 5 (MCP-5), but none reached 
significance after correction for multiple comparisons (Figure 5.7). 
 







Figure 5.7 Astrocyte morphology and inflammatory markers 
 
A) Representative images of GFAP staining in the molecular layer of the cerebellum and 
quantification of the mean fluorescence intensity in the same area showing higher GFAP 
expression in the CASPR2-IgG injected mice. 40X, scale bar 10 µm. B) Representative 
images of complement C3 expression on GFAP positive cells. Percentage of C3/GFAP area 
ratio per cell showed increased C3 expression of astrocytes in the hippocampus, 
somatosensory cortex and cerebellum of CASPR2-IgG injected mice. 40X, scale bar 10 µm. 
C) Representative pictures of the z-stack projected GFAP staining used for morphological 
analysis (40X, 10 µm). The astrocytes from CASPR2-IgG injected mice showed a smaller cell 
total body size and shorter maximal ramification length than HC-IgG injected mice, 
compatible with an activated phenotype, in the hippocampus. D) Compared to HC-IgG 
injected mice, CASPR2-IgG exposed animals showed changes in several cytokines and 








In this Chapter, the results of brain analysis of mice injected with CASPR2-IgG were presented. 
After LPS, CASPR2-Abs were able to access and bind to the brain parenchyma. CASPR2-IgG 
injected mice showed a mild loss of Purkinje cells with cerebellar astrocytosis and increased c-
fos expression in the hypothalamus and piriform-entorhinal cortex. Moreover, CASPR2-IgG 
injected mice displayed increased microglia density and increased numbers of microglia and 
astrocytes with a reactive phenotype. This observation was supported by a trend toward 
elevated levels of microglia and astrocyte derived cytokines and chemokines.  
In modeling of brain antibody-mediated disease through peripheral administration of 
the antibodies, it is often necessary to disrupt the BBB integrity in order to allow them to reach 
their target antigen. Previous studies showed that LPS is able to breach the BBB (Kowal C et 
al. 2004; Banks WA et al. 2014) and allow peripherally administered antibodies to penetrate 
the brain parenchyma without causing, per se, sustained neurotoxicity (Kowal C et al. 2004). 
According to these studies, we observed increased human IgG in the brain parenchyma of 
CASPR2-IgG injected mice. Human IgG was localised mainly in the somatosensory cortex, in 
the hippocampus and in the thalamus in the perfused brains. Although the preferential 
localisation of the IgG in the CASPR2-IgG injected mice might be related to a preferential 
penetration of the antibodies in some regions, as has been observed in a feline model of LGI1 
encephalitis (Tröscher AR et al. 2017), it might also be related to a selective opening of the 
BBB by the LPS. Indeed, a previous study showed that LPS-induced BBB disruption occurred 
mainly in the frontal cortex, thalamus, pons-medulla and cerebellum (Banks WA et al. 2014).  
Once in the brain, antibodies targeting neuronal antigens can cause their effects through 
different mechanisms, such as internalisation of their target and consequent loss of function, 
blocking of the interactions with other molecules, inflammation and complement-dependent 
cytotoxicity with consequent cell lysis (Ludwig RJ et al. 2017). Mechanisms of action of 
CASPR2-Abs are still largely unclear. CASPR2-Abs are IgG4, often in association with IgG1; 
they are most likely to act through a disruption of CASPR2 interaction with associated 
molecules than through internalisation and complement activation. Accordingly, a recent study 
showed that CASPR2-Abs do not reduce CASPR2 expression on the surface of cultured 
hippocampal neurons, but they may act by reducing CASPR2 interaction with contactin-2 
(Patterson KR et al. 2017). By contrast, a neuropathological study on human tissue showed a 
reduction of CASPR2 staining in the cortex of a patient with autoimmune encephalitis (Sundal 
C et al. 2017) and in the previous mouse model we found a reduction in Kv1 channel surface 
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expression on DRG neurons following CASPR2-Abs treatment, consistent with an increased 
internalisation of CASPR2 following antibody binding (Dawes JM et al. 2018) as shown 
previously for many antibodies (e.g. Drachman DB et al 1978; Hughes EG et al. 2010). In our 
model, CASPR2-Abs did not appear to be associated with a reduction of CASPR2 surface 
expression although we cannot exclude that, at the time of our observation, a compensatory 
mechanism had not intervened to compensate for an initial reduction in CASPR2 expression. 
Indeed, a trend towards higher total CASPR2 levels was noted by western blotting of the brains 
of CASPR2-IgG injected mice. 
Antibodies can change neuronal activity through several mechanisms, including 
modification of channels and receptor expression or neuroinflammation. C-fos is an immediate 
early gene product, produced by individual neurons and commonly used as a marker of cell 
activation. CASPR2-IgG exposed mice showed significantly higher levels of c-fos expression 
in the entorhinal-piriform cortex and in the dorsomedial and lateral hypothalamus. The 
expression in the latter area could be related to the sleep-wake cycle. Particularly, c-fos 
expression has been shown to be increased during the dark period, when the mice are active, 
and decreased during the light period, when they are asleep (Basheer R et al. 1997) consistently 
with the presence of wake-active neurons in the lateral hypothalamus (Hsieh KC et al. 2011). 
Therefore, an increase of c-fos expression during the light period in our animals (euthanized 
between 1:00 and 5:00 p.m.) might suggest an increased wakefulness, consistent with the 
insomnia typical of patients with Morvan’s Syndrome (Liguori R et al. 2001). 
Complement activation has been reported in neuropathological studies of patients with 
CASPR2-Abs (Körtvélyessy P et al. 2015, Sundal C et al. 2017). Although we did not directly 
evaluate the presence of apoptotic cells or complement C9 expression, there was no loss of 
NeuN positive cells in the cortex and hippocampus. In the cerebellum, however, CASPR2-Abs 
caused a mild loss of Purkinje cells (PC) but not a reduction of NeuN positive cells in the 
molecular layer. CASPR2-Abs bind to the axons of granule cerebellar neurons in the molecular 
layer and have been associated with cerebellar ataxia in some patients (Becker E et al. 2013) as 
well as with morphological changes of PC in a neuropathological case (Sundal C et al. 2017). 
The loss of PC we observed was modest and this might explain why we did not observe ataxia 
in mice. It is also possible that the neuronal loss needed more time to manifest extensively and 
that the behavioural motor tests were performed at a time when the effects were not yet 
complete. The mechanisms of the Purkinje cell loss are not clear, and they might be related to 
a direct effect of the antibodies or indirectly to an effect of neuroinflammatory changes. 
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 Indeed, one of the most striking finding in this work is the activation of microglia and 
astrocytes. Microglia are neuroglia cells that represent the major immune cells in the brain and 
together with astrocytes are responsible for the innate immunity. Microglia and astrocyte 
functions are strictly interconnected, and, on the one hand, astrocytes support microglia 
functions, while on the other, microglia activation is required to initiate and support the 
astrocytic response (Pascual O et al. 2012). Previous studies showed that, under physiological 
condition, astrocytes express C3 complement (Lian H et al. 2016; Liddelow SA et al. 2017). In 
pathological conditions, (Lian H et al. 2016; Liddelow SA et al. 2017) activated microglia are 
able to induce reactive astrocytes, which up-regulate C3 expression and become responsible for 
neurotoxicity and synaptic loss. Accordingly, alongside microglia activation and increased 
density we found increased C3 expression on the surface of astrocytes and higher numbers of 
activated astrocytes in CASPR2-IgG injected mice. These findings were supported by trends 
towards elevated levels of cytokines produced by and targeted to astrocytes and microglia, such 
as GM-CSF, MCP-5 and VEGF. The microglial and astrocyte activation was particularly 
evident in the cerebellum. Here, reactive microglia have been shown to cause PC death during 
development (Marin-Teva JL et al. 2004) and in a mouse model of cerebellar degeneration an 
increase of activated microglia has been associated with PC loss and reactive gliosis (Zaho Z 
et al. 2011). 
Interestingly, microglia activation has been reported in neuropathological cases of 
patients with CASPR2-Abs encephalitis (Sundal C et al. 2017; Körtvélyessy P et al. 2015). 
Moreover, microglia activation and increased density was noted in the infralimbic, pre-limbic 
and somatosensory cortex of animal exposed to CASPR2-Abs in utero and this activation 
persisted in adulthood (Coutinho E et al. 2017). By contrast, the peripheral administration of 
CASPR2-IgG, without LPS, induced only a mild increase of microglia in the spinal cord and 
not in the somatosensory cortex of exposed animals (Dawes JM et al. 2018), suggesting that 
microglia activation might be dependent on the contact with IgG and that, once initiated, this 
process might be maintained independently from the initial trigger. In our model, LPS allowed 
the penetration of the IgG antibodies into the brain where they could have bound to the Fc 
receptors expressed on microglia, but the alternative possibility that the CASPR2-Abs bound 
to neurons and that this initiated inflammatory reactions that up-regulated microglia would 
explain better the differences between CASPR2-IgG and HC-IgG injected mice. 
Although the mechanisms by which CASPR2 antibodies produce neuropathological 
changes are not clear, we showed that peripheral injection of CASPR2-IgG can produce, after 
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a single dose of LPS, extensive CNS changes. This model needs to be further investigated with 
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Chapter 6. General discussion 
 
In the last decades, the discovery of antibodies directed against neuronal surface antigens has 
provided aetiology and treatment for many disorders for which those were previously unknown. 
In the meantime, several questions have emerged, including the role of these antibodies in 
patients with different phenotypes or other neurological disorders, and their pathogenicity in 
these circumstances. Moreover, despite the circumstantial clinical evidence of the pathogenic 
role of these antibodies in classical autoimmune encephalitis, only in a few cases have these 
been supported by a definite proof through a passive transfer animal model. The work of this 
thesis aimed to answer some of these questions by investigating the frequency and role of 
antibodies directed against neuronal antigens in patients with different central nervous system 
disorders and in controls, and by establishing a passive transfer animal model of CASPR2 
antibody, one of the most commonly encountered antibodies in clinical practice.  
 The results showed that antibodies against neuronal surface proteins are more frequent 
in patients with central nervous system disorders compared to healthy controls or patients with 
peripheral nervous system disorders. An important finding in this respect was that this 
difference was significant only when CBAs or the combination of positivity by different 
methods was used, suggesting that the combined approach ensured more specificity. A few 
studies have also shown antibodies against neuronal antigens are ubiquitous in the sera of both 
healthy and disease controls when using immunohistology (Levin EC et al. 2010; Nagele RG 
et al. 2011).   
Overall, the frequency of antibodies was similar among patients, despite differences in 
the distribution of some specific antibodies, which were more prevalent in one cohort compared 
to others (i.e. NMDAR antibodies in narcoleptic patients). This implies that, irrespective of the 
clinical diagnosis, a percentage of patients, between 15 and 40%, could potentially benefit from 
immunotherapy. However, the clinical features of patients with antibody reactivity were only 
rarely suggestive of a possible autoimmune encephalitis, and typical imaging or CSF 
inflammatory changes were often absent. Moreover, the majority of patients with specific 
antibodies did not show the usual clinical, and sometimes not even demographic, features 
associated with that antibody; this adds difficulties to the interpretation of the results but could 
reflect the influence of age and gender on the clinical presentation associated with particular 
antibodies, and partially explain these atypical presentations. 
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This study has several limitations. Patients and controls were not demographically 
homogeneous and the clinical information available was sometimes limited or not available at 
all. Antibodies were not systematically titrated, and subclasses were not determined. Moreover, 
CSFs were not available for testing; the finding of the antibodies in the CSFs would have 
supported their pathogenic role, although the pathogenic relationship between serum and CSF 
antibody is not clear in all patients with autoimmune encephalitis, let alone the disorders that 
were investigated here. Finally, the retrospective nature of the study means that seropositive 
patients were not treated and followed up. Therefore, the main question about the significance 
of these findings remains open.  
The results are also complicated by those of others, using the commercially available 
fixed CBAs. Antibodies against brain proteins were found in healthy individuals (Dahm L et 
al. 2014; Lang K and Prüss H, 2017) as well as in patients with several neurological or 
psychiatric presentations (reviewed in Pollak TA et al. 2016; Balint B et al. 2018). Whereas the 
physiological role of some natural occurring antibodies is partially understood (i.e. cellular 
debris removal) (Panda S and Ding JL, 2015), for antibodies against specific neuronal antigens 
this is unknown, nor are the possible circumstances and mechanisms that may turn these 
potentially ‘harmless’ antibodies into disease-relevant ones. Dahm L et al. (2014) found no 
difference in immunoglobulin classes distribution (IgM, IgG and IgA) or antibody titres 
between patients and controls. Therefore, the role of the blood-brain barrier (BBB) in defining 
the disease status was investigated. It was found that schizophrenic individuals with a past or 
present history of BBB disturbance were more likely to have more pronounced neurological 
symptoms if NMDAR antibody seropositive (Hammer C et al. 2014). It is of interest that in the 
narcolepsy type 1 patients studied here, seropositive status was associated with BBB disruption.  
An important possibility is that the difference between health- or disease-status could 
be related to different functionality or epitope specificity of the antibodies. Castillo-Gomez E 
et al. (2017) showed that all NMDAR-Ab positive sera, derived from randomly selected 
individuals, were able to induce NMDAR internalisation in inducible pluripotent stem cell 
(IPSC)-derived human cortical neurons. Several different epitopes recognised by NMDAR-Abs 
were identified, without any consistent functional or epitope pattern related to health/disease 
state. However, these findings were contradicted by a subsequent study showing different 
functional effects of NMDAR-Abs from schizophrenic patients versus those found in healthy 
individuals (Jezequel J et al. 2017). NMDAR-Ab from patients, but not from healthy subjects, 
were shown to alter the surface dynamics and nanoscale organisation of synaptic NMDAR and 
its anchoring partner the ephrin-B2 receptor in heterologous cells, cultured neurons and in 
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mouse brain and preventing long-term potentiation at glutamatergic synapses, while leaving 
NMDAR-mediated calcium influx intact. 
It is clear that more studies are needed to clarify the role of the antibodies in health and 
disease, mainly to identify the factors associated with the disease status, looking not only at the 
antibodies per se but also at all those factors that could influence their ability to reach their 
targets (i.e. blood-brain barrier integrity) and those which could modulate the immune response 
(i.e. HLA status). The implications of these findings could help support the use of 
immunotherapy in patients that otherwise would have remained untreated and avoid ineffective 
and potentially harmful treatment in those cases which would not benefit.  
Part of the process of investigating antibody-associated diseases is to prove the 
pathogenicity of disease-relevant antibodies, which was the aim of the second part of this work 
(Chapters 4,5). Since there was no clear novel antibody emerging from the work in Chapter 3, 
and because the quantities of IgG needed for pathogenicity studies can only be obtained from 
plasma exchange, a passive transfer animal model was established to investigate the pathogenic 
role of CASPR2 antibodies. Mice injected with CASPR2-IgG showed working memory deficits 
and anxiety-like behaviour during social tasks with a global reduction of locomotor activity. 
Neuropathology showed that CASPR2-Abs were able to access and to bind to the brain 
parenchyma. CASPR2-IgG injected mice showed a mild loss of Purkinje cells with cerebellar 
astrocytosis and increased c-fos expression in the hypothalamus and piriform-entorhinal cortex. 
Moreover, CASPR2-IgG injected mice displayed increased microglia density and increased 
microglia and astrocytes with a reactive phenotype. This observation was supported by a trend 
towards elevated levels of microglia and astrocytes derived cytokines and chemokines. 
Surprisingly, no changes in CASPR2 expression were observed, suggesting that the main 
mechanisms of the antibodies might not be the internalisation of the protein but the interaction 
with its partners, namely Kv 1.1 and Kv 1.2 and contactin-2. 
The results strongly suggest that CASPR2-Abs can affect many different brain regions 
and therefore potentially different functions. CASPR2-Abs have been associated with a broad 
range of clinical manifestations, many of which, e.g. autonomic and sleep dysfunction, would 
require additional tests that were not available on the Home Office license. The main finding 
was a mild memory impairment, which might appear inconsistent with the lack of histological 
changes in the hippocampus. However, although working memory is related to hippocampal 
integrity, other brain areas play a role in these tasks (Lalonde R, 2002). Among those the 
entorhinal cortex, where CASPR2 is highly expressed (Gordon A et al. 2016), is the main 
source of hippocampal afferents from the neocortex and is involved in different forms of 
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memory (van Groen T et al. 2003). Indeed, in mouse models of Alzheimer’s disease, memory 
impairment was associated with an early hyper-excitability of the entorhinal cortex (Xu W et 
al. 2015) which would be consistent with increased neuronal excitability following reduction 
in Kv1 expression seen in the dorsal root ganglia (DRG) in the peripheral CASPR2-Ab model 
(Dawes JM et al. 2018). These changes may have been responsible for the higher levels of c-
fos expression in the entorhinal-piriform cortex, rather than in the hippocampus.   
The long-term effects of CASPR2-Abs are not clear in patients but in general brain MRI 
studies do not demonstrate brain atrophy. This would be consistent with previous findings 
(Dawes JM et al. 2018) as CASPR2-Abs did not caused frank neuronal loss in the periphery, 
and with the findings here where the only neuronal abnormality identified was a mild loss of 
cerebellar Purkinje cells. More striking was the activation of microglia and astrocytes. 
Microglial activation has been reported in neuropathological cases of patients with CASPR2-
Ab encephalitis (Körtvelyessy P et al. 2015; Sundal C et al. 2017). Moreover, microglial 
activation and increased density was noted in cortex of animals exposed to CASPR2-Abs in 
utero and this activation persisted into adulthood (Coutinho E et al. 2017). By contrast, the 
peripheral administration of CASPR2-IgG, without LPS, induced only a mild increase of 
microglia in the spinal cord but not in the somatosensory cortex of exposed animals (Dawes JM 
et al. 2018).  
This study also has limitations. The use of LPS, could have induced additional 
inflammation and contributed to determining the site of BBB disruption, leading to or changing 
some of the antibody effects observed. Indeed, the intracerebroventricular (ICV) injection of 
the antibodies could have overcome the need to use other molecules to open the BBB, 
guaranteeing a direct access of the antibodies to the brain; but there is no evidence yet that the 
ICV approach provides a more realistic or complete model of autoimmune disorders 
(Planagumà J et al. 2015; Wright S et al. 2015). Indeed, as there is an incomplete understanding 
regarding the relative roles of CSF and serum antibodies in some of these conditions, a direct 
comparison between the two approaches could be very interesting. The behavioural studies 
were broad but did not focus on all the features of CASPR2-related encephalitis, as mentioned 
above, and these need to be investigated in further studies. The experimental timing we chose 
could have prevented us from seeing the acute effects of the antibodies while some behavioural 
and histological effects might have required more time to become fully established.  
Finally, other questions remain unanswered such as the mechanisms by which CASPR2-
Abs affect CASPR2 function in the CNS and if the glial changes are relevant in the human 
disease. In vitro studies would have been useful to clarify if CASPR2-Abs caused 
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internalisation of the antigen as seems suggested by studies on DRG neurons (Dawes JM et al. 
2018), or an alteration of their interaction with other proteins as suggested by these findings 
and other studies (Patterson KR et al. 2017). However, due to the lack of time, these studies 
could not be performed during the course of this PhD. 
Many of the recently-described antibody-mediated CNS diseases have higher serum 
than CSF antibody levels, emphasizing that in many or most cases they are likely to be initiated 
by a peripheral immune response. It was timely, therefore, to see whether peripheral injection 
of antibodies could, under conditions where the BBB is briefly compromised, lead to evidence 
of CNS dysfunction. Despite the mentioned limitations, this study not only supports the 
pathogenic effect of CASPR2-Abs, but also supports a model where peripherally administered 
CASPR2-Abs, in the presence of a temporary breach in the BBB, are able to access the brain 
and produce histological and behavioural changes.  
The data collected in this thesis should stimulate further research, both epidemiological and 
experimental, into the role of potentially pathogenic antibodies against neuronal surface 
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